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Abstract
In the rat, magnocellular oxytocin neurones within the supraoptic nucleus
(SON) become both tolerant to and dependent upon the central inhibitory
actions of morphine (Pumford et al., 1991 J. Physiol. 440: 437). Previous
studies have shown that tolerance can be demonstrated at the level of the
single neurone and may be a result of p-opioid receptor downregulation.
However dependence as shown by withdrawal excitation of neurones upon
administration of the opioid antagonist naloxone would appear to be a
property of an intact neuronal network. Withdrawal excitation of oxytocin
neurones is mediated by a variety of excitatory inputs which converge upon
the neurones to share a limited number of post-effector mechanisms leading
to transduction of the electrical event. During morphine treatment normal
excitability returns to the oxytocin neurone probably by increasing the
contribution of excitatory input. Removal of morphine inhibition by naloxone
may leave an upregulated system to respond in typical hyperexcitatable
fashion. This study has focussed on the inputs responsible for driving
oxytocin neurones during the withdrawal process.
Systemic administration of sulphated cholecystokinin octapeptide (CCK8S)
activates central noradrenergic pathways (including possibly the A6 cell
group of the locus coeruleus which projects to the SON) and this stimulus to
oxytocin secretion into the blood measured by radioimmunoassay was dose-
dependently inhibited by the a2-adrenergic agonist clonidine and by
morphine; a2- and p-receptor mediated effects may converge on the same
post-receptor mechanism. Cells of the locus coeruleus also show tolerance
and dependence to opioids. Withdrawal hypersecretion of oxytocin was
significantly attenuated by clonidine, possibly by pre-synaptically blocking the
noradrenergic input from the A6 cell group although activation of this
pathway by CCK8S alone did not initiate withdrawal.
Magnocellular oxytocin neurone action potentials exhibit a Ca2+ dependent
shoulder on the repolarisation phase. Withdrawal excitation of oxytocin
neurone firing rate resulting in secretion of oxytocin into blood from the
neurohypophysis, and release of oxytocin within the SON measured by
microdialysis was attenuated by prior intracerebroventricular (ICV)
administration of the L-type Ca2+ channel blocker verapamil, indicating
involvement of L-type Ca2+ channel activation in this excitation. Oxytocin is
excitatory to its own release within the SON. ICV injection and infusion of a
specific oxytocin antagonist reduced withdrawal hypersecretion of oxytocin
into blood implicating a requirement for autofacilitation of oxytocin release for
the withdrawal process to be sustained. CCK is co-released with oxytocin
from magnocellular neurones and has been proposed to act as an
endogenous opioid antagonist. CCK8S opposed the inhibitory actions of
morphine on firing rate of putative oxytocin neurones in the hypothalamic
slice whilst CCK8S binding site density measured by receptor
autoradiography was increased within the SON of morphine dependent rats
suggesting that endogenous CCK mechanisms may be upregulated during
morphine dependence.
Thus withdrawal excitation of supraoptic oxytocin neurones may involve an
excitatory noradrenergic input from the A6 cell group which may become
more active during dependence. Tolerance to opioids on excitatory inputs to
the SON and within the SON itself may increase the expression of several
components excitatory to oxytocin neurones such as endogenous CCK
function. An amplification in release of noradrenaline within the SON after
removal of central morphine inhibition by naloxone, may then excite oxytocin
neurones directly by increasing a voltage dependent Ca2+ conductance. Co-
release of oxytocin and CCK would feed back onto the oxytocin neurones
and sustain the withdrawal process, whilst the increase in synaptic drive from
the A6 cell group and locally within the SON would continue until release of
oxytocin and CCK or a pool of readily available Ca2+ had become depleted





1.1. Morphine; a historical perspective
The opium poppy Papaver Somniferum ('the poppy that brings sleep')
through its chemical products which have potent analgesic actions, has
eased human suffering for thousands of years, but has also caused
considerable misery throughout history, through widespread abuse of the
euphoric properties of the same products. A great deal of governmental
effort has gone, unsuccessfully, into controlling its cultivation and
distribution, and so a greater understanding of the physical and chemical
properties of the constituents is obviously required.
The opium poppy has provided one of the greatest of all pain killers.
Morphine, in the form of opium has been employed in medicine in the
Eastern Mediterranean, the Middle East and Western Asia since the earliest
times. Extraction of the opium, or latex, is achieved by cutting the green
capsule with a small sharp implement and scraping off the soft material which
exudes over the next twenty-four hours. The poppy remains the prime
source of morphine and the capsules contain at least twenty-five alkaloids,
four of which have been exploited medicinally- the phenanthrene derivatives
morphine and codeine, and the benzylisoquinoline derivatives, papaverine
and noscapine (Jaffe and Martin, 1990).
Archaeological evidence suggests that over 5000 years ago in
Mesopotamia the Sumerians treated various illnesses with medicines
obtained from the poppy. Such skills were to be inherited and practised by
the Assyrians and Babylonians whilst the ancient Egyptians considered the
poppy so important that pharaohs' were entombed with it at their sides
(Zackon, 1988). Egyptian traders were to sail across the Mediterranean to
Greece and Rome where opium was often regarded as a gift from the Gods
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as referred in Homers' Odyssey- "Into the wine they were drinking, Helen, of
the line of Zeus cast an Egyptian drug which melted sorrow and sweetened
gall, which made men forgetful of their pains." The Greek physician
Hippocrates, often regarded as the father of modern medicine prescribed
opium frequently for relief from medical ailments. Another Greek physician,
Galen, who practised in the Roman Empire in the 2nd century, created a
recipe called mithridate, by standardising the preparation of opium.
By the 7th century the Turks had succeeded in cultivating large crops of
the poppy and Arab merchants, who traded with peoples and new markets in
India and China provided an economic incentive for its cultivation.
The drinking or eating of mild opium potions to ease the pain of minor
ailments continued for centuries although by the 14th century Arab scientists
had noted that continued use of the drug led to a deterioration of the users'
mind, with common knowledge that a single overdose could lead to death
(Zackon, 1988).
In Europe, the strict medical doctrine of the Catholic church saw a decline
in use of the opium poppy, until the 16th century when Paracelsus, a Swiss
physician and chemist with remarkable insight, created a potion called
laudanum, whose principal ingredient was opium (Sigerist, 1941). His
fantastic claims for the rejuvenating powers of laudanum were to attract a
widespread following and throughout the Western world laudanum was
eventually to become one of the most popular and abused medications of all
time. However until the 18th century the availability of strong opium in
Europe was still limited until a new era was to dawn with increases in trade.
Under the auspices of the British Crown the British East India Company in
its endeavours to maximise English trade in India and the far East was to
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saturate the markets of Southeastern Asia at this time, and although the use
and frequent abuse of opium contravened many strongly held religious
beliefs and cultural values in these areas they were no match for the profit-
seeking traders. Indeed, the British were also to aquire an opium habit of
their own where chemists and pharmacists were only too willing to praise the
virtues of the drug to a naive market. Although doctors were aware of the
contraindications for the drug, it was difficult to document social health
problems at the time and many were frequent consumers themselves, such
that even educated opinion (along with valuable revenue for the
Government) would render a cheap and plentiful availability of the drug
(Berridge, 1977).
In 1803, Frederick Serteurner, a German scientist, derived from opium a
crystal alkaloid so potent that extremely small amounts could produce
pronounced effects. Serteurner was to call this chemical morphine after
Morpheus (the Greek god of dreams and sleep), (Jaffe and Martin ,1990).
Morphine, even more so than opium, would transform the practise of
medicine over the following 20 years and with it the experience of drug
addiction.
The nature of morphine abuse was to be further aggravated by the
development of the hypodermic syringe by Dr. Alexander Wood of Edinburgh
and its refinement in the 1840's and 1850's. The hypodermic syringe made
possible the administration of morphine by injection, which was much more
quickly absorbed into the bloodstream, than the enteral route, giving
maximum intensity of effect extremely rapidly. This method of morphine
administration was initially practised only by doctors, since intravenous
injection required a degree of experience and skill, but such was their
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affirmed confidence in this mode of administration that soon patients were
able to obtain hypodermic syringes with appropriate instruction. The rapidity
and degree of euphoria experienced with injection led to a new populus who
were to become addicted to opiates. In the United States, this method of
administration was to render the over-use of morphine in the American Civil
War as the "army-disease" (it was taken medicinally as a painkiller to combat
dysentery).
Not everyone however, was so eager to celebrate the drug-induced
euphoria of opiate addiction. The British writer Thomas de Quincey
published in 1822 a mesmerising account of opiate addiction called
"Confessions of an English Opium Eater." This is his personal confession of
how he was to acquire a need for laudanum that transgressed the bounds of
mere medicinal use and eventually led him to living a nightmare. His intimate
description documented the requirement for increasing quantity of laudanum
to achieve a given state of euphoria with repeated administration, and the
mental and physical trauma associated with cessation of use (Schiller, 1976).
The smoking of raw opium in China at this time heralded a massive
increase in the trade of opium from the British traders to the Chinese. So
huge was the market and its profits and such was the Emperors' contempt for
the trade that in 1839 the Opium War began. The Chinese effort was futile
and in 1852 a second war began and again, failure. At this point in history
imperial exploitation was at its very peak (Zackon, 1988).
The incidence of opiate dependence grew dramatically in the United
States along with the rapid expansion and dispersion of its population.
Legislation came in the form of the Narcotic Act of 1914 but the problem was
never fully eradicated. Similarly in the United Kingdom the Dangerous Drugs
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Act of 1920 was imposed to try and curb the problem of dependence.
Earlier in 1874, a British chemist, C.R. Wright synthesised
diaceytlmorphine or diamorphine from morphine. This compound aceylated
at both -OH groups was to receive a wider audience 25 years later when in
1898 Heinrich Dreser synthesised diamorphine and gave it its common
name, heroin.
Heroin is catabolized to morphine in the body and because of its greater
lipid solubility it crosses the blood-brain barrier quicker than morphine and so
gives a more intense euphoria or "rush" than morphine. Heroin is reputed to
be less emetic than morphine, another added attraction to abusers of the
drug. However there is no evidence that heroin differs from morphine in
either its respiratory depressant effect or in its liability to cause dependence
(Jaffe and Martin, 1990).
1.2. Chemical Aspects of Opioids
Figure (1.2.1.)- Chemical structure of morphine.
Morphine is a substituted phenanthrene molecule, with two planar rings
and two aliphatic ring structures which occupy a plane roughly at right angles







The other opiate used throughout the studies in this thesis is the general
antagonist naloxone, which preferentially blocks p-receptors, but also the 6
and k types (Kosterlitz, 1985). Naloxone differs from morphine at position 6
where the alcoholic OH is substituted by an oxygen atom, lacks a double
bond between carbon atoms 7 and 8 and at the nitrogen atom at position 17
where the methyl group is replaced with a -CH2CH=CH2 extension.
1.3. Pharmacology of Opioids
It was postulated that morphine and its derivatives produce their effects by
binding to specific receptor sites in the central nervous system (CNS) and
elsewhere. Morphine is an extremely effective analgesic acting within the
CNS on pain pathways to reduce the sensation of pain and the associated
distress. As mentioned previously morphine induces a strong feeling of
happiness and relaxation (euphoria) which is an important component of its
analgesic effect, and this euphoria is particularly intense when morphine is
injected intravenously, leading in part to the use of opiates solely for
recreational purposes. For several minutes a pleasant surge, reportedly felt
initially in the abdomen, spreading throughout the body occurs, before these
feelings fade and are followed by several hours of gradually decreasing
sensation. Intravenous injection can often result in vomiting in the non-
habitual user (Jaffe and Martin, 1990).
Morphine is a powerful depressant slowing the pulse and acting on
respiratory centres in the brain stem to depress breathing rate. Lethal effects
of morphine are almost always a result of respiratory depression. Thus
naloxone is used clinically to antagonise such agonist effects in the case of




Propulsive contractions of the small intestine are markedly reduced by
morphine, and in the colon peristalsis is abolished by direct actions on local
opioid receptors. Consequently constipation is a common feature of
morphine administration (Jaffe and Martin, 1990).
1.4. Opioid receptors and endogenous opioid peptides
A family of opioid receptors was first postulated by Martin in 1967 to
explain the dual action of nalorphine in humans, where although analgesic, it
was also capable of antagonising morphine analgesia. It was concluded that
this effect was mediated by the k-receptor (Martin, 1967). Differing
pharmacological profiles and binding site characteristics of opiates in
neurophysiological and behavioural tests in the spinal dog (Martin, 1976),
and in the guinea-pig ileum and mouse vas deferens preparations (Lord et al,
1977), have indicated the existence of three classically defined opioid
receptors, termed p-, 5- and k (Goldstein and James, 1984; Paterson et al.,
1983; Zukin and Zukin,1984). Morphine binds preferentially to the p-receptor
with little relative affinity for the k- or 5-subtype of opioid receptor (Kosterlitz,
1985). Recently the 5-opioid receptor has been cloned by functional
expression (Evans et al., 1992) and appears to show closer homology with
the somatostatin receptor, than with a putative k-receptor which has also
been cloned (Xie et al., 1992; Meng et al., 1993); although this receptor is
also a member of the G protein-coupled receptor family.
It is now firmly established that there are three major classes of
endogenous opioid peptides. The enkephalins (Hughes et al., 1975),
endorphins (Bradbury et al., 1976) and dynorphin-related peptides (Goldstein
et al., 1981) arise from three separate precursor molecules encoded by
different genes (Weber et al., 1983) which have some differential receptor
7
Introduction
specificities (see Table 1.4.1.).
Polypeptide Principal endogenous Exogenous Receptor
precursor ligands ligand specificity




Proopiomelanocortin P-endorphin Morphine p, 8
DAGO
Prodynorphin Dynorphin (1_17) U50, 488H K>p, 8
Dynorphin (1.13) K>p, 8
Dynorphin (1.8) K> p, 8
[Leu5]-enkephalin 8> >p
Table 1.4.1.- Pharmacological profile of opioid peptides.
The longer dynorphin-related peptides are more stable and probably act
as long-acting diffusible neurotransmitters, whereas the shorter forms and
the enkephalins are subject to rapid hydrolysis by various peptidases,
indicative of a typical neurotransmitter function (McKnight et at., 1983).
1.5. Morphine Tolerance and Dependence
Tolerance is defined as a requirement for an increase in dose of a
particular drug to elicit a pre-determined pharmacological effect or, after
repeated administration a given dose of the drug produces a decreased
effect (Jaffe, 1990). Physical dependence develops with repeated
administration of a drug, whereupon the neuronal system in question
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undergoes a form of adaptation to the drug, thereby resulting in the
manifestation of an associated characteristic withdrawal response upon
removal of the drug (Jaffe, 1990).
With the realisation that different physiological responses are effected by
the binding of an opiate to a proposed particular receptor subtype it has been
deemed plausible that the analgesic component of an opiate such as
morphine could be differentiated from the component which renders a subject
dependent upon it (Woods et at., 1992). This however requires a full
understanding of the cellular mechanisms underlying these distinct
phenomena. As far as dependence is concerned this has been well
characterised in a number of neuronal systems such as rat locus coeruleus
cells and the guinea pig myenteric plexus.
Tolerance and dependence to the actions of morphine and opiates in
general at the cellular level can potentially involve receptor down-regulation
and/or internalisation, altered ionic conductances (particularly Ca2+),
modulation of receptor coupling with intracellular second messenger systems
and increased activity of proposed endogenous antagonists. It should be
noted however that although dependence has a cellular component it is
extremely difficult to demonstrate in neuronal cell lines and isolated
preparations since an important aspect of dependence appears to be derived
from excitatory synaptic inputs which converge upon the neurone to share a
common pool of second messenger systems leading to neuronal activation.
It has been speculated that changes in the balance of these inputs modulate
these second messenger systems to initiate dependence so that removal of
the inputs renders its demonstration impossible.
Opiates have been shown to inhibit acutely adenyl cyclase, the enzyme
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responsible for the synthesis of cAMP (Sharma et al., 1975), and an
accumulation of evidence suggests that this and other acute opiate actions
are mediated by G proteins (Aghajanian and Wang, 1986). The ability of
opiates to regulate neuronal activity can be attenuated by treatment with
pertussis toxin (Nestler et al., 1989). This selectively inactivates two types of
G protein designated G; and G0, by catalysing the ADP-ribosylation of their a
subunits and it has been proposed that neuronal p-receptors may be linked
to these G proteins (Ueda et al., 1990). In these same neurones binding to
p- and S-opioid receptors activates a K+ conductance responsible for
prolonged after hyperpolarisation (North and Williams, 1985). This in turn
contributes to a shortened action potential and may attenuate an associated
Ca2+ conductance thereby slowing down gene transcription and turnover of
essential neurotransmitters (North, 1989). Activation of K-receptors reduces
Ca2+ conductance but is without effect on the K+ conductance suggesting a
direct mode of action (North, 1986).
Several studies have shown that voltage-dependent Ca2+ channel blockers
such as the phenylalkylamines and modulators (typified by the
dihydropyridines) diminish morphine tolerance (Contreras et al., 1988) and
attenuate the behavioural signs associated with morphine withdrawal in rats
(Bongianni et al., 1986; Baeyens et al., 1987) and mice (Barrios and
Baeyens, 1991). In vitro they reduce naloxone-precipitated [3H]-
noradrenaline release from cortical slices of dependent rats (Pellegrini-
Giampietro et al., 1988). This is accompanied by an increase in
dihydropyridine binding after prolonged morphine treatment (Ramkumar and
El-Fakahany, 1988).
In the locus coeruleus opiate withdrawal dramatically increases firing rate
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of the neuronal population and this is defined as a physical demonstration of
dependence (Rasmussen et al., 1990). Another aspect to this response, is
the expression of c-fos mRNA and subsequently of Fos protein within the
locus coeruleus (Hayward et al., 1990). The proto-oncogene c-fos is an
immediate early gene which serves to transmit information within and
between cells by encoding the general transcription factor protein product
Fos, which is induced by various enviromental signals (Morgan and Curran,
1991). Thus immunohistochemical staining for Fos within the nuclei of cells,
can be used as an indicator of neuronal activity in response to a variety of
stimuli at the level of the single cell (Morgan and Curran, 1991).
1.6. Oxytocin; a historical perspective
After it had been shown that intravenous injection of an extract of whole
hypophysis into a dog displayed vasopressor activity (Oliver and Schafer,
1895), Sir Henry Dale whilst investigating the physiological actions of ergot in
the cat accidentally discovered the uterotonic action of neural lobe extract
(Dale, 1906). Dale was attempting to show that the pressor activity of the
extract could be reversed by ergot. However, the cat from which the
recordings were being taken happened to be in the early stages of
pregnancy with the result that the extract not only retained its pressor activity
in the presence of ergot, but also produced a strong contractile response of
the uterus. Interest in the active components contained within the neural
lobe extracts was stimulated further by Ott and Scott (1910) who
demonstrated the milk-ejection activity of such extracts.
It was questionable at this point in time as to whether the same agent
within the neural lobe extract accounted for both its pressor and oxytocic
activities. Dudley (1919) was able to separate these activities by extraction
11
Introduction
with butanol and to show that they were subject to degradation by proteolytic
enzymes, concluding therefore that they were peptidergic in nature (Dale and
Dudley, 1921). The progression towards isolating the two active principles of
neural lobe extract was continued by Kamn and colleagues in 1928 when
they succeeded in isolating highly active pressor and oxytocic fractions
(Kamn et al., 1928). The amino acid sequence of oxytocin was elucidated in
1950 (Pierce and Du Vigneaud, 1950) and the structure (Fig 1.5.1.)
simultaneously determined by Du Vigneaud and by Tuppy (Du Vigneaud et
al., 1953a; Tuppy, 1953).
4 5 6 7 8 9
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Figure (1.5.1.)- Structure of the neurohypophysial hormones oxytocin and
vasopressin.
The structure of vasopressin was determined shortly afterwards (Fig
1.5.1.), (Du Vigneaud et al., 1953b) and the synthesis of both hormones
completed by 1954 (Du Vigneaud et al., 1953a and 1954) laying to rest the
controversy as to the number of physiologically active components contained
within the neural lobe also referred to as the neurohypophysis . Interestingly,
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all the jawed vertebrates examined thus far possess neurohypophysial
hormones similar to those of mammals, differing only in amino acid
constituents at positions 3, 4 and 8, suggesting that they may have evolved
from a common ancestral form which is presumed to be arginine vasotocin.
As understanding of neuronal structure and function improved with clearer
morphological and biochemical evidence, the concept of neurosecretion and
the hypothalamic origin of oxytocin and vasopressin became firmly
established as shown by Bargmann and Scharrer (1951) and Scharrer and
Scharrer (1954). By transecting the neural stalk and using the "Gomori stain"
for identification purposes they were able to demonstrate a proximal
accumulation and a distal depletion of neurosecretory material. They were to
conclude that the supraoptic and paraventricular nuclei (SON and PVN) were
the site of hormone synthesis and that the neurosecretory material was
transported from here by axonal flow to the nerve terminals in the
neurohypophysis.
Oxytocin is synthesised as part of a large precursor molecule together with
neurophysin I (Schmale and Richter, 1980) and post-translationally modified
en route along the axons from its site of synthesis to the neurohypophysial
nerve endings (Ivell and Richter, 1984) where they are released separately.
1.7. Electrical properties of magnocellular neurones
Studies concerning the neural control of the neural lobe advanced
significantly with work completed by Barry Cross in the late 1950's. Cross
made the first electrical recordings from putative magnocellular neurones
(Cross and Green, 1959) whilst applying osmotic and other stimuli known to
liberate neurohypophysial hormone release. Such recordings were later to
be characterised by antidromically activating neurones projecting from the
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SON and PVN to the neurohypophysis (Dyball and Koizumi, 1969). Further
characterisation, enabling distinction between oxytocin and vasopressin
neurones, followed with the discovery by Jonathan Wakerley in the lactating
rat that suckling pups showed a stretch response every 5-10 min followed by
voracious suckling for approximately 10 s; the first description of the milk-
ejection reflex in the rat (Wakerley and Lincoln, 1971a). Thus,
antidromically-activated continuously active neurones within the PVN and
SON responded to a continuous suckling stimulus with pulsatile secretion of
oxytocin (reflecting increased electrical activity in the range of 50-80 spikes/s
lasting 2-4 s from a background firing rate of 1-5 spikes/s some 10 s before
the rise in intramammary pressure indicative of milk-ejection), (Lincoln and
Wakerley, 1971, 1974; Wakerley and Lincoln, 1973).
By exclusion, previous recordings of cells from the PVN in the rat, which
fired in phasic bursts, with 20-40 s periods of activity alternated with similar
durations of silence and firing rate in the range of 5-15 spikes/s were
identified as vasopressinergic since activity did not correlate with the release
of oxytocin at milk-ejection (Wakerley and Lincoln, 1971b). More recently
this correlation of phasic activity with vasopressin neurones has been
demonstrated with staining techniques combined with electrophysiology
(Yamashita et al., 1983; Cobbett etai, 1984; Cobbett et al., 1986).
Such a wealth of evidence suggests that magnocellular neurosecretory
cells are extremely dynamic as regards firing pattern and release of
hormone. Indeed, stimulation of the isolated neural lobe preparation has
been used to demonstrate that release of oxytocin and vasopressin
increases with stimulation intensity, and can be further augmented by
clustering the stimuli into bursts rather than by applying the same number of
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stimuli at a fixed frequency (Bicknell, 1988). This optimisation of
neurohormone release is more readily appreciated when one looks at the
various stimuli which cause release of oxytocin and vasopressin from the
neurohypophysis into the bloodstream.
1.8. Established stimuli for oxytocin release
Milk-ejection reflex
The synchronised bursting of oxytocin neurones which occurs during the
milk-ejection reflex results in a bolus release of 0.5-1.5 mil of oxytocin from
the neurohypophysis. This causes contraction of the myoepithelial cells
surrounding the alveoli and ducts of the mammary gland some 10-20 s later,
with a corresponding increase in intramammary pressure and subsequent
milk let-down.
Injection of intracerebroventricular (i.c.v.) oxytocin increases the frequency
and amplitude of these bursts unlike intravenous injection (Freund-Mercier
and Richard, 1981, 1984) and can initiate bursts in the anaesthetised
lactating rat previously unable to display milk-ejections (Freund-Mercier and
Richard, 1984). Furthermore, centrally administered oxytocin promotes rapid
recruitment of oxytocin neurones at the beginning of suckling (Moos and
Richard, 1988) with evidence that oxytocin is released within the SON during
the milk-ejection reflex (Moos et ai, 1989; Neumann et a!., 1993). Since
i.c.v. injection of an oxytocin antagonist can interrupt the milk-ejection reflex
(Freund-Mercier and Richard, 1984), the role of endogenous oxytocin in
autofacilitating its own release is paramount in promoting the regular bursting
activity of oxytocin neurones stimulated by suckling. Oxytocin is probably
released from dendritic and axonal processes within the SON (Pow and
Morris, 1989) where it can bind to oxytocin binding sites located on the
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dendritic processes (Freund-Mercier and Stoeckel, 1993). This
autofacilitation may be partly mediated via the bed nucleus of the stria
terminalis which contains specific oxytocin binding sites that increase in
density during lactation (Insel, 1990) and injection of oxytocin into this region
facilitates bursting of magnocellular oxytocin neurones within the SON during
milk-ejection (Moos et al., 1991).
Parturition
Oxytocin plays an important role in regulating the progress of parturition in
the rat. Uterine responsiveness to oxytocin increases rapidly in late
gestation up to the period of parturition (Fuchs, 1984). At parturition oxytocin
is released in response to distension of the vagina and cervix (Higuchi et al.,
1986b), stimuli associated with the Ferguson reflex and in response to the
forceful abdominal contractions which propel the foetus along the birth canal;
the foetal-expulsion reflex (Higuchi et al., 1986b; Higuchi et al., 1987).
Measurement of plasma oxytocin concentrations following the birth of the first
three pups has shown that there is an increase in oxytocin release once
parturition has started and that levels continue to increase throughout
parturition (Higuchi et al., 1986b; Leng et al., 1987). The electrical activity of
antidromically-identified magnocellular oxytocin neurones is similar to that
seen during milk-ejection, with an increase in background firing interspersed
with periods of bursting activity; 10-32 Hz lasting 6-14 s after each forceful
abdominal contraction and short 32-80 Hz bursts lasting 5-12 s some 15-28 s
before the delivery of each pup (Summerlee, 1981). Such bursts tend to
occur just before delivery of individual pups. Although this bursting activity is
associated with pulsatile release of oxytocin in the milk-ejection reflex
(Higuchi et al., 1986c) it has been extremely difficult to show using plasma
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sampling such a manner of release during parturition, probably due to the
short half-life (approximately 90 s) of oxytocin in the plasma (Higuchi et al.,
1986c).
Oxytocin and osmotic balance
Considering the homology in structure which is conserved between
oxytocin and vasopressin and that approximately one half of the
magnocellular cells in the SON and PVN synthesise oxytocin (Rhodes et al.,
1981), it is hardly surprising that oxytocin has overlapping actions with
vasopressin in addition to its involvement in lactation and parturition.
Magnocellular neurosecretory neurones within the SON respond to systemic
hyperosmotic stimulation by increasing their electrical activity (Brimble and
Dyball, 1977) which leads to release of oxytocin and vasopressin from the
neurohypophysis (Brimble et al., 1978, Wakerley et al., 1978). Interestingly,
this enhancement in release of oxytocin is achieved by a gradual increase in
spontaneous activity rather than intermittent high frequency bursting (Brimble
and Dyball, 1977). Hyperosmotic stimulation also leads to increased Fos-like
immunoreactivity (Giovannelli et al., 1990) and induces c-fbs-mRNA
(Hamamura et al., 1992) and eventually oxytocin-mRNA expression within
the hypothalamic magnocellular nuclei (Lightman and Young, 1987).
Magnocellular neurosecretory neurones are known to be directly
osmosensitive (Leng et al., 1982) and direct osmotic stimulation of the SON
using the microdialysis technique has been shown to induce release of
vasopressin (Landgraf and Ludwig, 1991; Ludwig and Landgraf, 1992) and
oxytocin (Neumann et al., 1993) within the SON as well as into the periphery.
Firing rate of supraoptic neurones within isolated slices or explants is
increased following perfusion with hypertonic saline (Wakerley et al., 1983)
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and the associated depolarisation persists in Ca2+-free media suggesting a
post-synaptic location on the neurones themselves (Bourque and Renaud,
1984). Recently isolated magnocellular neurosecretory cells from the SON,
devoid of long neuritic processes, have been shown to be directly
osmosensitive (Oliet and Bourque, 1993). In addition, the persistence of a
reduced osmosensitivity among supraoptic neurones in the absence of
synaptic transmission indicates that their osmosensitivity is enhanced
through synaptic input from adjacent neurones such as those located in the
region anterior and ventral to the third ventricle (AV3V region). Indeed it is
necessary for the functional integrity of afferent pathways from regions such
as the subfornical organ (SFO) and the AV3V region to be maintained in
order for magnocellular neurosecretory neurones to express full
osmoresponsiveness (Leng et al:, 1989). The SFO has efferent connections
with the AV3V preoptic area and the hypothalamus (Miselis, 1981) and a
predominantly excitatory influence on the excitability of both oxytocinergic
and vasopressinergic neurosecretory cells (Sgro et al., 1984). Ablation of
structures in the AV3V region results in reduced secretion of both oxytocin
and vasopressin in response to a systemic hyperosmotic stimulus (Leng et
al., 1989).
1.9. Modulation of magnocellular neurosecretory activity
It is apparent that magnocellular oxytocin and vasopressin neurones are
subject to well defined forms of excitation and inhibition in terms of their
expression of firing pattern to a given physiological stimulus. Such regulation
is likely to be derived from modulation by local neurotransmitters, of ionic




The presence of cholecystokinin (CCK) as immunoreactive 'gastrin-like'
material was first demonstrated by Vanderhaeghen and colleagues
(Vanderhaeghen et al., 1975) and the majority of this 'gastrin-like' material is
present as the C-terminal octapeptide, (CCK (26-33) or CCK8S). This
peptide is widely distributed throughout the CNS (Hokfelt et al., 1988; Hokfelt
et al., 1991) and has been shown to be immunocytochemically co-localised
within magnocellular neurosecretory neurones located within the SON of the
hypothalamus (Hokfelt et al., 1988). Two types of receptor are known to exist
within rat brain (CCKA or 'peripheral' receptors and CCKB or 'central'
receptors) as demonstrated by varying sensitivities of a number of
preparations to a variety of agonists and antagonists (Innis and Snyder,
1980; Moran et al., 1986), and further verified by their recent cloning (Wank
et al., 1992).
The proposed role for CCK acting as a neurotransmitter is now well
supported since its exogenous application into the CNS is associated with
specific behavioural changes (Crawley, 1985; Moran et al., 1986) and its co-
localisation and synthesis within central neurones is associated with
functionally identified receptors (Boden and Hill, 1988a; Boden and Hill,
1988b; Jarvis et al., 1992).
CCK is able to selectively evoke release from magnocellular oxytocin
neurones via separate peripheral and central sites of action. Systemic
injections of CCK8S selectively activate oxytocin-secreting neurones and not
vasopressin neurones in a dose-dependent manner via a vagally mediated
mode of action (Verbalis et al., 1986; Verbalis et al., 1991; Hamamura et al.,
1991; Leng et al., 1991). Lesions in the vicinity of the area postrema
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attenuate this response (Carter and Lightman, 1987) and there is evidence to
suggest that the principal action of systemic CCK8S is mediated via the
nucleus tractus solitarius (NTS), which is adjacent to the area postrema
where it has an inhibitory effect on NTS spike discharges (Morin et al., 1983).
Consequently the strong noradrenergic components of the NTS which project
to the SON release noradrenaline when stimulated by systemic CCK8S, and
the noradrenaline is principally excitatory to oxytocin neurones (Yamashita et
al., 1987; Kendrick et al., 1991). In vitro electrophysiological studies clearly
demonstrate that CCK8S and associated fragmented peptides can directly
influence the excitability of magnocellular neurosecretory cells (Jarvis et al.,
1992) whilst in vitro autoradiographic studies have shown high-affinity
binding for [125I]-CCK8S in the SON which can be modulated by osmotic
activation of the hypothalamo-neurohypophysial axis (Day et al., 1989; Hinks
et al., 1993). CCK has been proposed to act as an endogenous opioid
antagonist in some systems since central administration blocks opioid
analgesia (Faris et al., 1983) whilst specific CCK receptor antagonists can
enhance morphine analgesia and attenuate development of morphine
tolerance (Dourish et al., 1990a).
Opioid peptides
Vasopressin synthesising neurones express prodynorphin mRNA
(Sherman et al., 1986) and contain prodynorphin products, including [Leu5]-
enkephalin (Seizinger et al., 1984). Osmotic activation of vasopressin
neurones results in enhanced expression of both provasopressin and
prodynorphin mRNA (Lightman and Young, 1987).
Oxytocin synthesising neurones contain [Met5]-enkephalin (an enkephalin
not contained in the prodynorphin precursor), (Martin and Voigt, 1981; Martin
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et at., 1983a). Although neurohypophysial oxytocin is depleted in response
to chronic osmotic stimuli, such stimuli have been shown to be without effect
on [Met5]-enkephalin content (Zamir et at., 1985; Nordmann et at., 1986a)
whereas content of prodynorphin derived peptides is depleted. However
[Met5]-enkephalin neurohypophysial content has been shown to be depleted
along with a simultaneous decline in oxytocin content in response to
naloxone-precipitated morphine withdrawal whilst having no effect on either
vasopressin or dynorphin content within the neurohypophysis (unpublished
observations). Furthermore immunocytochemical studies indicate that these
opioid peptides are colocalised within neurosecretory granules with their
respective neurohypophysial peptide (Martin et at., 1983a; Adachi et at.,
1985; Nordmann et at., 1986a).
Early on, opioid binding sites were observed in membranes prepared from
bovine hypophysis (Simantov and Snyder, 1977) and comparative studies
using rat brain have demonstrated that the high concentration of opioid
binding sites is located in the hypothalamus and hypophysis (Castanas et at.,
1986). Within the neurohypophysis these opioid binding sites have been
characterised as being predominantly or exclusively K-sites by various
groups (Bunn et at., 1985; Herkenham et at., 1986; Falke and Martin, 1986).
Within the hypothalamus itself both p- and K-binding sites have been shown
to be present (Mansour et at., 1986; Morris and Herz, 1986) and although
initially only K-type receptors were found to be present in the SON (Mansour
et at., 1988; Tempel and Zukin, 1987), it has since been demonstrated that
both \x- and K-types are present in this nucleus (Sumner etal., 1990).
1.10. Oxytocin and opioid interactions
In magnocellular neurosecretory cells the action potentials display a
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frequency dependent Ca2+ shoulder on the repolarisation phase both in vitro
(Bourque and Renaud, 1985b; Bourque et al., 1993) and in vivo (Renaud and
Bourque, 1989) which is most probably a primary target of action for
neurotransmitters and neuropeptides. Magnocellular oxytocin and
vasopressin secreting neurones are subject to regulation by exogenously
administered opioids and speculatively by endogenous opioids. Opioids act
both at the level of the cell bodies to reduce electrical activity (Arnauld et al.,
1983; Wakerley et al., 1983a; Inenaga et al., 1990; Pumford et al., 1991;
Bourque et al., 1993) and at the terminals in the neurohypophysis to
attenuate release into blood (Iversen et al., 1980; Bicknell and Leng, 1982;
Zhao et al., 1988: Russell et al., 1993).
In urethane-anaethetised rats, magnocellular neurosecretory neurones do
not appear to be subject to a tonically active input from endogenous opioids
since systemic administration of naloxone has very little effect on neuronal
firing rate (Shibuki et al., 1988; Bicknell et al., 1988), although naloxone does
increase release of oxytocin; indicative of it acting at the neurohypophysis.
Both acute and chronic intracerebroventricular (i.c.v.) infusion of morphine
initiate a profound inhibition of oxytocin release (Russell et al., 1989a;
Pumford et al., 1991) and in lactating rats to failure of milk let-down upon
induction of a suckling stimulus from the pups. During chronic morphine
treatment, within two days milk let-down returns and after 5 days oxytocin
release is normal (Rayner et al., 1988).
In the magnocellular oxytocin system dependence is demonstrated when a
morphine tolerant rat is administered naloxone producing a withdrawal
excitation of the neurones. This involves a large increase in neuronal firing
rate and consequently a hypersecretion of oxytocin from both the dendritic
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processes within the SON (Neumann et at., 1993) and from terminals in the
neurohypophysis (Bicknell et at., 1988). Since this action of naloxone at the
neurohypophysis does not appear to differ between morphine treated and
morphine naive animals (Russell et at., 1993) it would appear that tolerance
to and dependence upon morphine as regards release of oxytocin develops
centrally. Previous reports of i.c.v. morphine having no effect on bursting
activity of oxytocin neurones in the lactating rat (Clarke et at., 1979) can
probably be explained by a reduced sensitivity to inhibition by opioids as the
intensity of stimulation increases (Pumford et at., 1991; Pumford et at., 1993).
Earlier reports that the AV3V region provides a tonic excitatory input to
oxytocin neurones necessary for their full expression of the effects of
withdrawal have since been modified to suggest that it is at the level of the
magnocellular nuclei (both SON and PVN) themselves, or upon afferents
other than those from the AV3V region that are the sites of morphine
withdrawal with respect to hypersecretion of oxytocin (Russell et at., 1992).
By now much has been mentioned about the extensive interactions
between oxytocin, opioids and the mechanisms of tolerance and dependence
both in vitro and in vivo. The inhibitory actions of opioids on magnocellular
neurosecretory neurones and oxytocin neurones in particular certainly
provides an excellent paradigm to both study and understand these
phenomena, but what of their physiological relevance in the intact animal?
At the end of gestation in the rat, neurohypophysial content of oxytocin is
increased by approximately 30% and is depleted by the same amount
thereafter (Fuchs and Saito, 1971) whilst the pulsatile release of oxytocin into
the periphery is essential for the normal progress of parturition (Luckman et
ai, 1993). Since exogenous administration of morphine or U50,488H which
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are selective for p- and K-opioid receptors respectively, can interrupt
parturition (Gosden et al., 1985; Douglas et al., 1993) one could speculate on
numerous roles for endogenous opioids within the neurohypophysial oxytocin
system at this time. Dynorphin(1„8) which is selective for the K-receptor
(Corbett et al., 1982) and co-released with vasopressin binds to K-receptors
located on neurosecretory terminals isolated from rat neurohypophyses
(Falke et al., 1989) and inhibits stimulated release of oxytocin (Falke, 1988).
Similarly in the isolated neural lobe preparation U50,488H inhibits stimulated
release of oxytocin (Zhao et al., 1988a) although this action is less
pronounced at the end of pregnancy (Douglas et al., 1993). Consequently it
would appear that another opioid mechanism (probably related to the fa-
receptor) is responsible for the central inhibition of oxytocin release during
gestation.
Aim of thesis
This study has focussed on the relative contributions of excitatory inputs
and adaptive cellular changes, both locally within the SON and those located
perhaps within the brainstem, postulated to drive magnocellular oxytocin








Female Sprague-Dawley rats obtained from Bantin & Kingman were used
throughout this work, except where specified. They were housed under
controlled conditions, ambient temperature 21-23°C with a 12 h light/12 h
dark cycle and had free access to food (standard breeder diet) and water.




For non-recovery experiments rats were anaesthetised with urethane
(ethyl carbamate; 25% weight/volume solution, Sigma, UK). A single i.p.
(intraperitoneal) dose of 1.25 g/kg is known to produce a level of anaesthesia
which can be maintained for up to 12 h. In experiments involving the milk-
ejection reflex a lower dose of 1.1 g/kg was used since this is less likely to
impair the occurrence of the milk-ejection reflex.
2. Xylocaine
To supplement the low dose of urethane (1.1 g/kg) in experiments
involving the milk-ejection reflex animals were given the local anaesthetic
'Xylocaine 2%' (Lignocaine hydrochloride BP; Astra Pharmaceuticals Ltd,
England) sub-cutaneously at sites of surgery.
3. Ether
For recovery experiments involving the induction of morphine tolerance
and dependence rats were anaesthetised by ether inhalation (diethyl ether,
peroxide free; May & Baker, UK). The rats were anaesthetised in a glass
25
General Methods
bowl containing cotton wool soaked in ether and the level of anaesthesia
maintained throughout the period of surgery with a cotton wool plug soaked
in ether, contained in an open glass vial positioned over the rat's nose.
2.3. Surgical preparation
1. Cannulation of the femoral artery and vein
Portex cannulae (size 3FG; Portex Ltd, Kent) connected to 1 ml
polypropylene syringes (Steriseal, Worcestershire) were filled with
heparinised saline (50 units per ml isotonic, 0.9% saline). The rat was laid
flat on its back and a small horizontal incision was then made just below the
rostral left inguinal nipple. The exposed musculature and connective tissue
was then gently but firmly teased apart with blunt forceps to reveal the
femoral artery, femoral vein and nerve enclosed within a sheath of
connective tissue. This sheath was carefully opened with sharp forceps and
two silk ligatures (EP 1; Davis & Geek, Lancashire) were placed around the
vein. The distal ligature was tightened to prevent venous return. A small
incision was made proximal to this ligature and the cannula inserted
approximately 1 cm into the length of the vein at which point the proximal
ligature was tightened to prevent blood loss. The cannula was then pushed
further into the vein until it had passed under the inguinal ligament and if
blood could be drawn back the second ligature was fully tightened. The
same procedure was followed for cannulation of the femoral artery except
that the vessel was clamped rostral to the second ligature to prevent rapid
arterial blood loss when the vessel was opened for insertion of the cannula.
This clamp was removed enabling the cannula to be fully inserted into the
artery. With both cannulae tied in place the wound was closed with 2-3
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sutures (EP 2; Davis & Geek).
2. Cannulation of the mammary gland
On Day 7-13 of lactation, a day prior to experimentation, all pups but one
were separated from the mother overnight enabling the mammary glands to
engorge with milk. Depending on the experimental protocol 1-3 glands (1
abdominal and 2 inguinal) were cannulated. The teat of the mammary gland
to be cannulated was stretched and the end secured. The milk duct was
exposed and two ligatures (EP 1) placed around it. The tissue duct was
incised for the insertion of a polythene cannula (Portex; o.d. 0.96 mm) filled
with isotonic saline. The cannula was pushed in until saline passed easily
into and out of the gland and milk was seen in the cannula, at which point the
ligatures were tightened to secure the cannula. The cannula was connected
to a pressure transducer (Model P231 d; Gould Stratham Instuments Inc.)
relayed to a chart recorder (Model BS 314; Kontron Electronik, GmbH or CR
652S Recorder; J.J. Instruments Ltd, Southampton) for measurement of
intramammary pressure changes. Two hours after surgery was complete four
doses of 0.1, 0.25, 0.5 and 1.0 or 0.25, 0.5, 0.75 and 1.0 mil (milliunits)
synthetic oxytocin (Syntocinon, 10 units/ml diluted in saline to 12.5
milliunits/ml; Sandoz Pharmaceuticals, Middlesex) were each intravenously
injected as a bolus in random order 3 min apart to construct dose-response
curves for the mammary glands.
3. Induction of morphine tolerance and dependence
Female Sprague-Dawley rats (virgin or lactating) were anaesthetised with
ether and placed in a stereotaxic frame. The dorsal surface of the skull was
exposed by a skin incision along the midline and the underlying tissue
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retracted to expose bregma. Two 1.3 mm diameter holes were drilled
through the bone lateral to the cannula placement to hold two stainless steel
screws (3.2 mm x 10 BA). A 1.0 mm diameter guide hole was drilled 2 mm
right lateral and 3 mm posterior to bregma through which to introduce the
infusion cannula. The infusion assembly consisted of a stainless steel
cannula made from a 1 cm length of 21 gauge tubing bent at 90° 4.5 mm from
its tip and bevelled at 45°. This was attached to an 18 cm length of coiled
polythene tubing (1.2 mm o.d., 0.76 mm i.d.; Portex Ltd, Kent) which was
attached temporarily at the other end to a 100 pi microsyringe. The whole
assembly was then positioned close to the skull and the infusion cannula
inserted vertically through the guide hole so that its tip lay in the right lateral
cerebral ventricle, 4.0 mm below the skull surface. The cannula was held
firmly in place by a mound of dental acrylic (Simplex Rapid; Associated
Dental Products Ltd, Swindon) bonded to the two stainless steel screws
which were anchored to the skull. An osmotic mini-pump (1 pl/h, Alzet 2001;
Alza Corp.) was placed subcutaneously in the subscapular region, the
microsyringe detached and the cannula connected to the mini-pump. Three
reverse sutures were used to close the wound.
Morphine sulphate B.P. was dissolved in sterile pyrogen-free water and
filtered (Millex - GV, 0.22 pm; Millipore S.A., Molsheim, France) to give a
stock solution of 50 mg/ml. All dilutions were made from this stock solution
which was kept at 4°C. The osmotic mini-pump was filled with the stock
solution of morphine sulphate and left to prime in 0.9% saline overnight at
room temperature. Prior to insertion the infusion cannula was filled with 40 pi
of a 20 mg/ml morphine solution, a 1 pi air bubble and then 40 pi of a 10
mg/ml morphine solution. Thus the infusion system was filled with morphine
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sulphate solution in increasing concentration (10 pg/h for 40 h, 20 pg/h for 40
h and 50 pg/h for 40 h) in order to increase the degree of tolerance achieved
over 5 days (Bicknell et al., 1988).
4. Blood sampling
In all experiments each blood sample taken was of 0.3 ml volume. The
sample was placed into a pre-numbered 1.5 ml polypropylene tube
(Eppendorf; Hamburg, Germany), chilled and spun for 2-3 min at 13,000 g
(MSE Micro Centaur). A 150 pi aliquot of oxytocin-containing plasma could
then be pipetted off and stored immediately on ice. The remaining red blood
cells were then resuspended in 150 pi warmed isotonic saline prior to
reinjection after the next blood sample had been obtained. In all experiments
0.3 ml isotonic saline was injected straight after the first blood sample had
been taken in order to maintain blood volume. At the end of the experiment
samples were stored at -20°C prior to radioimmunoassay for oxytocin
content.
2.4. Radioimmunoassay for oxytocin
1. Introduction
The radioimmunoassay used to determine oxytocin content (pg/ml) of
unextracted rat plasma samples was a modified method from that of Higuchi
et al., (1985a). The specificity of the assay was determined by comparing
the inhibition of binding of 125l-labelled oxytocin to the first antibody with that
of various peptides including arginine-vasopressin and arginine-vasotocin.
Melanocyte stimulating hormone-release inhibiting factor had the highest
cross-reactivity with the raised antibody at 0.0017%. Recovery of oxytocin
after the antibody had been incubated with plasma from non-pregnant or
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pregnant rats was 94-107%.
First antibody was added to solutions containing a fixed amount of 125l-
oxytocin and either rat plasma aliquots of unknown concentration or
aliquoted oxytocin of known concentration (for preparation of the standard
curve) in phosphate buffer. Mixtures were left to equilibrate after which the
proportion of 125l-oxytocin to oxytocin bound to first antibody reflects the
concentration of oxytocin present. This conjugate was then precipitated from
solution using a second antibody which binds to the first antibody. To further
aid precipitation a suspension of white Pansorbin cells was added prior to
centrifugation. The supernatant was then aspirated and the radioactivity of
the precipitate measured. Radioactivity of the tubes to which known amounts
of oxytocin had been added was then used to compile a standard curve
against which concentration of the unknown samples could be determined.
2. Materials
Phosphate buffer
Phosphate buffer (pH 7.0) was prepared in double distilled de-ionised
water containing;
0.025% (w/vol) sodium dihydrogen orthophosphate NaH2P04.2H20 (BDH)
0.119% (w/vol) disodium hydrogen orthophosphate Na2HP04 (BDH)
0.1% (w/vol) sodium azide NaN3 (BDH)
0.5% (w/vol) bovine serum albumin BSA (RIA grade) (Sigma)
(BDH Ltd, Dorset. Sigma Chemical Company Ltd, Dorset).
First antibody buffer
Frozen-stored normal rabbit serum was thawed and diluted (usually 1:
400) in phosphate buffer to aid the binding of the second antibody. This
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concentration was the lowest concentration of normal rabbit serum that
produced the highest % binding of 125l-oxytocin in the precipitates and was
determined from trial assays containing standards only.
First antibody
Rabbit anti-oxytocin antibody THF-3 was kindly donated by Dr. T. Higuchi,
stored diluted at 1: 200 in phosphate buffer at -20°C and used at a final
concentration of 1: 120,000 in phosphate buffer.
Second antibody
Donkey anti-rabbit serum was obtained from IDS, Tyne and Wear, stored
at 4°C and diluted to 1: 100 in phosphate buffer.
1251-oxytocin
lodinated oxytocin was obtained from the AFRC Babraham Institute,
Cambridge, stored at -20°C and diluted in phosphate buffer to a
concentration calculated to give 6-8000 cpm/50 pi aliquot.
Standardised Pansorbin cells
These were supplied as a 10% (w/vol) solution in phosphate buffered
saline containing 0.1% (w/vol ) sodium azide, stored at 4°C, diluted 1: 25 in
phosphate buffer and obtained from Novabiochem (UK) Ltd, Nottingham.
3. Methods
In order to determine the unknown oxytocin concentration of rat plasma
samples a standard curve of precipitated radioactivity versus oxytocin
concentration was compiled. Previously lyophilised stock oxytocin aliquots
containing 10 pg oxytocin (Sigma) stored at -70°C were used. On the
morning of assay phosphate buffer was added to the lyophilised oxytocin to
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obtain a top standard dilution of 2500 pg/ml. A further ten serial doubling
dilutions of this solution yielded a range of concentrations from 2.44-2500
pg/ml, which were then used to compile the standard curve. Three further
standards were also required for preparation of the curve:
TC, contained an aliquot of 125l-oxytocin alone to determine Total Count of
radioactivity added.
NSB, contained aliquots of 125l-oxytocin and second antibody to determine
Non-Specific Binding of radioactivity.
B0, contained aliquots of1251-oxytocin, first and second antibody to determine
the maximum percentage binding of radioactivity.
Next, experimental plasma samples were removed from the freezer as
required, thawed to 4°C and centrifuged for 1-2 min at 15,000 g (Haemofuge,
Heraeus-Christ, Osterode, Germany) before being aliquoted into the
appropriate tube. The assay was performed in pre-numbered 0.75 ml plastic
tubes (LP2 tubes, Luckham Ltd, Sussex). Standards were assayed in
triplicate and intraassay, interassay standards and rat plasma samples in
duplicate. Any samples which were expected to contain a concentration of
oxytocin in excess of 500 pg/ml were assayed also, diluted appropriately
(usually 1: 3) in phosphate buffer. The protocol for the addition of reagents
to the tubes is shown in Table 2.4.3.1. overleaf:
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Day 1 Day 2 Day 5 Day 7
TC: nothing 50 pi 125|_ 100 pi antibody 50pl pansorbin
NSB: 100 pi RIA oxytocin was buffer and 100 pi cells were
buffer added to all second antibody added to all
B0: 50 pi first tubes. were added to all tubes except
antibody solution tubes except TC. TC.
Standards/samples:





After addition of reagents on the appropriate day, tubes were vortex
mixed, covered in aluminium foil and left for the specified time at 4°C. On the
final day after all tubes had been vortex mixed (except TC) they were then
centrifuged for 30 min at 3,000 rpm and 4°C (Minifuge 2, Heraeus-Christ,
Germany). The resulting supernatant was carefully aspirated and the
radioactivity of each suspended pellet then measured for 3 min in a gamma
scintillation counter (LKB-Wallac 1272 Clinigamma, Wallac Oy, 20101 Turku
10, Finland).
4. Calculation of radioimmunoassay results
Assay Sensitivity
The sensitivity of an assay, which provides information as to the minimum
acceptable peptide content per sample was determined using the following
equation;
[Bn - (2 x SD) - NSB]
B0-NSB
where SD is the standard deviation around the mean of B0. The value
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obtained from this equation was then compared against a series of values for
% B0 radioactivity bound by each standard of known concentration. The %
B0 radioactivity bound by each standard (2.4-2500 pg/ml) was calculated
from the equation;
mean standard cpm - (2 x SD Bn) - NSB
B0-NSB
Assay sensitivity was taken at the point where the value obtained using
the first equation was greater than those values obtained for the standards
using the second equation and converted to a concentration in pg/ml.
Inter- and intraassav variation
Variability between samples of comparable experiments from different
assays could be determined from known concentrations of hormone which
were stored in aliquots at -20°C, and for each assay six duplicates of each
concentration (three at the beginning of the assay and three at the end) were
included. This also allowed any intraassay variation to be determined. In
practise, all samples from any experiment were measured in a single assay.
2.5. Microdialysis
1. Introduction
The microdialysis sampling technique can be used for the in vivo
measurement of release of specific neurotransmitters during particular
behavioural and neuroendocrine events. In the context of this work
microdialysis has been used to sample oxytocin release within the supraoptic
nucleus upon a particular challenge to the magnocellular oxytocin system.
The microdialysis probe has a length of semi-permeable tubing connected to
separate inflow and outflow cannulae. Artificial cerebrospinal fluid (aCSF)
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can then be pumped through the closed environment of the probe and as the
membrane is semi-permeable and the concentrations of peptide in the tissue
are greater than in the dialysate, a concentration gradient is established
enabling small amounts of peptide to pass from the extracellular
compartment across the membrane and into the aCSF pumped through the
probe. The sample can then be collected at the outflow of the probe and
peptide content determined by radioimmunoassay.
2. Probe Specifications
The dialysis probe consisted of a 1.3 mm U-shaped dialysis fibre
(molecular weight cut-off 5 kDa, 3 mm total length and 0.2 mm outside
diameter; probe diameter 1 mm), glued into the ends of two pieces of parallel
attached 24-gauge stainless steel tubing connected to a syringe pump (flow
rate 3 pl/min) via polythene tubing (PE 20; Beckton Dickinson, New Jersey,
USA). The microdialysis fibre was threaded with a fine stainless steel wire to
strengthen and guide the fibre through the brain tissue.
In vitro recovery of oxytocin has been tested and estimated previously
(Neumann et ai, 1993). Typical recovery of oxytocin for these microdialysis
probes, which were similar to the those used in the studies outlined here
were 1.99% for [3H]oxytocin and 1.62% for [125l]oxytocin.
3. aCSF composition
The probe was perfused with either normal aCSF [pH 7.2, (mM); NaCI
138, KCI 3.36, NaHC03 9.52, Na2HP04 0.49, urea 2.16, CaCI2 1.26, MgCI2
1.18] or aCSF made hypertonic (0.5 M) by adding NaCI.
4. Surgery
Lactating or virgin female rats were anaesthetised with ether or urethane
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depending on whether the experimental protocol was of a recoverable or
non-recoverable nature respectively. Animals were placed in a stereotaxic
frame, holes drilled through the skull and a small slit was made in the dura
using a sharp needle. Microdialysis probes were positioned into the left or
both left and right supraoptic nuclei 1.1 mm posterior to bregma, 1.8 mm
lateral to midline and 9.1 mm below the surface of the skull. They were then
anchored to the skull with two stainless steel screws and dental acrylic.
5. Histological and morphological verification of probe location
At the end of an experiment brains were removed, fixed in formal saline
and serial frontal 60 pm Vibratome sections cut to locate the placement of the
microdialysis probe histologically (see Fig 2.5.5.1.). In addition either during
or at the end of an experiment direct hyperosmotic stimulation (0.5 M NaCI
aCSF) of the perfused area via the probe was used in order to verify its
placement in the region of the SON. It has previously been demonstrated
that the 'rebound effect' (where oxytocin content increases in the dialysate
containing isotonic aCSF following hyperosmotic stimulation) is a reliable
indicator of probe placement within the SON (Neumann et al., 1993). Both
methods were analysed independently and then taken in conjunction to
positively verify probe placement within the SON.
6. Radioimmunoassay
Acidified (10 pi 0.1 M HCI) microdialysates were lyophilised and oxytocin
content measured without extraction by specific radioimmunoassay as
previously described (Neumann et al., 1993). Typical assay sensitivity was
0.1 pg at 95% binding (50% inhibition occurring at approximately 4.0 pg).
The intraassay coefficient of variation was <10%. To eliminate interassay
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variation, all dialysates to be compared were measured in the same assay.
Oxytocin radioimmunoassays of microdialysates were expertly carried out by
Frau Brigitte Wolff at the University of Leipzig, Germany.
2.6 Drugs
Morphine sulphate B.P. was obtained from Edinburgh Royal Infirmary.
CCK8S (26-33) was purchased from Palliard (Palliard Chemical Co,
Sudbury, UK) and from Bachem (Bachem, Saffron Walden, UK).
± Verapamil hydrochloride was purchased from Sigma.
Naloxone hydrochloride was purchased from Sigma.
U50, 488H was purchased from Sigma.
2.7. Statistics
Unless otherwise stated, the non-parametric Wilcoxon Paired test was
used to test for statistical differences within groups of animals and the Mann-
Whitney U-test for differences between groups of animals. p<0.05 was




Figure (2.5.5.1.)- Representative 60 pm coronal brain section showing
bilateral location of microdialysis probe tracts (long arrows) within or
immediately adjacent to the SON (short arrows). Scale bar=1mm.
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BLOCKER VERAPAMIL ON SELECTED STIMULI TO OXYTOCIN RELEASE
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3.1. INTRODUCTION
Calcium ions (Ca2+) play a fundamental role in the regulation of synaptic
processing of information which is primarily mediated by exocytotic release of
various neurotransmitters (Perney et at., 1986). The role of Ca2+ in cellular
functioning cannot be overemphasised, since it serves to regulate enzymatic
activity such as kinases and phosphatases, ion channel function (Blatz and
Magelby, 1987) and expression of immediate early genes such as c-fos
(Morgan and Curran, 1991).
Ca2+ homeostasis
Intracellular Ca2+ acts as a second messenger and transduces electrical
activity in neurones into biochemical events (McBurney and Neering, 1987;
Scott et ai, 1991). There are two mechanisms which when activated,
produce an increase in intracellular Ca2+ concentration. The first involves
Ca2+ entry from the extracellular enviroment via voltage-activated Ca2+
channels, ligand gated channels and second messenger operated channels;
the result is membrane depolarisation and activation of Ca2+ dependent
processes. The second involves release of Ca2+ from intracellular stores
(mitochondria, endoplasmic reticulum) which may be activated directly by
extracellular Ca2+ or indirectly via ligand-receptor binding and the associated
post-effetcor signal transduction mechanism (G proteins), giving rise to
intracellular messengers and further processing of information. The resting
intracellular Ca2+ concentration may be 104 fold lower than the immediate
extracellular concentration. Intracellular Ca2+ is kept low by Ca2+ binding
buffering proteins (e.g. calmodulin, parvalbumin) which vary in concentration
within different tissues, uptake into Ca2+ stores and export back into the
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extracellular enviroment by cation exchange and active transport pumps.
It is hardly surprising therefore given this range of functions which Ca2+
has within a cell, that multiple types of Ca2+ channels can coexist within the
same cell. Four types of Ca2+ channel have been identified according to their
biophysical properties (Tsien et al., 1991). It is widely accepted that there are
two classes of voltage-activated Ca2+ channels as defined by the pattern of
channel activation: low voltage-activated, also termed T (transient) and high
voltage-activated channels, which include the remaining three subclasses; L
(long-lasting), N (neuronal) and P (Purkinje cell), (Bertolino and Llinas, 1992;
Catterall and Striessnig, 1992). More recently a high voltage-activated Ca2+
channel with novel functional properties has been identified in rat cerebellar
granule neurones (Ellinor et al., 1993).
Characteristics of L-type channels
L-type Ca2+ channels are not strongly inactivated by depolarisation to -
40mV, have the largest single-channel conductance among the voltage-
activated Ca2+ channels and have both a slow voltage-dependent, and a
more prominent Ca2+ dependent mechanism of inactivation.
Studies with monoclonal antibodies specific for the L-type Ca2+ channel
have revealed a wide distribution throughout the CNS. Microfluorometric
imaging studies have reported their localisation on the cell bodies and
dendrites of neurones (Thayer et al., 1987).
The properties of voltage-activated L-type Ca2+ channels are altered by a
number of Ca2+ channel antagonist drugs. There are two main groups- the
phenylalkylamines typified by verapamil and the dihydropyridines typified by
nifedipine and nitrendipine (Catterall and Streissnig, 1992). The
dihydropyridines are modulators of the L-type Ca2+ channel exhibiting
40
Chapter 3
antagonistic and agonist modes of action. They bind with high affinity to
inactivate Ca2+ channels and bind to their receptor site from the extracellular
surface of the Ca2+ channel. The phenylalkylamines have a more profound
inhibitory effect on Ca2+ channel function as the channels become more
activated by depolarising pulses, indicating that they gain more rapid access
to the receptor site when the channel is open (Lee and Tsien, 1983). It has
been suggested that the phenylalkylamines bind to an intracellular binding
site to occlude the channel pore (Catterall and Striessnig, 1992).
The L-type Ca2+ channel is present in high concentrations in the
transverse tubules of vertebrate skeletal muscle, which has enabled their
purification using high-affinity dihydropyridine Ca2+ channel antagonists
which isolate the protein constituents of the channel. These channels are
composed of five protein subunits. The subunit is the central functional
component of the unit and contains the dihydropyridine and phenylalkylamine
binding site (Tanabe et al., 1987). asubunits are present in a complex with
four remaining subunits designated a2, (3, y and 8. There are in turn, five
major classes of a1 subunits described in mammalian neurones (termed A, B,
C, D and E), and functional studies are beginning to associate the
biophysical properties of these cloned Ca2+ subunits with the individual Ca2+
channel types previously mentioned (Zhang et al., 1993).
Opioid receptor interaction with Ca2+ channels
A number of studies have described the interaction of p-opioid agonists
such as morphine with Ca2+ channels in vitro (North, 1986; Pelligrini-
Giampietro et al., 1988; Kennedy and Henderson, 1991; Kennedy and
Henderson, 1992; Carter and Medzihradsky, 1993) and in vivo (Bongianni et
al., 1986; Baeyens et al., 1987; Barrios and Baeyens, 1991). Acute exposure
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to opioids in vivo has been shown to decrease the number of dihydropyridine
binding sites within regions of rat brain (Gandhi and Ross, 1988) which is
consistent with their ability to reduce Ca2+ conductance by direct (North,
1986) and indirect (North, 1989) modes of action; this latter mechanism
involves direct activation of a K+ conductance with sustained
hyperpolarisation of the neurone, and as a result the neurone may reduce
the level of Ca2+ in the cell body thereby slowing gene transcription and
reducing turnover of essential transmitters, receptors and channels. Chronic
exposure to opiates in vivo in the morphine dependent rat on the other hand,
increases the number of dihydropyridine binding sites in the brain
(Ramkumar and El-Fakahany, 1988) which could reflect an increase in the
number and/or affinity of L-type Ca2+ channels.
Numerous behavioural studies have demonstrated that dihydropyridine L-
type Ca2+ channel inhibitors and the phenylalkylamine verapamil, can inhibit
the expression of several naloxone precipitated withdrawal signs in morphine
dependent rats (Bongianni et a!., 1986; Baeyens et at, 1987) and mice
(Barrios and Baeyens, 1991). Related in vitro work has corroborated these
findings where Ca2+ channel inhibitors have been shown to inhibit naloxone-
induced release of [3H]noradrenaline from cortical slices of morphine
dependent rats (Pelligrini-Giampietro et ai., 1988). This Ca2+ sensitive
component is absent in morphine naive rats. The ability of verapamil to
inhibit the expression of withdrawal signs in morphine dependent rats would
appear to depend on route of administration. I.c.v. administration of
verapamil has been reported to reduce body weight loss and jumping
behaviour whereas diarrhoetic weight loss was only prevented after
intraperitoneal injection (Baeyens et a!., 1987). Such actions are supported
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by the autoradiographic localisation of centrally located Ca2+ channels
(Gould et al., 1985; Ramkumar and El-Fakahany, 1988). Thus the relative
efficacy of verapamil in differentially inhibiting behavioural signs associated
with withdrawal would appear to depend upon route of administration.
In cultured SH-SY5Y human neuroblastoma cells chronic exposure to
morphine has been shown to induce tolerance to p-opioid receptor inhibition
of an N-type voltage-dependent Ca2+ channel current (Kennedy and
Henderson, 1991), although in this cell line morphine does not induce
dependence by changing either N- or L-type Ca2+ channel activity (Kennedy
and Henderson, 1992). The absence of morphine dependence in these cells
may result from the inability of these cells to express the intracellular
mechanisms associated with dependence or may be due to lack of functional
synapses between the cells (Kennedy and Henderson, 1992). This suggests
that tolerance and dependence to opioids can evolve as separate entities
within neurones, and that the integration of a functional neuronal network
would appear to be required for the expression of dependence in neuronal
populations.
Effector responses mediated by ion channels can be directly regulated
by G proteins. The bacterial exotoxin pertussis toxin blocks the receptor
mediated activation of certain G proteins such as G, and G0 through the ADP
ribosylation of the a-subunit. This toxin interferes with the inhibitory actions
of the 5-opioid agonist D-Ala-D-Leu enkephalin on Ca2+ currents recorded
from NG108-15 cells (Hescheler et al., 1987). Evidence from various
preparations suggests that Ca2+ current inhibition by activation of opioid
receptors involves a pertussis toxin sensitive G protein (Surprenant et al.,
1990; Seward et al., 1991). Tolerance to morphine in SH-SY5Y cells may be
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due to an uncoupling of p-receptors from associated G proteins enabling it to
develop at the level of the single neurone (Kennedy and Henderson, 1991).
The inhibitory actions of morphine on magnocellular oxytocin neurone activity
would appear to involve mediation by Gj and G0 proteins (Pumford et al.,
1993) which may affect Ca2+ conductance within these cells.
Ca2+ channels in magnocellular neurosecretory neurones
Magnocellular neurosecretory cells display a frequency dependent Ca2+
shoulder on the repolarisation phase of the action potential both in vivo
(Renaud and Bourque, 1989) and in vitro (Bourque and Renaud, 1985b;
Bourque et at., 1993). A similar mechanism may occur at the terminal level in
the neurohypophysis, accounting for the frequency and pattern dependent
release of neuropeptide observed in the isolated neural lobe preparation
(Bicknell, 1988). The cell bodies of magnocellular neurosecretory cells
express T-, N-, and L-like Ca2+ currents whereas isolated nerve terminals
would appear not to express a T-type current suggesting that the cell bodies
and terminals of these cells can differentially regulate the expression of Ca2+
channels (Fisher et a/., 1992). Other experiments have shown that a major
part of the inward Ca2+ current during sustained depolarisation of
neurosecretosomes with K+ (Kato et al., 1992) is carried by dihydropyridine
sensitive L-type Ca2+ channels (Tsien et al., 1988). N-type Ca2+ channels
appear to mediate the majority of Ca2+ entry and secretion when
depolarisation is evoked by Na+ action potentials in the neural lobe
preparation (Von Spreckelsen et al., 1990).
In view of the roles undertaken by Ca2+ within a cell one might expect
that i.c.v. injection of verapamil would have profound effects on neuronal
activity, and on established oxytocin release in particular. This appears not
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to have been reported thus far as regards such stimuli, especially withdrawal
excitation of oxytocin neurones in morphine dependent rats. It may well be
that the development of tolerance and dependence to opiates in SON
oxytocin neurones is mediated primarily by changes in Ca2+ channels on
these neurones. Therefore the actions of verapamil were studied in
morphine dependent and morphine naive rats on 1) naloxone-induced
release of oxytocin both within the SON and from the neurohypophysis into
blood measured by microdialysis and blood sampling 2) on oxytocin release
into blood stimulated by systemic CCK8S and 3) on suckling-induced
oxytocin release measured by simultaneous microdialysis of the SON and
intramammary pressure changes to examine the role played by L-type Ca2+
channels in the regulation of magnocellular oxytocin neurones.
Since magnocellular neurones appear to differentially regulate the
expression of Ca2+ channels within the SON and the neurohypophysis, and
the ability of verapamil to attenuate specific behavioural withdrawal signs
appears to depend on route of administration, it was also decided to conduct
a series of experiments which could localise the site of action of verapamil.
Therefore neural stalk stimulation at a frequency and magnitude within the
range elicited by bursting activity of oxytocin neurones during the milk-
ejection reflex (Russell et ai, 1993) was utilised and the corresponding
intramammary pressure recordings monitored to determine the effect of
centrally administered verapamil on this response. Finally, use of an in vivo
electrophysiological approach (Leng, 1981) enabled extracellular recordings
from supraoptic magnocellular putative oxytocin neurones exposed by ventral
surgery to be made, giving a direct indication as to whether the attenuation of
withdrawal, induced by verapamil is peripherally or centrally mediated.
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3.2. MATERIALS AND METHODS
3.2.1.1.c.v. verapamil on withdrawal hypersecretion of oxytocin
1. Animals
Virgin female Sprague-Dawley rats ( body weight mean ± SEM; 268 ± 4 g,
n=14) were used, housed singly with access to food and water ad libitum on
a 12 h light/dark cycle at an ambient temperature of 21-23°C.
2. Intracerebroventricular (i.c.v.) infusion
Under ether anaesthesia rats were implanted with an i.c.v. cannula into
the right lateral cerebral ventricle, attached to an infusion assembly
consisting of a polythene cannula and osmotic mini-pump (Alzet 2001, Alza
Corp.), which was to deliver morphine over 5 days in increasing dose (10
pg/h for 40 h, 20 pg/h for 40 h and 50 pg/h for 40 h; see General Methods,
section 2.3.3. for full details). A guide cannula (22ga, C313G Plastics One
Inc, USA) was also inserted (1.6 mm lateral and 0.6 mm posterior to bregma
for i.c.v. injection of verapamil (160 pg/5 pi 0.9% isotonic saline) or vehicle
and sealed with a dummy cannula of wire until the day of the experiment.
3. Blood sampling/injection procedure
On the morning of the experiment, 5 days after implantation of i.c.v.
cannulae, rats from both treatment groups were anaesthetised with urethane
(1.25 g/kg; 25% w/vol, i.p.). The femoral artery and vein were then
cannulated for withdrawal of blood samples and injection of drugs (see
General Methods, section 2.3.1.). Upon completion of surgery a 2 h
equilibration period enabled effects of operative stress to subside. Rats were
randomly assigned to the control or experimental groups (n=7 for each
group). After a basal sample had been obtained sample 2 was taken 10 min
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later, and immediately followed with an i.e.v. injection of verapamil or vehicle
and 10 min later the third sample was followed by an i.v. injection of
naloxone. Finally two samples were taken 5 and 20 min after injection of
naloxone. Blood samples were of 0.3 ml volume. A 150 pi aliquot of plasma
was removed and stored immediately on ice. The remaining red blood cells
were then resuspended in 150 pi warmed isotonic saline prior to reinjection
after the next blood sample had been obtained. At the end of the experiment
samples were removed and stored at -20°C ready for radioimmunoassay for
oxytocin content (see General Methods, section 2.4.).
3.2.2. I.c.v. verapamil on naloxone-stimulated release of oxytocin in
normal rats
1. Animals
Virgin female Sprague-Dawley rats (254 ± 3 g, n=16) housed under
standard conditions were anaesthetised with urethane (ethyl carbamate, 1.25
g/kg i.p.) and the femoral artery and vein were cannulated for blood sampling
and injection of drug. Animals were then placed in a stereotaxic frame
(Stoelting) and a midline skin incision over the skull made and the skin
retracted. The skull surface was levelled between lambda and bregma and a
guide cannula inserted (1.6 mm lateral and 0.6 mm posterior to bregma) for
1.c.v. injection of verapamil (160 pg) or vehicle (5 pi isotonic saline) and
sealed with a dummy cannula of wire until the start of the experiment.
2. Blood sampling/injection procedure
The protocol used was the same as outlined previously in section 3.2.1.3.
except that a second i.c.v. injection of either verapamil or vehicle was given
10 min immediately after the fifth blood sample and 10 min before an i.v.
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injection of CCK8S (20 pg/kg). A final blood sample was taken 5 min after
the injection of CCK8S.
3.2.3. Effect of i.c.v. verapamil on central and peripheral oxytocin
release during naloxone-induced morphine withdrawal
1. Animals
Virgin female Sprague-Dawley rats (275 ± 3 g, n=13) under ether
anaesthesia were implanted with i.c.v. cannulae for infusion of morphine
sulphate over 5 days and acute injection of either verapamil (160 pg/5pl) or
vehicle on the day of experiment (see section 3.2.2.). After 5 days rats were
anaesthetised with urethane (1.25 g/kg) and the left femoral artery and vein
were cannulated for withdrawal of blood and injection of drug respectively.
Rats were then placed in a stereotaxic frame and a U-shaped microdialysis
probe implanted into the right SON, 1.8 mm lateral, 1.0 mm posterior to
bregma and 9.1 mm below the skull surface (see General Methods, section
2.5.4).
2. Dialvsate/blood sampling
After a first 30 min dialysate had been discarded, six more consecutive 30
min dialysates were collected via the microdialysis probe. At the end of the
first collection proper, verapamil (160 pg/5pl) or vehicle was injected i.c.v.
and 5 min later naloxone (5 mg/kg) was injected i.v., immediately after which
the second microdialysis collection was started. After the third perfusion with
aCSF, the fourth perfusion was with aCSF made hypertonic by adding 0.5 M
NaCI followed by the fifth and sixth perfusions with normal aCSF. Blood
samples were taken 5 min before i.c.v. injection of verapamil or vehicle and 5
min after injection of i.v. naloxone. The separated plasma was stored on ice
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and then at -20°C ready for radioimmunoassay for oxytocin content as
previously described (General Methods, section 2.4.).
3.2.4. Effect of i.c.v. verapamil on CCK8S-stimulated oxytocin release
1. Animals
Virgin female Sprague-Dawley rats housed under standard conditions
(261 ± 3 g, n=31) were anaesthetised with urethane (1.25 g/kg) and the left
femoral artery and vein were cannulated for withdrawal of blood and injection
of drug, and return of resuspended red blood cells. A guide cannula was
stereotaxically implanted as described in section 3.2.2.1.
2. Blood sampling/injection procedure
CCK8S (20 pg/kg; i.v.) was given directly after the first blood sample.
After second and third blood samples had been taken 5 and 25 min after
CCK8S, the rats received an i.c.v. injection of either verapamil (160 pg/5pl)
or vehicle and a fourth blood sample was taken 10 min later. A second
injection of CCK8S was given at this point, 5 min before the next blood
sample. Rats which had previously been treated with verapamil or vehicle
were given a second similar i.c.v. injection immediately after the sixth blood
sample had been obtained at t=60 min. A seventh blood sample was taken
10 min later before both groups of rats were given an i.p. injection of 1.5 M
NaCI (4 ml/kg) and the time course of this response followed with three more
blood samples taken at 10 min intervals.
3.2.5. Effect of i.c.v. verapamil on suckling-stimulated central oxytocin
release in the lactating rat
1. Animals
Lactating Sprague-Dawley rats (302-373 g, n=12) were used. These
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animals were day 7 to 13 post partum and had been housed with their litter,
with free access to food (standard breeder diet) and water under standard
conditions (see General Methods, section 2.1.). On the evening prior to
experimentation all but one of the pups were removed from the mothers
overnight, to ensure that the pups would be hungry enough to suckle and the
mammary glands engorged the following day. The mother was
anaesthetised with a low dose of urethane (ethyl carbamate, 1.1 g/kg i.p.)
since level of anaesthesia can interfere with the milk-ejection reflex. This
was supplemented with local anaesthetic (Xylocaine 2%; Lignocaine
hydrochloride BP) at sites of surgery. The distal right inguinal mammary
gland was cannulated for measurement of intramammary pressure via a
pressure transducer relayed to a chart recorder (see General Methods,
section 2.3.2.). The left jugular vein was cannulated for i.v. bolus injection of
oxytocin 0.1, 0.25, 0.5 and 1.0 mil (12.5 mil/ml 0.9% saline; Syntocinon)
each separated by at least 3 min to give mammary gland responses enabling
a dose-response curve to be obtained.
A U-shaped microdialysis probe (5 kDa cut-off) was lowered
stereotaxically into the right SON (1.8 mm lateral, 1.0 mm posterior to
bregma and 9.1 mm below the skull surface) and a guide cannula was
implanted (1.6 mm lateral, 0.6 mm posterior to bregma) for i.e.v.
administration of verapamil (160 pg) or vehicle (5 pi 0.9% NaCI).
2. Microdialvsis sampling/injection procedure
Eight consecutive 30 min dialysates were collected via the microdialysis
probe after an initial 30 min dialysate had been discarded. Synthetic
oxytocin was given i.v. during the second perfusion as described, before the
third perfusion with normal aCSF. After the third microdialysis collection the
50
Chapter 3
pups which had been separated overnight were attached to the nipples and
allowed to suckle to initiate the milk-ejection reflex. When a first mammary
gland milk-ejection response had been observed verapamil or vehicle was
injected i.e.v. and 5 min later the fourth microdialysis perfusion was started.
After the fifth dialysate had been collected, the pups were removed from the
nipples prior to collection of a sixth post-suckling dialysate. With the seventh
perfusion the aCSF contained 0.5 M NaCI before a final 30 min perfusion
with normal aCSF.
As well as perfusing the SON in order to quantify central oxytocin release,
a count of milk-ejections was also made during the 30 min periods of the
fourth and fifth perfusions to give an on-line indication as to whether i.c.v.
verapamil was capable of attenuating the occurence of the milk-ejection
reflex which is related to release of oxytocin within the SON (Moos et at.,
1989).
Histological verification of the microdialysis probe placement was carried
out at the end of the experiment as previously described (General Methods,
section 2.5.5.)
3.2.6. Effect of i.c.v. verapamil on oxytocin secretion evoked by neural
stalk stimulation
1. Animals
Lactating Sprague-Dawley rats (day 7 to 13 post partum; 391 ± 9 g, n=4)
were housed with litter and free access to food (standard breeder diet) and
water under standard conditions (see General Methods, Chapter 2.1.). On





On the morning of experimentation the remaining pup was removed and
the mother was anaesthetised with a reduced dose of urethane (1.1 g/kg)
and supplemented with Xylocaine (2%) at sites of surgery. One abdominal
mammary gland milk duct and two inguinal milk ducts were cannulated for
measurement of intramammary pressure (see General Methods, Chapter
2.3.2.). The left femoral vein was cannulated for i.v. injection of oxytocin.
The rat was then placed in a stereotaxic frame and a midline skin incision
made. The skull surface was levelled between lambda and bregma and a
guide cannula inserted (1.6 mm lateral and 0.6 mm posterior to bregma) for
i.c.v. injection of verapamil (160 pig/5pil). This was fixed in position with a
mound of dental cement before drilling a second hole in the skull 4.0 mm
rostral to lambda through which to introduce the stimulating electrode. The
bipolar stimulating electrode (SNEX 200; Clarke Electrochemical
Instruments, Reading) was initially lowered 10.5 mm below the skull surface
and subsequently moved in 0.1 mm gradations to deliver from conventional
equipment, matched biphasic square-wave D.C. pulses (0.5 mA peak-to-
peak, 1.0 ms duration, 50 Hz) in trains of 60-150 pulses. The stimulating
electrode was judged to be resting on the neural stalk when a depth was
reached which provided an optimal intramammary pressure response to one
of the lower stimulation parameters.
3. Injection procedure
The rat was left for 1 h and then a series of pulse trains alternated with
bolus i.v. injection of 0.25, 0.5, 0.75 or 1.0 mil oxytocin (12.5 mil/ml 0.9%
saline; Syntocinon), each separated by approximately 3 min, were given at
least twice to elicit mammary gland responses. I.c.v. verapamil (160 pg/5pl)
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was then injected and the cycles of stalk stimulation and i.v. bolus injection of
oxytocin repeated using parameters which were most likely to be affected by
verapamil. In two animals i.c.v. verapamil injection and the following cycle of
stalk stimulations and oxytocin injections was repeated twice.
4. Histological verification of electrode placement
Location of the stimulating electrode was further confirmed at the end of
the experiment by passing unipolar current as a continuous train of pulses
(0.5 mA peak-to-peak, 1.0 ms duration, 100 Hz) for 60 s (reversing polarity
after 30 s) to deposit ferrous ions from the electrode tip. The brains including
the neural stalks were then removed and fixed in 10% formal saline
containing potassium ferro- and ferri-cyanide (0.4 mM and 0.5 mM
respectively) for 2-3 days to develop the Prussian Blue reaction. Using a
binocular dissecting microscope the ferrous ions were visualised as a blue
spot at the tip of the electrode and in all cases the electrode tips were in the
neural stalk.
3.2.7. Effect of i.c.v. verapamil on electrical activity of oxytocin
neurones stimulated by naloxone-induced morphine withdrawal
1. Animals
Under ether anaesthesia virgin female Sprague-Dawley rats (265-340 g,
n=5) were implanted with an i.c.v. cannula into the right lateral cerebral
ventricle, which was attached to an infusion assembly consisting of a
polythene cannula and osmotic mini-pump (Alzet 2001, Alza Corp.), which
was to deliver morphine over 5 days in increasing dose (10 pg/h for 40 h, 20
pg/h for 40 h and 50 pg/h for 40 h). See General Methods, section 2.3.3. for
full details. A guide cannula was also inserted (1.6 mm lateral and 0.6 mm
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posterior to bregma for i.c.v. injection of verapamil (160 pg/5 pi 0.9% isotonic
saline) or vehicle and sealed with a dummy cannula of wire until the day of
the experiment.
2. Electrophvsioloqy
On the 6th day of infusion rats were anaesthetised with urethane (1.25
g/kg) and the trachea and the left femoral vein cannulated. The rat was
mounted in a stereotaxic frame and the neurohypophysial stalk and right
SON surgically exposed (ventral surgery kindly performed by Dr. G. Leng;
Leng, 1981). A concentric bipolar stimulating electrode (SNEX 200; Clarke
Electrochemical Instruments) was placed on the neural stalk and a glass
microelectrode filled with 0.9% saline (20-50 MOhm) was placed into the
SON to obtain extracellular recordings from antidromically-activated
neurones. Neurones were antidromically activated by stimulation of the
neural stalk (1 ms matched biphasic pulses <1 mA peak-to-peak, 0.3 Hz) and
were tested for constant latency to confirm their projection from the SON to
the neurohypophysis. This enabled exclusive identification of magnocellular
neurosecretory neurones. To further identify oxytocin neurones i.v. CCK8S
(20 pg/kg) was given as this has been shown to selectively activate putative
oxytocin neurones while putative vasopressin neurones are unaffected or
inhibited (Renaud et at., 1987). Recordings of oxytocin neurones were
relayed from a spike processor (Digitimer D.130) to a digital to analogue
convertor (CED 1401) and stored on a Spike 2 software programme (version
3.22 CED Ltd, Cambridge) for later analysis. Firing rate was recorded for at
least 10 min prior to injection of i.v. naloxone in order to obtain a stable
control period. Once withdrawal was established i.c.v. verapamil was
injected. If at this point cell firing rate was abolished then the cell was
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antidromically activated to make sure that the cell had not drifted away from
the recording electrode. In two animals a repeated injection of i.c.v.
verapamil was given.
3.2.8. Radioimmunoassay for oxytocin
Oxytocin content of all blood plasma samples from experiments described
in this chapter was determined using the antiserum and modified method of
Higuchi et al., (1985a). Assay sensitivity was <4.8 pg/ml and the interassay
coefficient of variation was 18%. Intraassay coefficients of variation were
never more than 17% at standard concentrations of 10 pg/ml and 100 pg/ml.
All samples from a single experiment were measured in the same assay to
eliminate any interassay variation.
Microdialysis samples were assayed with typical recovery values as




3.3.1.1.c.v. verapamil on withdrawal hypersecretion of oxytocin
l.c.v. verapamil had no effect on basal plasma oxytocin levels compared
with vehicle alone (Fig. 3.3.1.1.). When naloxone was given i.v. 10 min after
i.c.v. verapamil plasma oxytocin concentration increased in verapamil-treated
rats by 275.1 ± 192.4 pg/ml and in vehicle-treated rats by 760.5 ± 152.7
pg/ml, and this augmentation from basal was significant 5 min and up to 20
min after the injection of naloxone (p<0.05, n=7; Paired Wilcoxon). The
observed rise in plasma oxytocin 5 min after the injection of naloxone was
significantly greater (p<0.05; Mann-Whitney U-test) in the vehicle group than
in the verapamil-treated group but this was not the case 20 min later, when
the level in the vehicle group tended to decline.
3.3.2. l.c.v. verapamil on naloxone-stimulated release of oxytocin in
normal rats
After i.c.v. injection of verapamil or vehicle there was no significant
difference in basal plasma oxytocin levels between the two groups. 10 min
after the initial i.c.v. injection an i.v. injection of naloxone was given which
significantly increased (p<0.05; Paired Wilcoxon) plasma oxytocin
concentration in both vehicle-treated rats by 80.0 ± 14.2 pg/ml and
verapamil-treated rats by 21.1 ± 10.6 pg/ml after 5 min respectively (Fig.
3.3.2.1.). The elevation in plasma oxytocin in the vehicle group was
significantly greater than in the verapamil group (p<0.05; Mann-Whitney Li¬
test) 5 min after naloxone injection. CCK8S given i.v. 10 min after a second
injection of either i.c.v. vehicle or verapamil increased plasma oxytocin
significantly in i.c.v. vehicle-treated rats by 298.4 ± 95.5 pg/ml, (p<0.005,
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Mann-Whitney U-test) but had no effect on oxytocin levels in i.c.v. verapamil-
treated rats.
3.3.3. Effect of i.c.v. verapamil on central and peripheral oxytocin
release during naloxone-induced morphine withdrawal
There was no significant difference (Mann-Whitney U-test) in mean basal
oxytocin release within the SON between rats which were to receive either
i.c.v. verapamil (1.20 ± 0.27 pg/sample, n=8) or i.c.v. vehicle (0.60 ± 0.29
pg/sample, n=5). Injection of i.v. naloxone 5 min after i.c.v. vehicle
precipitated withdrawal, increasing oxytocin release within the SON by 213.0
± 50.8% in the second dialysate whereas this release was completely
suppressed in animals injected with i.c.v. verapamil (p<0.01; Mann-Whitney
U-test), (Fig. 3.3.3.1.a.). The increase in intranuclear release of oxytocin
was sustained over the following 30 min perfusing period in the i.c.v. vehicle-
treated group although release fell to 121.0 ± 119.9% (no sig. diff.; Paired
Wilcoxon). Oxytocin release within the SON remained unchanged over this
period in the i.c.v. verapamil-treated group.
I.v. naloxone injection significantly increased plasma oxytocin
concentration in both i.c.v. vehicle-treated animals to 439.5 ± 186.4 pg/ml
(from 49.0 ± 9.4 pg/ml) and i.c.v. verapamil-treated animals to 106.6 ± 15.7
pg/ml (from 52.0 ± 7.2 pg/ml), (p<0.05; Paired Wilcoxon, Fig 3.3.3.1.b.).
Despite this however, prior i.c.v. verapamil injection reduced the increment in
plasma oxytocin concentration by 86% (p<0.05; Mann-Whitney U-test).
3.3.4. Effect of i.c.v. verapamil on CCK8S-stimulated oxytocin release
Injection of i.v. CCK8S significantly increased plasma oxytocin from basal
levels, from 24.0 ± 2.1 pg/ml to 37.7 ± 4.8 pg/ml in the vehicle-treated group
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(p<0.002, n=15; Paired Wilcoxon) and from 24.3 ± 1.9 pg/ml to 36.3 ± 2.1
pg/ml in the verapamil-treated group (p<0.0005, n=16; Paired Wilcoxon),
(Fig. 3.3.4.1.). Injection of i.e.v. verapamil 10 min before a second injection
of CCK8S completely eliminated (p<0.00001; Mann-Whitney U-test) the
CCK8S-stimulated release of oxytocin observed in the i.c.v. vehicle-treated
group, (p<0.001; Paired Wilcoxon). Rats previously given i.c.v. vehicle were
then given an i.p. injection of hypertonic saline which increased oxytocin
secretion markedly (p=0.0001; Paired Wilcoxon) over the following 10 min
and it continued to increase over the following 20 min. I.c.v. injection of
verapamil 10 min before injection of hypertonic saline significantly attenuated
the oxytocin response for at least 20 min (p<0.0005; Mann-Whitney U-test),
although 30 min after injection of hypertonic saline the increase was
significant (p<0.01; Paired Wilcoxon), but still less than in i.c.v. vehicle-
treated rats (p<0.05)
3.3.5. Effect of i.c.v. verapamil on suckling-stimulated central oxytocin
release in the lactating rat
In rats treated subsequently with either i.c.v. vehicle or verapamil mean
basal oxytocin release for the first 3 dialysates within the SON was 0.52 ±
0.26 pg/sample and 0.35 ± 0.11 pg/sample respectively (no significant
difference; Paired Wilcoxon). After injection of i.c.v. vehicle in the first 30
min perfusion during suckling, oxytocin recovery increased significantly by
266 ± 46 % (p=0.01; Mann-Whitney U-test) while in rats which received i.c.v.
verapamil there was no change in oxytocin release during either this
perfusion or the second perfusion during the suckling period (Fig. 3.3.5.1.).
However oxytocin release returned to its pre-suckling level in the i.c.v.
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vehicle-treated group. There was no further change in either group of
animals during the sixth perfusion period after the pups had been removed.
During the first 30 min perfusion period the total number of observed milk-
ejections was significantly less (p<0.01; Mann-Whitney U-test) in the i.c.v.
verapamil-treated group than in the group which received i.c.v. vehicle (Fig.
3.3.5.2. and Fig. 3.3.5.3.). There was no difference in number of milk-
ejections between groups as suckling continued during the second 30 min
perfusion.
3.3.6. Effect of i.c.v. verapamil on oxytocin secretion evoked by neural
stalk stimulation
Pulse trains of 90-120 stimulus pulses at 50 Hz (typical parameters for an
oxytocin neurone milk-ejection burst) applied to the neural stalk evoked the
release of approximately 0.75 mil oxytocin (Fig. 3.3.6.1.a.). Injection of i.c.v.
verapamil in all four animals appeared to initially diminish the mammary
gland response to exogenous oxytocin (Fig. 3.3.6.1.a.) and to neural stalk
stimulation (Fig. 3.3.6.1.a. and Fig. 3.3.6.1.b.), although this was not deemed
to be significant (Paired Wilcoxon).
3.3.7. Effect of i.c.v. verapamil on electrical activity of oxytocin
neurones stimulated by naloxone-induced morphine withdrawal
Injection of i.v. naloxone increased the firing-rate of antidromically-
identified putative oxytocin neurones (excited by i.v. CCK8S, 20 ptg/kg)
recorded from morphine dependent rats by 4.7 ± 1.0 spikes/s from a mean
basal level of 2.3 ± 1.4 spikes/s (p<0.05, n=5; Paired Wilcoxon). Once
withdrawal was fully established an initial injection of i.c.v. verapamil
abolished firing completely in 3 cells for approximately 12 min (Fig.
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3.3.7.1.a.) and attenuated firing-rate in a further 2 cells by 6.3% and 8.5%
(p<0.05 by confidence limits; Fig. 3.3.7.1.b.).
In one cell once firing rate recovered to a level comparable with that
observed during the initial control period after i.c.v. injection of verapamil (48
































Figure (3.3.1.1.)- Effect of i.c.v. verapamil on withdrawal hypersecretion of
oxytocin release in the morphine-dependent rat. I.v. naloxone (5 mg/kg)
given 10 min after i.c.v. verapamil (160 jig/ 5pl) increased plasma oxytocin
both in verapamil ( ▲ ; n=7) and in vehicle-treated (O; n=7) rats and this
elevation was significant at both 5 min and 20 min after injection of naloxone
(*p<0.05; Paired Wilcoxon). The elevation of plasma oxytocin in the vehicle
group was significantly greater than that observed in the verapamil group
















Figure (3.3.2.1.)- Effect of i.c.v. verapamil on naloxone-induced and CCK8S-
stimulated release of oxytocin in the virgin female rat. I.v. injection of
naloxone 10 min after i.c.v. verapamil significantly increased plasma
oxytocin in both vehicle-treated (O; n=8) and verapamil-treated ( ▲ ; n=8)
groups (*p<0.05; Paired Wilcoxon; ) after 5 min. The elevation of plasma
oxytocin in the vehicle group was significantly greater than in the verapamil
group (#p<0.05; Mann-Whitney U-test) 5 min after naloxone injection.
CCK8S (i.v.; 20 pg/kg) given 10 min after either a second injection of i.c.v.
vehicle or verapamil significantly increased plasma oxytocin in i.c.v. vehicle-




Figure (3.3.3.1; overleaf)- Effect of i.e.v. verapamil on central and peripheral
oxytocin release during naloxone-induced morphine withdrawal.
(a) l.v. injection of naloxone increased oxytocin content within the SON in
the second dialysate in i.c.v. vehicle-treated animals (open bars), (**p<0.01;
Mann-Whitney U-test). Prior injection with i.c.v. verapamil (hatched bars)
completely suppressed this increase. Central release of oxytocin remained
unchanged in the following dialysate for both groups relative to the previous
respective dialysate.
(b) Injection of i.v. naloxone increased peripheral release of oxytocin in
both i.c.v. vehicle-treated (open bars) and i.c.v. verapamil-treated animals
(hatched bars), (*p<0.05, n=5 and n=8 respectively; Paired Wilcoxon)
although prior administration of i.c.v. verapamil reduced the increment in
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Figure (3.3.4.1.)- Effect of i.c.v. verapamil on CCK8S-stimulated release of
oxytocin secretion in virgin female rats. I.v. injection of CCK8S resulted in a
significantly increased release of oxytocin in both vehicle-treated (O;
*p<0.002, n=15; Paired Wilcoxon;) and verapamil-treated animals
( ▲ ;**p<0.0005, n=16). Injection of i.c.v. verapamil 10 min prior to a second
injection of CCK8S completely abolished (#p<0.00001; Mann-Whitney U-test)
the CCK8S-stimulated increase in oxytocin concentration seen in the i.c.v.
vehicle-treated group, (Tp<0.001). In rats given hypertonic saline (4 ml/kg,
i.p.) oxytocin secretion increased dramatically (TTp=0.0001) over the
following 10 min and continued to increase steadily for the next 20 min. Prior
injection of i.c.v. verapamil delayed this increase in plasma oxytocin





















































30 min. perfusion no.
Figure (3.3.5.1.)- Effect of i.c.v. verapamil on suckling-stimulated central
oxytocin release in the lactating rat. Suckling-induced oxytocin release
within the SON increased significantly from basal levels (**p=0.01; Mann-
Whitney U-test) after injection of i.c.v. vehicle (open bars) 10 min before
collection of the fourth dialysate whereas there was no change in central
oxytocin release after i.c.v. verapamil injection (hatched bars), during this
perfusion or the following perfusion during the suckling period. Central
oxytocin release returned to pre-injection levels during the fifth perfusion.
There was no further change in central oxytocin levels in either group during




Figure (3.3.5.2.)- Effect of i.c.v. verapamil on the milk-ejection reflex.
Injection of i.c.v. verapamil (hatched bars) reduced the total number of
observed milk-ejections (**p<0.01; Mann-Whitney U-test) during the first 30
min perfusion following injection compared with i.c.v. vehicle (open bars). As
suckling continued through a second 30 min perfusion period there was no



















Figure (3.3.5.3.)- Typical intramammary pressure recordings obtained from
urethane-anaesthetised rats (7-13 days post-partum). In the upper trace (a)
injection of i.c.v. verapamil impaired milk-ejection (*) for at least 12 min in
contrast to the lower trace (b) where i.c.v. vehicle had no effect on milk-
ejections. Black arrow denotes 0.5 mU exogenous oxytocin (i.v.) and MD4
represents microdialysis dialysate number 4.
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Figure (3.3.6.1.; overleaf)- Effect of i.e.v. verapamil on oxytocin secretion
evoked by neural stalk stimulation.
(a) Stimulation of the neural stalk with 60-120 pulses at 50 Hz produced a
graded increase in release of oxytocin into the periphery (measured from
intramammary pressure) in lactating rats (n=4) which was unchanged after
administration of i.c.v. verapamil.
(b) Typical recording obtained from a urethane-anaesthetised rat showing
graded increases in intramammary pressure (which reflects oxytocin
secretion) in response to electrical stimulation with 60-120 pulses (empty
arrows) of the neural stalk and i.v. bolus injection of oxytocin (filled arrows).
I.c.v. verapamil had an apparent though not significant transient depressing








































Figure (3.3.7.1.; overleaf)- Traces of electrical activity of supraoptic putative
oxytocin neurones showing the two most extreme responses obtained after
injection of i.c.v. verapamil. I.v. injection of CCK8S (20 pg/kg) caused a
rapid, transient increase in firing rate in both cells tested.
(a) I.c.v. injection of verapamil (48 pg) completely abolished the naloxone-
induced withdrawal increase in firing rate for 10-12 min before the cell slowly
began to recover to a firing rate similar to that seen during the control period.
A second injection of verapamil completely blocked the recovery in firing rate.
(b) I.c.v. injection of verapamil (160 pg) significantly attenuated the
withdrawal-induced increase in firing rate (p<0.05) as measured by the 95%
confidence limits during the post-injection period compared with the period








Naloxone-induced release of oxytocin
The withdrawal excitation of magnocellular oxytocin neurones after
intravenous injection of naloxone results in a pronounced hypersecretion of
oxytocin into blood from the neurohypophysis as shown in this (Figs. 3.3.1.1.
and 3.3.2.1.b.) and previous studies (Bicknell et al., 1988; Leng et at.,
1989b).
The involvement of L-type Ca2+ channels would appear to be central to
this response, since injection of verapamil into a lateral cerebral ventricle
significantly attenuated the withdrawal-induced release of oxytocin into blood
(Figs. 3.3.1.1. and 3.3.2.1.b.) and within the SON (Fig. 3.3.2.1.a.). In
morphine naive animals anaesthetised with urethane, i.c.v. injection of
verapamil although diminishing the oxytocin secretory response to systemic
injection of naloxone, did not block it completely. This is consistent with an
action of naloxone at the neurohypophysis, as shown by the unaffected firing
rate response in untreated rats (Shibuki et at, 1988) and intimates that
verapamil probably does not act at the neurosecretory terminals to attenuate
release of oxytocin into blood. Prolonged exposure to morphine in vivo
increases dihydropyridine binding site density within the brain (Ramkumar
and El-Fakahany, 1988) and this could explain the effect of verapamil in
attenuating naloxone-induced oxytocin release in morphine dependent rats.
This may well infer that L-type Ca2+ channels play a profoundly important role
in the withdrawal excitation of oxytocin neurones.
CCK8S- and osmoticallv-stimulated release
In morphine naive animals i.v. injection of naloxone would appear to have
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potentiated the CCK8S-stimulated release of oxytocin in animals which had
previously been treated with i.c.v. vehicle; in a separate study which was
assayed together with the present study (Fig. 3.3.2.1.), the CCK8S-
stimulated increase in plasma oxytocin although significant in itself was
approximately 10 fold lower. This agrees with reports of naloxone
potentiated release of oxytocin induced by systemic administration of CCK
(Flanagan et al., 1988; Leng et al., 1992).
Systemic administration of CCK8S excites magnocellular oxytocin
neurones as shown by their increased electrical activity and by the
expression of Fos protein within the SON following application of this
stimulus (Hamamura et al., 1991). Consequently there is an increase in
plasma oxytocin as shown by this and previous studies (Blackburn and Leng,
1990). The pathway extends from the gastric vagus (Verbalis et al., 1986)
and involves a central noradrenergic component projecting to the NTS,
onwards by direct and indirect pathways to the hypothalamic magnocellular
system. Since i.c.v. injection of verapamil completely abolished CCK8S-
induced oxytocin release into blood from the neurohypophysis, this indicates
that L-type Ca2+ channels may be an important factor in mediating the
response. CCK8S also facilitates release of both vasopressin and oxytocin
when applied to the isolated rat neural lobe (Bondy et al., 1989a) although
this is apparently independent of external Ca2+. Consequently verapamil
when injected centrally, would appear not to act at the neurohypophysis to
block release of oxytocin in response to systemic CCK8S.
Interestingly i.c.v. injection of verapamil also attenuated the osmotic
activation of oxytocin neurones. The region anterior and ventral to the third
ventricle (AV3V region) which receives projections from the organum
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vasculosum of the lamina terminalis (OVLT) provides a major input to
supraoptic magnocellular oxytocin neurones which is essential for
maintaining their full osmoresposiveness (Leng et al., 1989), although this
pathway does not seem to be essential for either withdrawal excitation of
oxytocin secretion (Russell et al., 1992) or systemic CCK8S-stimulated
oxytocin release (Blackburn and Leng, 1990). The subfornical organ (SFO)
projects to the magnocellular nuclei and the AV3V region (Miselis et al.,
1981), and may also be involved in the full maintenance of
osmoresponsiveness of magnocellular neurones (Leng et al., 1989).
Peripheral osmotic activation of oxytocin neurones involves at the cellular
level a steady increase in continuous firing of oxytocin neurones which is
reflected by a gradual increase in plasma oxytocin concentration (Fig.
3.3.4.1.). The delay in onset of activation of oxytocin secretion after i.e.v.
injection of verapamil resembles that which takes place after lesioning of the
SFO and AV3V region (Leng et al., 1989). Cells within the OVLT are
themselves intrinsically osmosensitive, and it has been suggested that an
osmotically activated depolarising response is relayed to magnocellular
neurosecretory cells whereby it can be amplified and manifest itself as an
electrical event in these cells, only if their intrinsic osmosensitivity is still
intact (Bourque et al., 1993). An action of verapamil at either of these sites
would effectively interrupt synaptic transmission and delay the magnocellular
response to the hypertonic stimulus. The eventual appearance of the
response was probably a result of verapamil ceasing to antagonise after a
given period, the movement of extracellular Ca2+ into the cells responsible for
affecting either directly (within the SON) or indirectly (on afferents from the




The suckling stimulus initiated by a hungry litter of rat pups has previously
been shown to provide a reliable on-line bioassay of oxytocin release from
the neurohypophysis (Wakerley and Lincoln, 1971a). The pathway involved
in suckling-induced release of oxytocin has not been clearly described
although a number of components essential for its normal functioning have
been identified. One of the most important of these is the role of oxytocin
itself in facilitating its own release within the magnocellular nuclei during the
suckling process. Oxytocin release measured by push-pull perfusion and
microdialysis within the SON increases during the milk-ejection reflex (Moos
et al., 1989; Neumann et al., 1993) and this release is significantly reduced
by replacing Ca2+ in the perfusion medium with EGTA (Neumann et al.,
1993). In these present experiments the rise in intramammary pressure
associated with bolus release of oxytocin occurring over regular intervals (the
milk-ejection reflex) was to provide a correlate as to the actions of verapamil
on both peripheral and central oxytocin release. Injection of verapamil into a
lateral cerebral ventricle significantly attenuated the frequency of milk-
ejections and their magnitude (the magnitude of the intramammary pressure
response being related to the amount of oxytocin released from the
neurohypophysis). Recent reports have suggested that modulation of Ca2+
channels can directly influence the occurrence of overlapping and functional
after currents in magnocellular neurosecretory cells, and hence spike-
induced Ca2+ influx which may be important for the bursting of oxytocin
neurones during milk-ejection (Bourque et al., 1993); such currents are likely
to be modulated by verapamil.
In view of the facilitatory effect of oxytocin on its own release within the
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magnocellular nuclei both in vivo and in vitro (Moos et al., 1984; Yamashita et
at., 1987) it is likely that the disruption of central oxytocin release by
verapamil prevented its further dendritic and axonal release within the SON
(Pow and Morris, 1989; Ward and Morris, 1993) and subsequent release
from the neurohypophysis. Release of oxytocin within limbic brain areas has
also been shown to be Ca2+ dependent (Landgraf et al., 1988) and it has
been proposed that in the suckled lactating rat, septal neurones could
modulate the bursting of oxytocin neurones within the PVN and SON via the
bed nucleus of the stria terminalis (Ingram and Moos, 1992). From these
data an action of verapamil at this site cannot be excluded although it is likely
that Ca2+ channel involvement occurs at both sites. However this problem
could be resolved by injecting verapamil directly into the SON of the lactating
rat using a modified triple probe system, and microdialysing for oxytocin upon
initiation of a suckling stimulus.
Verapamil acts centrally to attenuate activity of magnocellular oxytocin
neurones
Both the cell bodies and the terminals of magnocellular neurosecretory
cells express N- and L-type Ca2+ currents (Fisher et al., 1992). As a result
verapamil could attenuate release of oxytocin into blood from the
neurohypophysis by acting at either of these sites; modulation of Ca2+-
induced spike influx regulates firing pattern of magnocellular cells (Bourque
et al., 1993), whilst depolarisation of the terminal membrane opens Ca2+
channels allowing influx of extracellular Ca2+ and subsequent
neurohypophysial peptide secretion (Bicknell et al., 1993) which can be
suppressed by Ca2+ channel antagonists (Jorgensen et al., 1993). However
it would appear that the inhibitory actions of verapamil on SON oxytocin
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neurones are mediated centrally since i.c.v. verapamil a) attenuated oxytocin
release within the SON during suckling and morphine withdrawal b) had no
significant effect on oxytocin release from the neurohypophysis evoked by
stimulation of the neural stalk (Fig. 3.3.6.1.) and c) completely abolished the
withdrawal-induced firing rate in three magnocellular oxytocin cells and
significantly attenuated firing rate in a further two cells of morphine
dependent rats (Fig. 3.3.7.1.). Of course these central actions of verapamil
on magnocellular oxytocin neurones may have been mediated pre-
synaptically on afferents to these neurones and merit further investigation if a
precise location of action is to be specified. Recently it has been reported
that multiple L-type Ca2+ channels (which may be uniquely associated with
dendritic and somatic Ca2+ dependent functions) can be co-expressed within
the same cell (Tomlinson et al., 1993). Differential expression of such
channels within magnocellular oxytocin neurones could explain the wide
variation in firing rate response of these cells (Fig. 3.3.7.1.) to i.c.v. verapamil
administration.
Role of the Ca2+ channel in tolerance and dependence
The dihydropyridine L-type Ca2+ channel antagonist nimodipine,
attenuates naloxone precipitated noradrenaline release from various brain
regions in vivo in morphine dependent rats (Bongianni et al., 1986) and
prevents release in vitro from cortical slices taken from morphine dependent
rats (Pelligrini-Giampietro et al., 1988).
The SON receives noradrenergic inputs from the A2 cell group, and to a
lesser extent the A6 cell group located in the brainstem (Loizu, 1969;
Sawchenko and Swanson, 1982). Systemic administration of CCK8S
increases plasma oxytocin concentration and increases extracellular
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noradrenaline concentration measured by microdialysis and high
performance liquid chromatography in the dorsal region of the SON
(Kendrick et al., 1991). However it is not known if noradrenaline
concentration increases within the SON during withdrawal, although
intuitively it might be expected to do so. It is possible that verapamil injected
centrally attenuates a presynaptic Ca2+ conductance thereby preventing
release of oxytocin within the SON and perhaps ultimately into blood during
morphine withdrawal, via pre-synaptic inhibition of Ca2+-mediated
noradrenaline release. Paradoxically, noradrenaline itself, acting upon a2-
adrenoceptors has been shown to reduce the activity of high voltage-
activated Ca2+ channels (Lipscombe et al., 1989; for review see Scott et at.,
1991). However noradrenaline is principally excitatory to magnocellular
oxytocin neurones (Yamashita et al., 1987).
The part played by L-type Ca2+ channels in the control of oxytocin within
the SON and from the neurohypophysis in response to a wide range of
stimuli has been readily demonstrated from these studies. Whether this is as
a result of a direct action at the level of the channel itself (either pre- or post-
synaptically) or due to modulation of other post effector mechanisms remains
to be established. In relation to tolerance the reduction in Ca2+ conductance
which involves a pertussis toxin sensitive G protein (Seward et al., 1991) is
well defined. It is doubtful however whether inactivation of such G proteins is
important for the development of dependence in magnocellular oxytocin
neurones (Pumford et al., 1993). The establishment of tolerance and
dependence in this system to the inhibitory actions of morphine may result
from the ongoing occupancy of the p-opioid receptor by morphine and
adaptation of a Ca2+ current associated with the K+ conductance activated by
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morphine (North, 1989). An upregulation of Ca2+ channel expression
compensating for this decrease in Ca2+ conductance would mean that
displacement of morphine from the p-receptor by naloxone would remove the
inhibition exerted on these neurones and allow a massive flood of Ca2+ into
the cell. This in turn would initiate neuronal activation due to increased
intracellular Ca2+ concentration and associated turnover of second
messenger events to initiate exocytotic release of oxytocin both centrally
from dendritic processes and peripherally into the plasma (see General
Discussion, Fig. 7.1.).
However, maintenance of other excitatory afferent inputs may also be
required to mediate the full expression of withdrawal excitation in









Oxytocin is released from the neurohypophysis into the periphery in
response to a variety of stimuli including parturition, suckling, osmotic
activation, stress, gastric distension and peripheral administration of CCK8S
(Higuchi et al., 1985b; Lang eta!., 1983 ; Brimble et ai, 1978; Higuchi et ai,
1986c; Renaud et al., 1989; Verbalis et al., 1986).
Oxytocin also has important actions when released within the brain being
actively involved in both male and female sexual behaviour (Arletti et al.,
1992) and facilitating maternal behaviour in the post-parturient rat (Pedersen
et al., 1992). Injection of exogenous oxytocin into a lateral cerebral ventricle
(unlike systemic oxytocin) can initiate the milk-ejection reflex in the
anaesthetised suckled lactating rat (Freund-Mercier and Richard, 1984)
whilst oxytocin has been shown to be stimulatory to oxytocin neuronal activity
in vitro (Moos et al., 1984; Yamashita et al., 1987). Since central
administration of an oxytocin antagonist not only prevents the facilitatory
effect of oxytocin, but when given alone interrupts the milk-ejection reflex
(Freund-Mercier and Richard, 1984) this indicates that endogenous brain
oxytocin is crucial for mediating its own release in response to specific
stimuli. This effect of the oxytocin antagonist in vivo combined with in vitro
evidence where, in contrast with oxytocin, exogenous vasopressin has been
reported to have no effect on oxytocin neurosecretion, suggests that these
effects are mediated by specific oxytocin receptors. Using traditional
autoradiographic techniques oxytocin binding sites have not been
demonstrated within the SON, (Tribollet et al., 1988; Tribollet et al., 1992),
until recently however, where oxytocin binding sites have been
histoautoradiographically shown to be located on the dendritic processes of
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the oxytocin neurones around the ventral rim of the SON (Freund-Mercier
and Stoeckel, 1993).
Separate studies using the push-pull perfusion and microdialysis
techniques have revealed that oxytocin release within the SON increases
during the milk-ejection reflex (Moos et al., 1989; Landgraf et al., 1992). The
rise in intranuclear release of oxytocin is both Ca2+ and Na+ dependent and is
likely to be dendritic in origin (Pow and Morris, 1989; Ward and Morris, 1993)
although the cell bodies of the oxytocin neurones themselves probably
contribute (Pow and Morris, 1989). Release of oxytocin within the SON is
also increased by both systemic and central administration of CCK8S
(Neumann et al., 1993) which correlates with the increase in electrical activity
of magnocellular oxytocin neurones in response to these stimuli (Leng et al.,
1991; Jarvis et al., 1992).
In the rat prolonged administration of morphine results in dependence
upon and tolerance to the inhibitory actions of morphine on oxytocin release,
whilst administration of naloxone results in a withdrawal hypersecretion of
oxytocin due to an increase in firing rate of the neurones (Bicknell et al.,
1988). Naloxone-induced withdrawal is a robust stimulus to oxytocin release
within the SON (Russell et al., 1992) and one may expect that this release of
oxytocin within the SON may have a profound autofacilitatory effect,
contributing to the hypersecretion of oxytocin and helping to sustain the
elevated electrical activity of these neurones during withdrawal. Until now,
the role of oxytocin within the SON in facilitating its own release during
morphine withdrawal has remained undetermined. Preliminary blood
sampling studies using a specific oxytocin antagonist (Manning et al., 1989)
administered into a lateral cerebral ventricle were undertaken to ascertain a
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4.2. MATERIALS AND METHODS
4.2.1. Effect of acute i.c.v. oxytocin antagonist injection on withdrawal
hypersecretion of oxytocin
1. Animals
Virgin female Sprague-Dawley rats (294 ± 4 g, n=15) housed singly in a 12
h light/dark cycle with free access to food and water were used.
Under ether anaesthesia the rats were implanted with an i.c.v. infusion
assembly connected to a sub-cutaneously implanted osmotic mini-pump (see
General Methods, section 2.3.3.). The infusate delivered over 5 days into a
lateral cerebral ventricle was morphine sulphate dissolved in sterile pyrogen-
free distilled water in sequentially increasing concentrations (10 pg/pl, 20
pig/pil and 50 pg/pl), each delivered at a rate of 1 jul/h over a 40 h period. A
guide cannula (1.6 mm lateral and 0.6 mm posterior to bregma) was also
implanted for acute injection of i.c.v. vehicle (1% 0.01 M HCI/5 pi 0.9% NaCI)
or oxytocin antagonist (1 pg) as required.
2. Properties of oxytocin antagonist
The oxytocin antagonist used was desGly, d(CH2)5[Tyr(Me)2, Thr4]OVT.
From hereon it is referred to as Manning 16 (Manning et al., 1989). This
peptide is an analogue of a peptide which was previously reported to have
nonselective oxytocin/vasopressin antagonist effects. Manning 16 however
exhibits substantially reduced antivasopressin potency compared with
antioxytocic potency in vivo. The pA2 values (negative log of the
concentration required to reduce the agonist effect by half) for its antioxytocic
activity in vitro and in vivo are 8.56 ± 0.09 and 7.61 ± 0.08 respectively. The
pA2 value for its antivasopressor activity in vitro is 6.98 ± 0.07. Finally, the
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ED50 (dose which reduces the response to an agonist by half) of Manning 16
required for an antivasopressor effect is 4.3 times greater than that required
for an antioxytocic effect (Manning et al., 1989).
3. Blood sampling/injection procedure
On the morning of the sixth day of i.c.v. infusion the rats were
anaesthetised with urethane (1.25 g/kg i.p.) and a femoral artery and vein
cannulated for the withdrawal of blood samples and injection of drugs (see
General Methods, section 2.3.1.). Rats were randomly assigned to the
control or experimental group (n=7 and 8 respectively) and a 2 h equilibration
period allowed before sampling commenced. One basal sample was
obtained before the second blood sample, which was immediately followed
with an i.c.v. injection of either vehicle or Manning 16 (1 pg). The second
sample was followed 10 min later with an i.v. injecton of naloxone (5 mg/kg).
A fourth sample was taken 5 min later and followed by three more samples
over the next 30 min to follow the time-course of the withdrawal response.
Plasma separated from the red blood cells was stored immediately on ice
and subsequently at -20°C prior to radioimmunoassay for oxytocin content
(see General Methods, section 2.4.).
4.2.2. Effect of i.c.v. oxytocin antagonist infusion on withdrawal
hypersecretion of oxytocin
1. Animals
Virgin female Sprague-Dawley rats (283 ± 9 g, n=15) housed singly under
standard conditions (see General Methods, section 2.1.) were used
throughout these experiments.
Surgery for induction of morphine tolerance and dependence and
85
Chapter 4
placement of the guide cannula for subsequent injection of vehicle or
oxytocin antagonist was as described in General Methods (section 2.1.) and
section 4.2.2.1.
2. Blood sampling/infusion procedure
The protocol used was the same as that outlined previously in section
4.2.3. except that the acute i.c.v. injection of either vehicle or antagonist was
followed immediately with a continued infusion over the following 15 min until
the first post-naloxone blood sample was obtained. 2 pg of antagonist
dissolved in 8 pi vehicle was infused at a rate of 0.5 pl/min from a slow
perfusion pump (B. Braun, GmbH). Similarly blood plasma samples were
taken and stored at -20°C prior to radioimmunoassay for oxytocin content.
4.2.3. Radioimmunoassay for oxytocin
Oxytocin content of all samples from experiments in this chapter were
assayed using a modified method and the antiserum of Higuchi et al.,
(1985a). Assay sensitivity was <4.8 pg/ml and the interassay coefficient of
variation between experiments was 0.3%. Intraassay coefficients of variation
were 8.8, 21.8 and 19.5% for standard concentrations of 20, 100 and 500
pg/ml respectively. All samples from a single experiment were measured in




4.3.1. Effect of acute i.c.v. oxytocin antagonist injection on withdrawal
hypersecretion of oxytocin
I.c.v. injection of oxytocin antagonist had no effect on basal plasma
oxytocin levels compared with vehicle alone (Fig. 4.3.1.1.). I.v. injection of
naloxone 10 min after the acute i.c.v. injection significantly increased plasma
oxytocin concentration in the antagonist-treated rats 5 min later, by 339.7 ±
105.3 pg/ml from a basal level of 14.4 ±1.9 pg/ml (p<0.05; n=8, Paired
Wilcoxon). A similar increase in oxytocin release of 476.9 ± 98.7 pg/ml was
seen in the vehicle-treated animals (p<0.05; n=7). The withdrawal-induced
elevation in plasma oxytocin remained significant in both groups of animals
up to 35 min after injection of naloxone (p<0.05).
4.3.2. Effect of i.c.v. oxytocin antagonist infusion on withdrawal
hypersecretion of oxytocin
Injection of i.v. naloxone 10 min after acute i.c.v. injection of vehicle and 5
min before the i.c.v. infusion of vehicle was due to end produced a
withdrawal-induced increase in plasma oxytocin release of 886.6 ± 182.8
pg/ml, significant at 5 min and up to 35 min after injection of naloxone
(p<0.02 n=7; Paired Wilcoxon), (Fig. 4.3.2.1.). The rise in plasma oxytocin of
274.8 ± 51.6 pg/ml after i.v. naloxone, in rats administered an acute i.c.v.
injection followed by infusion of oxytocin antagonist although significant
(p<0.05; n=8), was significantly less than that in the i.c.v. vehicle-treated
group (p=0.01; Mann-Whitney U-test). This difference in plasma oxytocin
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Figure (4.3.1.1.)- Effect of acute i.c.v. oxytocin antagonist injection on
withdrawal hypersecretion of oxytocin. I.v. naloxone (5 mg/kg) given 10 min
after i.c.v. oxytocin antagonist (1 pg/5pl) increased plasma oxytocin in both
vehicle-treated (O; n=7) and antagonist-treated animals ( A ;n=8) and this

















Figure (4.3.2.1.)- Effect of i.c.v. oxytocin antagonist infusion on withdrawal
hypersecretion of oxytocin. I.v. naloxone given 10 min after acute injection
and 5 min before the end of i.c.v. infusion ( ; 2 pg/8pl) of oxytocin
antagonist increased plasma oxytocin in both vehicle-treated (O; n=7) and
antagonist-treated ( ▲ ;n=8) animals (#p<0.02 and *p<0.05 respectively;
Paired Wilcoxon). This remained significant in both groups up to 35 min after
injection of naloxone (*p<0.05). The elevation in plasma oxytocin in the
vehicle-treated group was significantly greater than that observed in the
oxytocin antagonist-treated group (**p=0.01; Mann-Whitney U-test) 5 min




Intravenous administration of naloxone to the morphine dependent rats
produced an expected withdrawal-induced hypersecretion of oxytocin release
in both blood sampling experiments in accordance with previously reported
studies (Bicknell et at., 1988; Rayner et at., 1988; Leng et at., 1989); this is
due to increased electrical excitation of the magnocellular oxytocin neurones
in conjunction with removal of opioid tone at the nerve terminals in the
neurohypophysis. Acute i.c.v. injection of the oxytocin antagonist Manning
16 alone, had no significant effect on the time course of the withdrawal
response despite mean oxytocin release tending to be lower compared with
vehicle at each post-naloxone sampling point in the antagonist-treated group.
Since this particular oxytocin antagonist is derived from the peptide ornithine
vasotocin (Manning et a!., 1989) it is most probable that its half-life within the
brain would be of a short duration since peptides are subject to rapid
degradation by endogenous processing enzymes (McKelvy and Blumberg,
1986). Preliminary studies of its effects on the milk-ejection reflex (using a
similar concentration of Manning 16 for i.c.v. injection) initiated by stimulation
of the neural stalk as described for verapamil (see Chapter 3, section 3.2.6.),
or after i.v. administration, suggested that it may have a duration of action in
the range of 20-30 min (unpublished observations) since the established
milk-ejection reflex could be blocked for this amount of time.
The autofacilitatory effect of oxytocin on the bursting of oxytocin neurones
during the milk-ejection reflex is so pronounced (Freund-Mercier and
Richard, 1984) however, that it was decided to infuse the oxytocin antagonist
after the initial acute i.c.v. injection had been made. Since specific oxytocin
binding sites have been demonstrated histoautoradiographically (Freund-
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Mercier and Stoeckel, 1993) within the SON and these studies show that
i.c.v. oxytocin antagonist can affect oxytocin receptors within the SON, the
i.c.v. infusion of antagonist directly after the acute injection should have
ensured that a steady state of drug concentration was maintained, into the
early part of withdrawal, offsetting enzymatic hydrolysis of this peptide. In
this experiment administration of oxytocin antagonist significantly attenuated
the withdrawal process 5 min and up to 35 min after injection of naloxone
which is indicative of a central role for oxytocin in sustaining this process.
Whether acute injection followed by infusion of this antagonist could affect
the naloxone-induced increase in firing rate in the morphine dependent rat
remains to be established.
There is substantial immunocytochemical and electrophysiological
evidence in support of an oxytocin-containing pathway from the PVN to the
bed nuclei of the stria terminalis (BNST) in the lactating rat (Ingram and
Moos, 1992). The existence of specific oxytocin binding sites within the
BNST has been demonstrated (Insel, 1990) and microinjection of oxytocin
into this region facilitates the electrical activity of magnocellular oxytocin
neurones, within both the SON and PVN of lactating rats (Moos et al., 1991).
It has been suggested that afferents from the BNST may be involved in
autoexcitation of oxytocin neurones during the milk-ejection reflex (Ingram
and Moos, 1992). As yet this pathway, and a subsequent autoexcitatory
effect of oxytocin on magnocellular oxytocin neurones has not been
investigated in terms of withdrawal excitation of these neurones.
It is likely that this self-stimulating action of oxytocin during the withdrawal
response is a property of the magnocellular neurosecretory system, although
this system does share features with other neuronal systems such as the
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locus coeruleus which displays the typical withdrawal characteristics of
hyperexcitation of electrical activity and hypersecretion of noradrenaline
release (North and Williams 1985). In addition both systems show increased
expression of c-fos mRNA and Fos protein during withdrawal in the morphine
dependent rat (Hayward et al., 1990; Russell et al., 1992; Johnstone et at.,
1993). This then questions the functional significance of autofacilitatory
release of oxytocin during withdrawal. Since release of oxytocin within the
SON in vivo is Ca2+ dependent (Landgraf et al., 1992) and in the
hypothalamic slice preparation oxytocin can stimulate further dendritic
release of oxytocin by a voltage-sensitive Ca2+ channel mode of action
(Yamashita et al., 1987) it would appear that the whole withdrawal process is
primarily Ca2+ dependent with central oxytocin acting as a messenger for its
own release. Positive feedback would continue until the source of oxytocin
had become depleted, or another self-limiting process had become activated,
bringing the withdrawal process indicative of physical dependence to an end.
An intrinsic relationship between oxytocin and Ca2+ within the
neurohypophysial magnocellular neurosecretory system such as this merits
further consideration. Chronic exposure to morphine in vivo increases
dihydropyridine sensitive Ca2+ channel binding site density within the brain
(Ramkumar and Ei-Fakahany, 1988), probably as a compensatory measure
to ongoing occupancy of the p-opioid receptor by morphine, which is known
to decrease a K+ dependent conductance and may decrease an associated
Ca2+ dependent conductance in neuronal preparations (North, 1989). Since
oxytocin neurones become tolerant to the inhibitory actions of morphine
(Pumford et al., 1991) it is not entirely unreasonable to propose upregulation
of oxytocin receptor expression during this treatment in a compensatory
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fashion analogous to that achieved for the Ca2+ channel. Two adaptive
mechanisms such as these acting in concert with each other could provide a
partial explanation for withdrawal hypersecretion of oxytocin in the morphine
dependent rat.
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Two types of adrenergic receptor termed a and p were originally
proposed on the basis that adrenaline, isoprenaline and noradrenaline
produce excitatory, inhibitory and mixed excitatory/inhibitory effects in
smooth muscle respectively (Ahlquist, 1948). Later, p-receptors were
subdivided into p, (those in the myocardium) and p2 (smooth muscle and
most other sites), whilst recently a third receptor designated p3 has been
identified in human adipose tissue. Likewise a-receptors have been further
characterised as oq and a2. These receptor subtypes were first described on
the basis that in general oq-agonists were post-synaptically located and
excitatory to noradrenaline release from neurones, whereas a2-agonists were
pre-synaptically located and inhibitory (Lefkowitz et at, 1990). However it is
now clear that a2-adrenergic receptors are also present at post-synaptic sites
in several tissues. Thus the anatomical concept of pre-synaptic a2 and post¬
synaptic a., has been abandoned in favour of pharmacological and functional
classification. In addition the aforementioned receptors have been isolated
to different genes using molecular cloning techniques. Further subdivisions
of the a-receptor subtypes have been reported (for review see receptor
nomenclature supplement accompanying Trends Pharmacol. Sci. 1993).
Noradrenergic innervation of maqnocellular neurosecretory cells
A number of noradrenergic pathways project from the brainstem to
magnocellular neurones in the SON and PVN (Sawchenko and Swanson,
1982; Wilkin et a!., 1989). The most dense of these inputs projecting to the
SON is from the noradrenergic A1 cell group which passes through the
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ventrolateral medulla to almost exclusively innervate vasopressin neurones
(Raby and Renaud, 1989). The A2 cell group of the nucleus tractus
solitarius (NTS) and the A6 cell group originating in the locus coeruleus
although providing a less extensive projection framework innervate amongst
other regions oxytocin neurones within the SON. Oxytocin cells in the SON
are directly excited by electrical stimulation of the A2 group, whilst this
stimulation only affects vasopressin neurones indirectly via the ventrolateral
medulla (Raby and Renaud, 1989). Much less is known regarding direct
stimulation of the A6 group. However, unilateral lesions in the locus
coeruleus decrease catecholamine fluorescence in the SON (Loizu, 1969)
whilst direct injection of the fluorescent retrograde tracer doxorubicin into the
SON labels catecholamine cells within the A6 cell group identified by
histochemistry (Wilkin et at, 1989). Reports that lesions of efferents from the
A6 region result in impairment of the vasopressin secretory response to
haemorrhage (Everrit et at, 1983), may provide some physiological support
for an A6-magnocellular pathway.
The NTS acts as an extremely important integrative relay structure, its
afferents having been reported to convey a variety of information to the
hypothalamic nuclei. This information would appear to be gastrointestinal
rather than cardiovascular in origin, with gastric distension and peripheral
administration of CCK8S being potent stimuli to NTS neurones in the rat
(Raybould et al., 1985). These same stimuli are also able to selectively
excite oxytocin neurones within the SON (Renaud et at, 1987). Systemically
administered CCK8S induces expression of Fos protein within the NTS and
SON (Luckman, 1992; Hamamura et at, 1991) and increases firing rate of
SON oxytocin neurones (Hamamura et at, 1991) resulting in oxytocin release
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from the neurohypophysis into the periphery (Blackburn and Leng, 1990).
Despite the locus coeruleus having been reported to show no overall
increase in Fos-like immunoreactive material following systemic injection of
CCK8S, it has not been excluded that changes may take place within specific
neuronal populations in this region (Luckman et al., 1993). Further evidence
in support of direct NTS noradrenergic innervation of magnocellular oxytocin
neurones has been shown using microdialysis sampling of the SON, where
noradrenaline concentration within the dorsal, oxytocin-rich region of the
SON increases in response to intravenous CCK8S injection (Kendrick et at.,
1991). The CCK8S-mediated oxytocin response is attenuated by lesions of
the area postrema, a circumventricular organ which provides a dense input to
the caudal NTS (Carter and Lightman 1987). This organ lacks a blood-brain
barrier and as such can conceivably receive blood borne signals. However it
is difficult to lesion the area postrema without damaging the NTS and it is
unlikely that CCK8S passes through this window to the brain to have direct
effects on magnocellular neurosecretory cells.
A proposed role for noradrenaline in withdrawal excitation of neurones
In the rat the neurones of the locus coeruleus become both tolerant to and
dependent upon the inhibitory actions of opiates in vivo (Aghajanian, 1978;
Kosten, 1992), although such evidence for dependence has been much
harder to obtain in related in vitro models (Christie et at, 1987). Locus
coeruleus neurones show increased expression of c-fos mRNA and Fos
protein 1-2 h after initiation of withdrawal (Hayward et al., 1990). These
neurones exhibit a hyperexcitation of firing rate during precipitated opiate
withdrawal which shows a similar time course to that of the behavioural signs
of withdrawal (Rasmussen et al., 1990). As yet dependence has not been
96
Chapter 5
demonstrated at the level of the single neurone (Christie et al., 1987) thereby
reinforcing the requirement for maintenance of synaptic input in order for
withdrawal excitation to be shown.
Locus coeruleus noradrenergic neurones are inhibited by noradrenergic
agonists such as clonidine (Aghajanian, 1978) acting at a2-adrenergic
receptors and by opiates which bind preferentially to the p-opioid receptor
(Christie et al., 1987). At the level of the single neurone, p-opioid and a2-
adrenoceptors appear to converge on the same post-receptor mechanisms,
utilising the same pool of pertussis-sensitive G proteins to modify the K+
conductance responsible for membrane hyperpolarisation and subsequent
inhibition of neuronal activity (Aghajanian and Wang, 1987; Christie et al.,
1987). Local infusion of the a2 agonist clonidine in the vicinity of the locus
coeruleus attenuates several behavioural changes associated with naloxone-
precipitated withdrawal as well as reducing hippocampal concentration of the
noradrenergic metabolite 3-Methoxy-4-hydroxyphenylglycol, indicative of
decreased noradrenaline turnover (Taylor et al., 1988). Systemic
administration of a non-lipophilic a2 agonist (clonidine is extremely lipophilic
and crosses the blood-brain barrier very easily) has no effect on
hippocampal noradrenaline turnover suggesting that clonidine attenuation of
naloxone-precipitated withdrawal in locus coeruleus neurones is site-specific.
Noradrenergic control of magnocellular secretory function
It has been mentioned previously that noradrenergic projections arising in
the brainstem can modulate activity of supraoptic oxytocin neurones by both
direct and indirect modes of action (Raby and Renaud, 1989).
In the rat magnocellular neurosecretory system, noradrenaline has been
proposed to facilitate release of vasopressin and oxytocin from
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neurohypophysial terminals via stimulatory actions on ar and (3-adrenergic
receptors within the neurohypophysis, although this only occurs once
presynaptic opioid or a2-regulated restraint of noradrenaline release has
been removed (Zhao et at., 1988b). Within the SON noradrenaline activates
magnocellular neurosecretory cells via actions on post-synaptically located
cq receptors (Yamashita et at., 1987). The co-release of opioid peptides with
oxytocin and especially vasopressin can inhibit oxytocin release partly
through inhibiting the facilitatory action of noradrenaline on oxytocin
neurones, both at the terminal level (Zhao et at., 1988a) and potentially at the
cell body in the SON (Douglas et at., 1993); increased endogenous opioid
tone acting on magnocellular oxytocin neurones during pregnancy has been
suggested to regulate oxytocin secretion at parturition (Douglas et at., 1993).
However the potential involvement of noradrenergic mechanisms in opioid
control of oxytocin neurones has remained relatively poorly understood.
Preliminary blood sampling studies were undertaken to investigate the
acute effects of opioids on oxytocin release stimulated by peripheral
administration of CCK8S which is known to involve noradrenergic projections
which originate in the NTS. This study was then repeated in morphine
dependent rats to ascertain whether supraoptic oxytocin neurones develop
tolerance to the actions of morphine on this excitatory noradrenergic input.
The relative contribution of this input to oxytocin neurones was then
determined by measuring release of oxytocin into blood from the
neurohypophysis after stimulation by systemic CCK8S in animals given an
intravenous injection of the a2 agonist clonidine. This blood sampling study
was also undertaken to give an indication as to the required dose of clonidine
needed to have a supposed influence on the initiation of withdrawal whilst
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having a minimal effect on blood pressure, since clonidine has well defined
hypotensive effects; initially increasing blood pressure via stimulation of
peripheral a2 receptors followed by a more lengthly fall as a result of its
central actions (Hoffmann and Lefkowitz, 1990). The effects of clonidine on
the withdrawal hypersecretion of oxytocin in the morphine dependent rat
were determined using blood sampling and radioimmunoassay for oxytocin
content in conjunction with measurement of arterial blood pressure. Finally
the control by endogenous opioids of oxytocin release initiated by peripheral
administration of CCK8S was investigated in the 21 day pregnant rat by
comparing the effects of naloxone on CCK8S-stimulated oxytocin release
from the neurohypophysis with oxytocin release in the virgin female.
It was hoped that this series of experiments would provide an insight into
the noradrenergic control of oxytocin release in response to various stimuli
and whether such control mechanisms could play a pivotal role in the




5.2. MATERIALS AND METHODS
5.2.1. Effect of acute i.v. and central morphine administration on
CCK8S-stimulated oxytocin release
1. Animals
Virgin female Sprague-Dawley rats (body weight 252-267 g) housed under
standard conditions (see General Methods, section 2.1.) were anaesthetised
with urethane (ethyl carbamate, 1.25 g/kg; i.p.). The femoral artery and vein
were then cannulated for withdrawal of blood samples and injection of drugs
respectively. I.c.v. injections were given via an implanted guide cannula (1.6
mm lateral, 0.6 mm posterior to bregma and 4.0 mm below the skull surface).
Rats were allowed to recover for 2 h after completion of surgery before
obtaining the first blood sample.
2. Blood sampling/injection procedure
In experiments in which rats were given acute morphine i.v. the first blood
sample was followed by an i.v. injection of CCK8S (20 pg/kg). Three more
i.v. injections of CCK8S, 35 min apart, followed the fourth, seventh and tenth
blood samples respectively. Five min after the third blood sample, rats
received an injection of i.v. morphine (0.5 mg/kg) or vehicle (0.9% NaCI; 0.5
ml/kg). A second, larger dose of i.v. morphine (5 mg/kg) or vehicle was given
5 min after the sixth blood sample. All rats were given naloxone (5 mg/kg)
i.v. immediately after the ninth blood sample was taken at t=95 min. Three
more blood samples were taken over the following 35 min.
Rats given an acute i.c.v. injection of morphine (10 pg) or vehicle (5 pi) 5
min after the third blood sample were given two injections of i.v. CCK8S
separated by 35 min. Both groups of rats then received an i.p. injection of
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1.5 M NaCI (4 ml/kg) after the sixth blood sample was taken and two more
samples followed separated by 10 min intervals. Blood samples were
centrifuged and the plasma separated and stored on ice before being frozen
to -20°C prior to radioimmunoassay for oxytocin content.
5.2.2. Effects of i.v. CCK8S and acute i.v. morphine administration on
oxytocin release in the morphine dependent rat
1. Animals
Virgin female Sprague-Dawley rats (274 ± 5 g, n=15) housed singly under
standard conditions with free access to food and water were used.
2. I.c.v. infusion
Under ether anaesthesia rats were implanted with an i.c.v. cannula (2 mm
lateral, 3 mm posterior to bregma, 4.5 mm below skull surface) for infusion of
morphine sulphate (up to 50 pg/h; see General Methods, section 2.3.3.)
delivered from a subcutaneously implanted osmotic mini-pump over 5 days.
The i.c.v. vehicle-treated group were implanted with an i.c.v. infusion
assembly as mentioned, but containing sterile pyrogen-free distiled water.
3. Blood sampling/injection procedure
On the morning of the sixth day the rats were anaesthetised with urethane
(1.25 g/kg i.p.) and the femoral artery and vein cannulated for blood sampling
and injection of drugs. The first blood sample was followed directly by an i.v.
injection of CCK8S (20 pg/kg) and two more i.v. injections of CCK8S followed
the fourth and seventh blood samples. Five min after the third blood sample
the rats were given an i.v. injection of morphine (0.5 mg/kg) and a
subsequent dose of i.v. morphine (5 mg/kg) was administered after the sixth
blood sample. Naloxone (5 mg/kg) was injected i.v. after the ninth blood
101
Chapter 5
sample. Two more blood samples were taken separated by 10 min intervals.
5.2.3. Effect of i.v. clonidine on the CCK8S-stimulated oxytocin
neurosecretory response
1. Animals
Virgin female Sprague-Dawley rats (261 ±2 g, n=12) housed in groups of
six animals, with free access to food and water were used. They were
maintained in a 12 h light/dark cycle at an ambient temperature of 21-23°C.
2. Blood sampling/ injection procedure
Rats were anaethetised with urethane (1.25 g/kg) and the femoral artery
and vein cannulated for withdrawal of blood samples and injection of
resuspended blood cells and drugs (see General Methods, section 2.3.4.).
Blood sampling was started 2 h after completion of surgery. CCK8S (20
pg/kg) was given i.v. directly after the first blood sample had been taken.
Two more i.v. injections of CCK8S followed the fourth and seventh blood
samples in both groups of animals. Immediately after the third blood sample,
rats received an i.v. injection of either clonidine (0.5 mg/kg) or vehicle (0.9%
NaCI). A second injection of i.v. clonidine (2.5 mg/kg) or vehicle was given
immediately after the sixth blood sample had been obtained. Animals in both
groups were given an i.v. injection of naloxone (5 mg/kg) following the ninth
blood sample and a final sample was taken 5 min later.
5.2.4. Effect of i.v. clonidine on withdrawal hypersecretion of oxytocin in
the morphine dependent rat
1. Animals and i.c.v. morphine infusion
Virgin female Sprague Dawley rats (278 ± 3 g, n=15) were housed singly
with access to food and water ad-libitum. Under ether anaesthesia the rats
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were stereotaxicaliy implanted with an i.c.v. cannula for infusion of morphine
sulphate over 5 days to induce morphine tolerance and dependence (see
General Methods, section 2.3.3.).
2. Blood sampling/injection procedure
On the morning of day 6 of i.c.v. infusion rats were anaesthetised with
urethane (1.25 g/kg). The femoral artery and vein were cannulated for
withdrawal of blood samples and injection of drugs as described previously
(General Methods, section 2.3.4.). After a first blood sample had been taken,
a single i.v. injection of either clonidine (2.5 mg/kg) or vehicle (0.9% NaCI)
was given directly after a second basal blood sample had been obtained. In
both groups of rats this was followed 10 min later with an i.v. injection of
naloxone (5 mg/kg). Two more samples were taken over the next 10 min to
monitor the withdrawal response. A further three samples were obtained 20,
40, and 70 min after injection of naloxone.
In a few rats the arterial cannula was connected to a pressure transducer
(Model P231 d; Gould Stratham Instruments) relayed to a chart recorder (J.J.
Instruments Ltd, Southampton) for on-line measurement of arterial blood
pressure and heart rate. Mean arterial blood pressure (MABP) was defined
as- diastolic blood pressure + 0.33 (diastolic-systolic blood pressure).
5.2.5. Effect of naloxone on CCK8S stimulation of oxytocin release
during pregnancy
1. Animals
Virgin female Sprague-Dawley rats (n=28) were housed under standard
conditions and given food, water and pellets ad libitum. One group was
mated overnight during oestrus with an experienced male and defined as
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pregnant following production of a vaginal plug the following morning. This
was designated day 0 of pregnancy and pregnant rats (404 ± 9 g, n=16) were
taken subsequently on day 21 of pregnancy. Where possible virgin female
rats (267 ± 4 g, n=12) from the same stock were used as control animals.
2. Blood sampling/injection procedure
All rats were anaesthetised with urethane (1.25 g/kg i.p.) and the femoral
artery and vein cannulated for withdrawal of blood samples and injection of
drugs respectively. CCK8S (20 pg/kg i.v.) was given directly after a third
basal sample had been obtained. Two samples were taken 5 and 45 min
later in order to follow the oxytocin response to CCK8S stimulation. At this
point either naloxone (2 mg/kg) or vehicle (0.9% NaCI) was injected
intravenously before three more blood samples were taken, each separated
by 5 min intervals. A second injection of CCK8S was followed by two final
blood samples taken at t=80 and t=90 min respectively.
5.2.6. Radioimmunoassay for oxytocin
Oxytocin content for all samples from experiments described in this
chapter was determined using the antiserum and modified method of Higuchi
et al., (1985a) as described previously (see General Methods, section 2.4.).
Assay sensitivity was <2.4 pg/ml and the interassay coefficient of variation
was 10.6%. Intraassay coefficients of variation were 10 and 11 % at standard




5.3.1. Effect of acute i.v. and central morphine administration on
CCK8S-stimulated oxytocin release
I.v. morphine
The first injection of i.v. CCK8S (20 pg/kg) increased plasma oxytocin
concentration by 123.7 ± 25.1 pg/ml (p<0.001, n=10; Paired Wilcoxon) and
two further i.v. injections of CCK8S 5 min after i.v. vehicle produced similar
significant increases (p<0.05, n=5), (Fig. 5.3.1.1.). Morphine was given i.v. 5
min before the second and third CCK8S injections and produced a dose-
related inhibition of oxytocin release significant after 5 mg/kg morphine
(p<0.05, vs the first CCK8S response and vs the third CCK8S response in
the vehicle controls; Mann-Whitney U-test). When naloxone was given i.v.
30 min after i.v. morphine (5 mg/kg) plasma oxytocin concentration increased
in both morphine-treated rats to 936.9 ± 401.4 pg/ml and in vehicle-treated
rats to 1343.8 ± 563.0 pg/ml, (p<0.05; Paired Wilcoxon). The response to i.v.
CCK8S given 10 min after i.v. naloxone was restored in the morphine-treated
rats (p<0.05).
I.c.v. morphine
Prior to acute i.c.v. morphine injection, an i.v. injection of CCK8S
increased plasma oxytocin concentration by 99.6 ± 19.5 pg/ml from a basal
level of 33.3 ± 5.7 pg/ml, (p<0.001, n=12; Paired Wilcoxon) and a second i.v.
injection of CCK8S given 35 min later, 5 min after injection of i.c.v. vehicle
produced a similar increase (p<0.05, n=5), (Fig. 5.3.1.2.). Morphine (2 pg/pl)
injected i.c.v. 5 min before the second injection of i.v. CCK8S abolished the
oxytocin response seen in the vehicle-treated animals (p<0.001, n=7; Paired
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Wilcoxon). Hypertonic saline injected i.p. 25 min after the second CCK8S
injection in i.c.v. vehicle-injected rats, increased plasma oxytocin
concentration by 277.7 ± 121.6 pg/ml (p<0.05, n=5; Paired Wilcoxon) over
the following 20 min but had no effect on plasma oxytocin in i.c.v. morphine-
treated rats.
5.3.2. Effects of i.v. CCK8S and acute i.v. morphine administration on
oxytocin release in the morphine dependent rat
After an initial injection of i.v. CCK8S plasma oxytocin concentration
increased by 29.0 ± 7.6 pg/ml from a basal level of 16.4 ± 2.3 pg/ml in the
i.c.v. vehicle-treated animals and by 27.3 ± 3.1 pg/ml from a basal level of
23.0 ± 6.8 pg/ml in the i.c.v. morphine-treated group, (p<0.02, n=8 and 7
respectively; Paired Wilcoxon). A second i.v. injection of CCK8S 5 min after
an injection of i.v. morphine (0.5 mg/kg) produced a similar significant
increase (p<0.02), (Fig. 5.3.2.1.). Two i.v. injections of morphine (0.5 and 5
mg/kg) were given 5 min before the second and third CCK8S injections
respectively. These produced a dose-related inhibition of the oxytocin
response to stimulation by CCK8S in the i.c.v. vehicle-treated animals
(p<0.02, second CCK8S response vs the first CCK8S response; p<0.05 third
CCK8S response vs the second CCK8S response) whilst in the morphine-
treated animals, only the second larger dose of i.v. morphine attenuated the
third CCK8S response (p<0.05, vs the first and second CCK8S responses).
Injection of i.v. naloxone 25 min after the final injection of i.v. CCK8S,
increased plasma oxytocin concentration 10 min after injection in both
vehicle-treated (by 239.8 ± 82.5 pg/ml) and in morphine-treated animals (by
844.4 ± 134.1 pg/ml), (p<0.05; Paired Wilcoxon). However the increase was
significantly greater in i.c.v. morphine-treated rats than i.c.v. vehicle-treated
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rats (p<0.005; Mann-Whitney U-test).
5.3.3. Effects of i.v. clonidine on the CCK8S-stimulated oxytocin
neurosecretory response
The first CCK8S injection increased plasma oxytocin concentration by 16.6
± 6.5 pg/ml from a basal level of 10.7 ± 3.7 pg/ml (p<0.005, n=12; Paired
Wilcoxon Fig. 5.3.3.1.). Two further injections of CCK8S after administration
of i.v. vehicle produced similar significant increases of 15.4 ±5.1 pg/ml and
15.0 ± 4.4 pg/ml respectively (p<0.05, n=5). Clonidine (0.5 and 2.5 mg/kg)
was given i.v. before the second and third CCK8S injections and produced a
complete inhibition of the oxytocin neurosecretory response to CCK8S
(p<0.005 and p<0.05 vs the respective CCK8S-stimulated oxytocin
responses in the vehicle controls; Mann-Whitney U-test). There was no
significant difference in the oxytocin response to systemic injection of
naloxone (5 mg/kg, i.v.) between vehicle-treated animals where plasma
oxytocin concentration increased by 45.7 ± 16.6 pg/ml (p<0.05), and in
clonidine-treated animals (n=7) where plasma oxytocin concentration
increased by 12.3 ± 4.3 pg/ml (p<0.05).
5.3.4. Effects of i.v. clonidine on withdrawal hypersecretion of oxytocin
in the morphine dependent rat
Administration of i.v. clonidine (2.5 mg/kg) had no effect on basal plasma
oxytocin levels compared with vehicle alone (Fig. 5.3.4.1.). I.v. injection of
naloxone (5 mg/kg) given 10 min after injection of either clonidine or vehicle,
increased plasma oxytocin from a basal level of 21.3 ± 4.5 pg/ml, in
clonidine-treated rats to 303.7 ± 113.3 pg/ml and in vehicle-treated rats to
702.4 ± 186.9 pg/ml 10 min after injection of naloxone and this elevation
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remained significant 40 min later (p<0.05, n=8 and 7 respectively; Repeated
measures ANOVA). The increase in plasma oxytocin in the vehicle-treated
group was significantly greater than that observed in the clonidine group
(p<0.05; lower tailed one-way f-test) 10 min after naloxone injection.
I.v. injection of vehicle had no effect on arterial blood pressure or heart
rate (Fig. 5.3.4.2.a). I.v. injection of clonidine produced an initial increase in
arterial blood pressure with a simultaneous decrease in heart rate from 420
bts/min (Fig. 5.3.4.2.b.). Naloxone given i.v. 10 min after injection of either
vehicle or clonidine produced a small, transient increase in blood pressure
lasting for approximately 10s in both groups, but had no effect on heart rate
in morphine dependent rats.
5.3.5. Effect of naloxone on CCK8S stimulation of oxytocin release
during pregnancy
Non-pregnant rats
The first CCK8S injection (20 pg/kg, i.v.) significantly increased plasma
oxytocin concentration in the vehicle-treated rats by 14.3 ± 4.4 pg/ml (p<0.05,
n=6; Paired Wilcoxon) from a basal level of 11.9 ± 3.3 pg/ml (Fig. 5.3.5.1.a.).
Similarly in rats given a subsequent injection of naloxone (5 mg/kg) plasma
oxytocin increased by 11.9 ± 3.3 pg/ml (p<0.05, n=6) from a basal level of
17.1 ±2.1 pg/ml. 10 min after injection of i.v. naloxone plasma oxytocin
concentration was sigificantly increased (p<0.05; Mann-Whitney U-test)
compared with i.v. vehicle. A second injection of CCK8S once more
significantly increased plasma oxytocin concentration by 13.7 ± 5.7 pg/ml in
the vehicle-treated animals (p<0.05). The 300% elevation (p<0.05) in the
oxytocin response stimulated by CCK8S in naloxone-treated animals was
significantly greater than the corresponding CCK8S response in animals
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injected with i.v. vehicle (p<0.05; Mann-Whitney U-test).
21 Day pregnant rats
As for the non-pregnant rats, the first CCK8S injection again increased
plasma oxytocin concentration in both groups of animals from a basal level of
8.5 ± 1.0 pg/ml (p<0.05, n=8 each group; Paired Wilcoxon Fig. 5.3.5.1.b.).
I.v. injection of naloxone significantly elevated plasma oxytocin concentration
by 27.4 ± 6.8 pg/ml from basal (p<0.02) 10 min after injection. This steady
increase in plasma oxytocin concentration was maintained over the following
10 min finally elevating plasma oxytocin by 61.2 ± 8.5 pg/ml (p<0.02) 20 min
after injection of naloxone. Oxytocin levels in the naloxone-treated rats were
significantly greater at each time point up to 20 min after naloxone injection
compared with animals given i.v. vehicle (p<0.001 in each case; Mann-
Whitney U-test). A second injection of CCK8S after naloxone, produced a
potentiation in release of oxytocin compared with the corresponding CCK8S-
stimulated oxytocin response in the vehicle-treated animals (p<0.001; Mann-
Whitney U-test), resulting in a 250% increase in plasma oxytocin
concentration (p<0.02) 5 min after injection.
The second CCK8S injection increased plasma oxytocin concentration to a
significantly greater overall level in the 21 day pregnant rats compared with




Figure (5.3.1.1.; overleaf)- Effect of i.v. morphine on CCK8S-stimulated
release of oxytocin in the virgin female rat. The first CCK8S injection
increased plasma oxytocin (*** p<0.001, n=10; Paired Wilcoxon) and two
further injections of CCK8S after i.v. vehicle produced similar significant
increases (* p<0.05). Morphine (0.5 and 5 mg/kg) was given i.v. before the
second and third CCK8S injections and produced a dose-dependent
inhibition of the oxytocin response to stimulation by CCK8S, significant after
5 mg/kg morphine (# p<0.05, vs the first CCK8S response and vs the third
CCK8S response in the vehicle controls, Mann-Whitney U-test). I.v. injection
of naloxone (5 mg/kg) increased plasma oxytocin in both vehicle-treated (O)
and morphine-treated animals ( ▲ ; #p<0.05). Naloxone restored the
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Figure (5.3.1.2.)- Effect of i.c.v. morphine on CCK8S-stimulated release of
oxytocin in the virgin female rat. The first CCK8S injection significantly
increased plasma oxytocin concentration (*** p<0.001, n=12; Paired
Wilcoxon) and a further injection of CCK8S after i.v. vehicle produced a
similar increase (* p<0.05). Morphine (10 pg; 2 pg/pl) injected i.c.v. before
the second CCK8S injection, abolished the oxytocin response, (# p<0.05, vs.
CCK1 and p<0.001, vs. CCK2 in the vehicle group). Hypertonic saline (4
ml/kg) injected i.p. 25 min after the second CCK8S injection increased
plasma oxytocin in i.c.v. vehicle rats (Q) over the following 20 min (T p<0.05,
n=5), but had no effect on plasma oxytocin in i.c.v. morphine rats (A).
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Figure (5.3.2.1.; overleaf)- Effects of i.v. CCK8S and acute i.v. morphine on
release of oxytocin in the morphine dependent rat. I.v. injection of CCK8S
increased plasma oxytocin from basal in both i.c.v. vehicle-treated and i.c.v.
morphine-treated rats (* p<0.02, n=8 and 7 respectively; Paired Wilcoxon)
and a second injection of CCK8S after i.v. morphine produced a similar
significant increase (* p<0.02). Morphine (0.5 and 5 mg/kg) was given i.v.
before the second and third CCK8S injections and produced a dose-related
inhibition of the oxytocin response to stimulation by CCK8S in the vehicle-
treated animals (TT p<0.02, second CCK8S response vs the first CCK8S
response; T p<0.05, third CCK8S response vs the second CCK8S response).
In the morphine-treated animals, morphine (5 mg/kg) reduced the third
CCK8S response (@ p<0.05) relative to the first and second CCK8S
responses. I.v. injection of naloxone (5 mg/kg) increased plasma oxytocin in
both vehicle-treated (O) and morphine-treated animals {a ; # p<0.05),
although the increase was significantly greater in the i.c.v. morphine-treated
animals (**p<0.005; Mann-Whitney U-test).
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Figure (5.3.3.1Effects of i.v. clonidine on the CCK8S-stimulated oxytocin
neurosecretory response. The first injection of CCK8S increased plasma
oxytocin from basal in rats later given vehicle (O) or clonidine ( a ),
(**p<0.005, n=12; Paired Wilcoxon). Two further injections of CCK8S
produced similar significant increases in vehicle-treated animals (*p<0.05;
n=7). I.v. injection of clonidine (0.5 and 2.5 mg/kg) before the second and
third CCK8S injections completely suppressed the oxytocin responses to
CCK8S seen in the vehicle-treated animals (**p<0.005 and *p<0.05; Mann-
Whitney U-test). Naloxone increased plasma oxytocin concentration in both




























Figure (5.3.4.10- Effects of i.v. clonidine on withdrawal hypersecretion of
oxytocin in the morphine dependent rat. I.v. injection of naloxone (5 mg/kg)
given 10 min after administration of i.v. clonidine (2.5 mg/kg) produced a
significant withdrawal-induced increase in oxytocin secretion in both vehicle-
treated (O) and clonidine-treated ( ▲ ) animals, (*p<0.05; Paired Wilcoxon)
and this remained significant at each sampling point up to 40 min later
(*p<0.05; Repeated measures ANOVA). The naloxone initiated withdrawal
response was significantly greater in the vehicle group than in the clonidine




Figure (5.3.4.2.; overleaf)- Typical recordings obtained from urethane-
anaesthetised morphine dependent rats showing changes in mean arterial
blood pressure (MABP) and heart rate in response to i.v. clonidine
administration.
(a) Injection of i.v. vehicle had no effect on MABP or on heart rate.
Naloxone (5 mg/kg i.v. ) given 10 min after vehicle produced a small increase
in MABP lasting approximately 10 s. Heart rate remained unchanged
measured at 360 bts/min.
(b) Injection of i.v. clonidine (2.5 mg/kg) produced an initial rapid, short-
lasting increase in MABP and simultaneous decrease in heart rate from 420
bts/min. Naloxone given i.v. had similar effects on MABP and heart rate to
those observed for the control animal.




















Figure (5.3.5.1.; overleaf)- Effect of naloxone on CCK8S stimulation of
oxytocin release during pregnancy.
(a) Non pregnant rats- plasma oxytocin concentration was significantly
increased in both groups of rats after a first injection of CCK8S (*p<0.05, n=6
each case; Paired Wilcoxon). I.v. injection of naloxone ( A ), (2 mg/kg)
significantly increased (*p<0.05; Mann-Whitney U-test) plasma oxytocin 10
min after injection compared with i.v. vehicle (O). A second injection of
CCK8S significantly increased plasma oxytocin concentration in vehicle-
treated rats (*p<0.05) and naloxone-treated rats (*p<0.05). This latter
increase was more marked in the naloxone-treated animals compared with
vehicle-treated animals (#p<0.05).
(b) 21 Day pregnant rats- a first injection of CCK8S (20 pig/kg) increased
plasma oxytocin levels in both treatment groups (*p<0.05, n=8 each case;
Paired Wilcoxon). Injection of i.v. naloxone ( A ) induced a gradual increase
in plasma oxytocin concentration (#p<0.02) up to 20 min after injection, which
was significantly different from each corresponding time point in the vehicle-
treated animals (O), (**p<0.001; Mann-Whitney U-test). CCK8S potentiated
release of oxytocin compared with the corresponding CCK8S-stimulated
oxytocin response in the vehicle-treated rats (Tp<0.001) when injected for a
second time.
The second CCK8S injection increased plasma oxytocin concentration to a
significantly greater level in the 21 day pregnant rats compared with the non¬


































Opioid control of oxytocin release stimulated by systemic CCK8S
Systemic administration of CCK8S excites magnocellular oxytocin
neurones within the SON via actions on the gastric vagus, which has been
proposed to activate centrally ascending noradrenergic pathways originating
from the brainstem. This proved to be a repeatable, short-lasting stimulus to
release of oxytocin from the neurohypophysis in agreement with previous
studies (Blackburn and Leng, 1990). The dose-dependent inhibition of this
response by the p-opioid agonist morphine, indicates that p-receptors are
present somewhere on the input to oxytocin neurones activated by
intravenous CCK8S or on the oxytocin neurones themselves, although their
location could not be verified from this single experiment alone. However
acute i.c.v. administration of morphine was able to completely abolish the
oxytocin response to stimulation by intravenous CCK8S, suggesting that
morphine acts centrally to inhibit oxytocin secretion in response to this
stimulus.
Opioid receptors are known to be widely distributed throughout the central
nervous system (Mansour et at., 1988) and they are present within the
magnocellular nuclei of the hypothalamus (Sumner et at., 1990), possibly on
the afferent inputs to the magnocellular nuclei (Sumner et at., 1990) and at
the terminal level in the neurohypophysis (Herkenham et at., 1986). Since
only K-agonists such as U50, 488 inhibit oxytocin secretion at the level of the
neurohypophysis (Zhao et at., 1988a) this further indicates the inhibitory
actions of morphine on CCK8S-stimulated release as being centrally located.
This also confirms that CCK8S enhances oxytocin secretion by a means
other than at the neurohypophysis which is possible since CCK binding sites
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have been localised in this region (Bondy et at., 1989b). However CCK-
evoked neurohormone release from the isolated neural lobe occurs only after
a long latency (Bondy et at., 1989a), whereas release in vivo is immediate
and selective for oxytocin.
In rats treated chronically with morphine for 5 days an initial injection of
systemic CCK8S was again able to stimulate oxytocin secretion and this
response was similar to that observed in control rats. This is in agreement
with in vivo electrophysiological studies where CCK8S is able to induce a
rapid increase in neuronal firing rate of putative oxytocin secreting neurones
in morphine dependent rats (Pumford et a!., 1993). Therefore tolerance to
the central inhibitory actions of morphine on CCK8S-stimulated oxytocin
secretion must have developed in these morphine dependent rats, since
acute i.v. and i.c.v. morphine can respectively dose-dependently and
completely inhibit oxytocin secretion in response to systemic CCK8S (Figs.
5.3.1.1. and 5.3.1.2.). As with morphine naive animals, morphine (5 mg/kg)
was able to significantly attenuate oxytocin secretion in response to
stimulation by CCK8S in morphine dependent rats although seemingly not in
a dose-dependent manner, indicating that tolerance to the inhibitory actions
of i.c.v. morphine on magnocellular neurones is incomplete (Pumford et at.,
1993); thus tolerance in these neurones to a systemic CCK8S stimulus is
quantitative.
The inhibitory actions of morphine on oxytocin neuronal function would
appear not to be stimulus-selective since the secretory response to
stimulation with hypertonic NaCI was also abolished after the response to
CCK8S had been suppressed by an acute i.c.v. injection of morphine.
Intravenous injection of naloxone increased basal oxytocin levels in
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morphine naive rats confirming that endogenous opioids inhibit oxytocin
secretion in urethane-anaesthetised rats, and this is at the neurohypophysis
(Bicknell et al., 1988). The observed hypersecretion of oxytocin after i.v.
injection of naloxone in chronic morphine-treated rats was indicative of
physical dependence in these neurones as has been previously described
(Bicknell et al., 1988). The potentiating effect of naloxone on oxytocin
secretion stimulated by CCK8S (Flanagan et al., 1988; Leng et al., 1992) was
confirmed in the first experiment where morphine naive rats had the CCK8S
response inhibited by acute morphine restored by naloxone, supporting the
interactive role postulated for noradrenaline and opioids in the control of
oxytocin secretion.
Adrenergic control of oxytocin release in response to peripheral CCK8S
In conjunction with selectively stimulating release of oxytocin into blood
and within the SON, intravenous CCK8S also increases noradrenaline and
serotonin release measured by microdialysis within the dorsal region of the
SON (Kendrick et al., 1991).
Using the isolated neural lobe preparation Zhao and colleagues have
reported a requirement for removal of pre-synaptic a2-mediated and opioid
mediated inhibition of noradrenaline release before noradrenaline can act on
P and a! receptors to facilitate oxytocin and vasopressin release (Zhao et al.,
1988b). Such a mechanism of pre-synaptic control of noradrenaline from
terminals in the SON and ultimately oxytocin release from dendritic and
axonal processes of oxytocin neurones (Pow and Morris, 1989), may also
occur within the SON.
Release of oxytocin from the neurohypopyhsis into blood in response to
systemic CCK8S stimulation was completely suppressed by prior
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administration of the a2 agonist clonidine, even at the lowest dose tested (0.5
mg/kg Fig. 5.3.3.1.). From this present study alone it is impossible to say
whether clonidine suppressed CCK8S-stimulated oxytocin release via direct
and/or indirect actions on oxytocin neurone firing rate within the SON or via
pre-synaptically mediated inhibition of oxytocin release from oxytocin
terminals within the neurohypophysis. However intracellular recordings from
the SON in the rat hypothalamic slice preparation have shown that
noradrenaline depolarises and increases the activity of magnocellular
neurosecretory cells through an action on a-adrenergic receptors (Yamashita
et al., 1987) and this would appear to be mediated by ar rather than a2-
receptors, since clonidine is without affect on firing rate or firing pattern of
SON neurones in vitro (Randle et al., 1984). However such reports concern
only the direct actions of clonidine on basal firing rate and not on firing rate
enhanced by a stimulus such as intravenous CCK8S. Despite CCK8S being
able to evoke release of oxytocin from the isolated neurohypophysis (Bondy
et al., 1989a), CCK8S when given systemically most probably increases
release of oxytocin via actions on oxytocin neurone firing rate (Hamamura et
al., 1991). It seems likely therefore that clonidine was able to completely
suppress the oxytocin response associated with administration of CCK8S by
a pre-synaptic inhibitory effect on firing rate, although an attenuation of
secretory activity at the neurosecretory nerve terminals cannot be ruled out.
Measurement of noradrenaline release by microdialysis of the SON (which
would be attenuated if clonidine were acting to pre-synaptically inhibit
oxytocin neurone activation in response to systemic CCK8S administration)
would resolve this issue.
It should be noted however that in the lactating rat clonidine has both
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inhibitory and facilitatory influences on the milk-ejection reflex depending on
the exact dose given (Bailey et al., 1993). Such a finding could be a result of
morphological reorganisation of magnocellular oxytocin neurones which
takes place during lactation (Theodosis et al., 1986), which in turn may
reflect the differential involvement of noradrenergic mechanisms in the
control of oxytocin release in response to various stimuli.
Adrenergic and opioid interaction in control of oxytocin secretion from the
neurohypophysis during tolerance/dependence
In morphine dependent anaesthetised rats intravenous administration of
naloxone greatly potentiates secretory activity of oxytocin neurones (Bicknell
et al., 1988) as illustrated by the present data (Fig. 5.3.4.1.). This robust
stimulus to both oxytocin release within the SON (Russell et al., 1992) and
secretion from the neurohypophysis into blood (Bicknell et al., 1988) was
significantly attenuated by prior administration of clonidine which is
consistent with pre-synaptic inhibition of noradrenergic input, and suggests
that this input is essential for expression of withdrawal excitation in
magnocellular oxytocin neurones.
In vivo electrophysiological recording of SON oxytocin neurone firing rate
in the morphine dependent rat has provisionally shown that clonidine can
attenuate the naloxone-induced withdrawal increase in firing rate, this being
a specific receptor mediated event, which can be reversed by the a2
antagonist idazoxan (unpublished data). Thus clonidine probably attenuates
the withdrawal-induced secretory response by decreasing firing rate of
magnocellular oxytocin neurones. This may be via the locus coeruleus
where clonidine reduces withdrawal excitation of noradrenergic neurones
which may project to the SON, or within the SON itself by inhibiting release of
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noradrenaline from adrenergic inputs such as the A6 or A2 cell groups.
It could be argued that the dose of clonidine chosen (2.5 mg/kg) in an
attempt to suppress the withdrawal response was too small since it did not
completely suppress this robust stimulus to oxytocin secretion from the
neurohypophysis. Even at this dose clonidine caused an initial rapid
increase in blood pressure and decrease in heart rate compared with vehicle
(Fig. 5.3.4.2.), presumably via stimulation of peripherally located post¬
synaptic a2 receptors which are thought to reside on smooth muscle cells of
the blood vessel. The terminal half-life of clonidine in the human is
approximately 9 h when taken orally, and the reported transient rise in blood
pressure is normally followed by a more prolonged fall as a result of its
central actions (Hoffmann and Lefkowitz, 1990), although this was not
followed since measurement of blood pressure was discontinued shortly after
administration of naloxone, which itself appeared to have little effect on blood
pressure and heart rate. Such fluctuations in cardiovascular function could
potentially modulate activity of magnocellular neurosecretory neurones; more
so vasopressin than oxytocin neurones (Harris, 1979).
Treatment with clonidine completely removed the CCK8S-stimulated
oxytocin response in control rats, but only partially removed the withdrawal-
induced oxytocin response in morphine dependent rats. Adrenergic a2
receptors perhaps located within the SON, and certainly upon inputs to SON
oxytocin neurones may be saturated during withdrawal explaining why this
robust stimulus to oxytocin secretion is only partially attenuated by prior
administration with clonidine. On this basis, such a saturation effect does not
appear to have been in evidence during CCK8S stimulation of oxytocin
secretion which was completely abolished by clonidine. It is also possible
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that a facilitatory noradrenergic input is not essential for the full expression of
withdrawal excitation, but is required for systemic CCK8S-stimulation of
oxytocin neurones.
Cells of the locus coeruleus have been extensively studied in terms of
opiate tolerance and dependence. Withdrawal excitation of their firing rate is
also attenuated by administration of clonidine (Aghajanian, 1978) and
tolerance to opioids, but not dependence is readily demonstrated in vitro
(Christie et al., 1987) . Supraoptic magnocellular oxytocin neurones can
become tolerant to the inhibitory actions of morphine in vivo as previously
described (Bicknell et al., 1988), but in vitro inconsistently display
hyperexcitable characteristics typical of dependence during perfusion with
naloxone. As such this infers that an intact neuronal framework is a
prerequisite for initiation of the complete withdrawal response in these
neurones, possibly requiring inputs from cells of the locus coeruleus.
Consequently any noradrenergic input from this region which could
potentially drive magnocellular oxytocin neurones in the hyperexcitable
fashion associated with withdrawal, could only be a representative feature of
dependence in the supraoptic cells to which the input projects.
Adrenergic and opioid interaction in control of oxytocin secretion from the
neurohypophysis during pregnancy
Endogenous opioids can restrain release of oxytocin from the
neurohypophysis (Zhao et al., 1988a) and potentially within the SON
(Douglas et al., 1993). Dynorphin which is co-localised with vasopressin
(Meister et al., 1990) is an endogenous ligand for the K-opioid receptor
(Corbett et al., 1982), the principal opioid receptor found in the
neurohypophysis of the rat (Herkenham et al., 1986). These receptors may
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be located post-synaptically on oxytocin neurosecretory terminals or on
pituicytes which surround the terminals (Zhao et al., 1988a). Both p- and k-
opioid receptors are located within the SON (Sumner et al., 1990) where the
appropriate endogenous ligand can act to suppress oxytocin neurone firing
rate by direct actions (Wakerley et al., 1983a; Inenaga et al., 1990) and
possibly indirectly by inhibiting excitatory afferent pathways to the oxytocin
neurones.
It has been demonstrated both here (Fig. 5.3.5.1.) and previously in the
female virgin rat that naloxone enhances secretion of oxytocin in response to
systemic CCK8S (Leng et al., 1992), whilst the firing rate response to CCK8S
is unaffected by naloxone (Leng et al., 1992). In 21 day pregnant rats where
endogenous opioid restraint of oxytocin release is increased, the CCK8S-
stimulated oxytocin response in terms of firing rate is significantly greater
after intravenous injection of naloxone (Douglas et al., 1993). On this basis it
had been expected that the naloxone potentiation of CCK8S-stimulated
oxytocin release from the neurohypophysis observed in virgin rats (Leng et
al., 1992) would have been further enhanced in 21 day pregnant rats. The
potentiation observed in virgin animals results from removal of endogenous
opioid tone at the terminals in the neurohypophysis. This restraining action
of opioid peptides is decreased towards the end of pregnancy within the
neurohypophysis (Douglas et al., 1993) and increased within the SON
(Douglas et al., 1993), although it would be expected that naloxone
antagonism of these actions would occur at both locations, as is the case in
rats treated chronically with morphine (Leng and Russell, 1989). As central
opioid tone increases during pregnancy it may be expected that excitatory
input activity to the magnocellular oxytocin sysytem would increase tending
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to offset the opioid inhibition on oxytocin neuronal function as has been
proposed for morphine dependent rats. The markedly higher oxytocin levels
in pregnant rats compared with virgin rats, in response to naloxone
potentiation of CCK8S-stimulated oxytocin release supports the
electrophysiological data where naloxone potentiation of CCK8S stimulation
of oxytocin neurone firing rate is signicantly greater in pregnant than in virgin
rats (Douglas et at., 1993)
A possible ionic mechanism for noradrenaline actions on maqnocellular
oxytocin neurones
As yet the exact ionic mechanism by which noradrenaline exerts its
influence upon neurosecretory cells remains to be fully defined.
Noradrenaline and the oq agonist methoxamine, depolarise SON
neurosecretory cells and this can be diminished by membrane
hyperpolarisation and raising extracellular K+ concentration (Bourque and
Renaud, 1991). Yamashita and colleagues have speculated that the
depolarising actions of noradrenaline on SON cells could be due to the
opening of voltage dependent channels (Yamashita et at., 1987). Central
administration of the L-type voltage-activated Ca2+ channel antagonist
verapamil abolishes intravenous CCK8S stimulation of oxytocin release and
significantly attenuates morphine withdrawal induced release of oxytocin from
the neurohypophysis (Munro et at., 1993; see also Chapter 3). This action of
verapamil has been shown to occur centrally since it has no effect on
oxytocin release evoked by stimulation of the neural stalk. As a result of this,
it can be speculated that noradrenaline may actually depolarise SON
neurosecretory cells principally by opening of Ca2+ channels in conjunction
with suppression of a steady-state K+ conductance as previously suggested.
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Conversely verapamil may attenuate exocytotic release of noradrenaline
within the SON. However the precise location of the effects mediated by
verapamil require further investigation. Pre-synaptic release of
noradrenaline would appear to have facilitatory actions on the ionic currents
mentioned, perhaps within the noradrenergic terminals which in turn can
directly enhance the activity of magnocellular oxytocin neurones.
At the molecular level it would be of interest to know whether clonidine and
a2 agonists in general can inhibit the expression of c-fos mRNA and the
associated protein product Fos in withdrawn animals, not only in
magnocellular oxytocin neurones, but also in neurones which show opiate
tolerance and dependence distributed throughout the CNS. These markers
of neuronal activation undergo increased expression within oxytocin
neurones of the SON after naloxone-induced morphine withdrawal (Russell
et al., 1992; Johnstone et al., 1993). Such a study would provide a clearer
indication as to where exactly clonidine acts to attenuate secretory activity of
magnocellular oxytocin neurones during morphine withdrawal.
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Two types of cholecystokinin (CCK) receptor have been identified using
agonist response profiles in various tissue preparations (Innis and Snyder,
1980; Moran et al., 1986), which have subsequently been designated CCKA
and CCKb. Recently these distinct receptor subtypes have been further
characterised by molecular cloning techniques (Wank et al., 1992). CCKA
receptors are located in the periphery and some distinct brain regions
whereas CCKB receptors are widely distributed throughout the brain (Dietl
and Palacios, 1989). Although several forms of CCK with varying lengths of
amino acid chains have been isolated from the mammalian central nervous
system, it is the sulphated octapeptide (CCK8S) fragment which appears to
predominate (Larssen and Rehfeld, 1979). CCK interactions with dopamine,
and specifically neuromodulation of dopamine release, have been
extensively studied in the mesolimbic and nigrostriatal dopamine systems
which have been implicated in the development of schizophrenia and
Parkinson's disease respectively (Crawley, 1992). CCK has also been
colocalised with opioid peptides in nociceptive neurones of the thalamus and
brainstem (Gall, 1987).
CCK and opioid interactions
The antagonistic role of CCK to the actions of opioids has previously been
demonstrated. Itoh et al., (1982) observed a blockade of i.c.v. p-endorphin-
induced analgesia after i.c.v. administration of the CCK agonist caerulein and
this finding was further refined to incorporate administration of physiological
doses of CCK and blockade of opioid analgesia (Faris et al., 1983). In this
second study CCK was also shown to modulate analgesia mediated by
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endogenous as well as exogenous opioids as seen by its attenuating effect
on classically conditioned front paw foot shock.
Neurones of the intralaminar nuclei of the thalamus respond with either
excitation or inhibition to noxious stimuli (Han, 1992). Systemically
administered morphine can suppress the excitation and enhance the
inhibition, and both effects are blocked by i.c.v. CCK8S. In addition
prolonged morphine treatment results in tolerance to the neurophysiological
responses of its acute effects. These interactions between opioids and CCK
at the neurophysiological level have been replicated using electro-
acupuncture instead of systemic morphine (Han, 1992); electro-acupuncture
stimulates the release of endogenous opioids and induces analgesia.
Recently it has been shown that CCK receptor antagonists can, depending
on receptor subtype (CCKA or CCKB), influence morphine place conditioning
in the rat (Higgins et al., 1992) as well as enhancing morphine analgesia and
preventing morphine tolerance (Dourish et al., 1988; Dourish et al., 1990a).
CCK does not cross the blood-brain barrier very readily (Verbalis et al., 1986;
Hamamura et al., 1991) and this could explain why some studies have failed
to show CCK precipitated withdrawal in morphine-treated animals
(Pournagash and Riley, 1991).
CCK and opioid interactions within the SON
Morphine inhibits secretion of oxytocin from the neurohypophysis as
shown by its effects on the milk-ejection reflex in the lactating rat and on
parturition. When administered intraventricularly morphine inhibits the milk-
ejection reflex, whilst after chronic administration milk let-down returns after 2
days and within 4-5 days oxytocin release is normal indicating tolerance to
the central actions of morphine (Rayner et al., 1988). Morphine given either
132
Chapter 6
subcutaneously or by i.c.v. injection interrupts parturition for up to several
hours (Gosden et al., 1985; Luckman et al., 1993) despite the uterus
remaining responsive to oxytocin. Supraoptic neurosecretory cell activity is
inhibited by morphine in the hypothalamic slice (Wakerley et al., 1983a)
while low doses of morphine inhibit the firing-rate of putative oxytocin
neurones in the supraoptic nucleus of virgin female rats indicating that p-
receptor inhibition of oxytocin release can occur centrally (Pumford et al.,
1991). This is supported further by p-receptor autoradiographic localisation
within the SON (Sumner et al., 1990).
CCK is colocalised within supraoptic magnocellular oxytocin neurones as
shown by immunocytochemistry (Vanderhaeghen et al., 1981; Hokfelt et al.,
1988) and in situ hybridisation histochemistry (Ingram et al., 1989), whilst
CCK levels within the neurohypophysis are depleted upon activation of the
oxytocinergic system (Deschepper et al., 1983). Exogenously applied
CCK8S can directly influence the excitability of rat supraoptic neurones
within the hypothalamic explant maintained in vitro and these receptors would
appear to be located on the oxytocin neurones (Jarvis et al., 1992).
Binding for [125I]-CCK8S within the SON is enhanced in salt-loaded and
homozygous Brattleboro rats (Day et al., 1989). Salt-loading is known to
activate the magnocellular neurohypophysial neurosecretory system as
shown by electrophysiology (Brimble and Dyball, 1977) and localised
expression of Fos immunoreactivity (Giovannelli et al., 1990). Furthermore,
following lesions anterior and ventral to the third ventricle, an identified
central site involved in the regulation of fluid balance, [125I]-CCK8S binding in
the SON still increases in response to salt-loading (Blackburn et al., 1990).
More recently salt-loading has been shown to increase both CCKA and CCKB
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receptor content within the hypothalamus, indicating that the reported
changes in binding site density probably reflect functional CCK receptors
(Hinks etal., 1993). Food deprivation and dehydration in rats decreases and
increases CCK receptor density within the SON respectively, and this is
thought to be regulated in line with neurochemical activity of predominantly
oxytocin neurones in this nucleus (O'Shea and Gundlach, 1993).
In view of the antagonistic actions between CCK and opioids (both
endogenous and exogenous) and the well defined changes in CCK8S
binding site density within the SON upon activation of the magnocellular
oxytocin system, we have employed an in vitro autoradiographic method to
try to assess if increased CCK8S binding within the rat SON may be
responsible for the development of tolerance to and be partially involved in






Under ether anaesthesia the rats (body weight; 241-282 g, n=6) were
implanted with an i.c.v. infusion assembly connected to a subcutaneously-
implanted osmotic mini-pump (Alzet 2001) containing morphine sulphate
solution in three sequentially increasing concentrations (10 pg/pl, 20 pg/pl
and 50 pig/pil) with each solution separated by a 1 pi air bubble and delivered
at a rate of 1 pl/h over a 40 h period (see General Methods, section 2.3.3.).
The infusate was delivered for 5 days into a lateral cerebral ventricle (2 mm
right lateral to bregma, 3 mm posterior to bregma and 4.5 mm below the skull
surface).
Rats in the i.c.v. vehicle-treated group (280-308 g, n=6) were implanted
with an i.c.v. infusion assembly as outlined above, but containing sterile
pyrogen-free distilled water.
The saline-treated group (249-291 g, n=4) had their normal drinking water
replaced with a solution of 2% w/v sodium chloride (NaCI) for 48 h.
The control group (252-302 g, n=4) received no experimental treatments.
2. Tissue
Preparation of tissue obtained from rats took place over a 6 day period.
On the first and second days, a number of rats prepared as above, were
taken from each group and decapitated. The brains were removed and
blocked coronally, including tissue 1 mm anterior to the optic chiasm through
to the posterior limit of the mammillary bodies. These blocks were
immediately frozen onto a pre-cooled layer of Tissue-Tek OCT compound on
a cold cryostat chuck standing on dry ice. Blocks were stored in the freezer
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at -70°C until sectioning was carried out at -18°C using a cryostat (Bright
Instrument Co. Ltd, Cambridge, model FS/FAS/M) over the remaining four
days. 10 pm transverse sections were thaw-mounted onto acid-cleaned,
chrome alum-gelatine-subbed slides. 10 sections were taken from each rat,
containing anteriorly located SON for the 3 incubation categories. Mounted
sections were stored at -70°C in sealed Kartell boxes, containing silica gel for
up to 11 days prior to the incubation stage.
3. Radioligand
The radioligand was CCK8 (sulphated), 125l-labelled with Bolton and
Hunter reagent, [125I]-CCK8S, (specific activity -2000 Ci/mmol, -74
TBq/mmol, Amersham International pic, Amersham, UK). Stock [125I]-CCK8S
was added to 10 mM HEPES buffer containing NaCI [130 mM], KCI [4.7 mM],
MgCI2 [5 mM], EGTA [1 mM], bacitracin [0.25 mg/ml], and bovine serum
albumin [5 mg/ml] to achieve a final concentration of 0.25 nM.
4. Unlabelled liqand
The unlabelled ligand CCK8 (sulphated), (Bachem, Saffron Walden, UK)
was made up to a final concentration of 1 pM in 10 mM HEPES buffer
containing [125I]-CCK8S (0.25 nM). The excess was required in order to
competitively displace the radioligand from the CCK binding sites in control
studies.
5. Preincubation with [125I1-CCK8S
[125I]-CCK8S was used as the radioligand to probe for CCK binding sites in
the SON and the following protocol was used (Day et a!., 1989). Sections
were preincubated for 15 min at room temperature in 50 mM Tris-HCI buffer,
pH 7.4, which was applied as a 40 pi puddle in order to completely immerse
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the section. Slides were kept in chambers moistened with the preincubation
medium for this period, after which the puddles of preincubation medium
were drained off the slides and replaced with 40 pi puddles of incubation
medium made up in 10 mM HEPES buffer, pH 7.4 at room temperature. In
this particular study we looked only for changes in specific binding to CCK
binding sites and so there were 3 incubation categories (see table 6.2.5.1.).
1. [125I]-CCK8S alone (total CCK binding) 2. [125I]-CCK8S plus unlabelled
CCK8S (non-specific CCK binding) 3. no [125I-CCK8S or unlabelled CCK8S
(chemographic control). The sections were then incubated for 2 h at room
temperature in chambers moistened with HEPES buffer, after which the
slides were removed and the incubation medium drained off. The slides
were then placed in racks and gently immersed in 3 consecutive ice-cold
buffer washes (50 mM Tris-HCI, pH 7.4 at 0°C) for 5 mi.n each wash. Finally,
sections were rinsed briefly in ice-cold double-distilled-deionised (DDD)
water to remove salts and dried in air. Sections were then ready for
autoradiography which was started on the same day as incubation.

















Sections were at room temperature and apposed to Hyperfilm-3H
(Amersham) keeping slides which had been incubated in [125I]-CCK8S only
and [125I]-CCK8S plus unlabelled CCK8S adjacent. Slides from a total of 5
rats were apposed to each sheet of film so that the sheet contained tissue
from at least 1 rat per treatment group. A pre-cut 20 pm thick section of a
[125l] standard (Autoradiographic [125l] microscales, Amersham) attached to a
glass slide was placed in the centre of each sheet of Hyperfilm. The sheets
of film with attached slides were then sandwiched between mirror-coated
glass tiles, held in place with masking tape. They were then enclosed in
aluminium foil, wrapped in brown paper and a black plastic bag to prevent
moisture and light penetration before being left to expose at 0-4°C in the
dark.
An initial exposure period of 2 days was employed to produce measurable
grain densities over tissue sections which were below saturation in all
positive incubations, but after trial this was adjusted to 4 days to obtain an
optimum image.
After exposure, the films and slides were brought to room temperature and
the slides removed for later histological preparation. The films were
developed at room temperature in Kodak D19 developer for 5 min, rinsed
briefly in tap water, fixed in llford Hypam rapid fixer for 5 min (1: 4 fixer: tap
water), rinsed for 30 min in running tap water and dried in air.
The sections were fixed for 10 min in acetic acid: alcohol: formaldehyde
(1: 17: 2 by volume), washed in running water for 5 min, dehydrated through
a series of alcohol baths (70, 90 and 100%; 2-3 min in each) and transferred
to a xylene bath for 10 min before rehydrating through alcohol baths in
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reverse. After a 5-10 min wash in running water sections were stained for
10-15 min in 1% Cresyl Fast Violet, washed briefly in running water and
dried. They were then dehydrated in absolute alcohol, transferred to an
alcohol/xylene bath (50/50), cleared in xylene, mounted in DPX and
coverslipped.
7. Measurement of autoradiographs
Pieces of film which corresponded to the apposed slides were cut out and
attached to clean microscope slides with clear adhesive tape.
Autoradiographs and stained sections were paired and examined under a
binocular dissecting microscope (Carl Zeiss, magnification x 1.6) to identify
the SON. The boundaries of the SON were outlined by scratching the
emulsion coated side with a fine needle under the dissecting microscope.
Silver grain density was then measured using a Joyce-Loebl pMagiscan
image analysing computer with video input from a COHU High Performance
CCD black and white camera (Brian Reece Scientific Ltd.) mounted on a
Vickers M17 microscope. Microscope magnification was x 10 (objective) and
x 1.6 (intermediate lens). The video monitor scale factor was 1.1878 pm per
pixel. A rectangular counting frame (201.63 x 133.04 pm) was outlined which
was smaller than the area of any SON so that measurements could be made
selectively over the dorsal region of the SON.
8. Expression of results as mean grain density values
Silver grain density was calculated as the total area of silver deposit/total
area of counting frame. A non-tissue background count was made after each
SON tissue count over an adjacent region of film and subtracted from the
corresponding tissue count. These subtracted counts were then averaged
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for each rat, and then for each group to obtain a mean grain density value for
each incubation category. To obtain a mean grain density value for specific
binding sites for CCK for each rat, the mean grain density value for non¬
specific binding was subtracted from the mean count achieved for total
binding. To account for variability between the sheets of film the 3 treatment
groups on a single sheet of film were indexed to the control (untreated) group
on that film. Mean grain density values for the 4 control sub-groups from the
4 sheets of film thus had an index value of 1. The mean grain density
indexed values for rats in a given treatment group were then grouped and a
mean value ± SEM obtained. All measurements of mean grain density were
made 'blind'.
9. r125ll polymer standards
Expression of mean grain density values as absolute values requires
reference to either [125l] brain paste standards or [125l] polymer standards.
Both enable the optical density values obtained for the tissue
autoradiographs to be expressed in radioactive units. Pre-cut strips of
polymer standards (Amersham) consist of 10 layers of radioactive polymer
arranged in order of increasing specific activity separated by non-radioactive
layers. A standard strip was attached to each sheet of Hyperfilm enabling a
standard curve of mean grain density vs radioactivity to be constructed. This
is necessary since Hyperfilm does not respond in an absolutely linear fashion
in terms of silver grain deposition upon exposure to increasing activity of
radioactive sources.
Ideally the conversion from mean grain density values obtained for each
treatment group should have been made to radioactive units to enable
expression of results in terms of fmole ligand bound/mg tissue. In order to
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obtain optimal images for measurement of silver grain deposition an
exposure period of four days was required. However the specific activity of
the standard strip (even after the removal of the top two steps) was so high,
that after this time considerable background fogging had occured around the
top two steps. Consequently when the background counts were subtracted
from the counts obtained for the respective steps, values markedly lower
than the previous three bottom steps were obtained. On this basis the
standard curve of mean grain density vs radioactivity would have had to have
been plotted using just three points. Furthermore mean grain density values
obtained for the chemography controls and vehicle-treated animals did not lie
on this line, so that extrapolation of the line was required. However since the
highest mean grain density values obtained for the remaining groups fell
upon this line which in essence was linear, it can be assumed with a degree
of confidence that the emulsion had responded in a linear fashion over the
uppermost observed range of receptor binding. Although an extrapolation of
the standard curve would have been required in order to estimate those
values at the bottom end of the range it would have been of a small enough
magnitude such that it would have been highly unlikely to be non-linear in
nature. It was decided therefore to express results solely as mean grain
density values since the aim was to seek changes between groups of
animals.
10. CCK antagonists
The specific CCK receptor antagonists MK-329 (L-364, 718; 1-methyl-3-(2-
indoloyl)amino-5-phenyl-3H-1,4-benzodiazepin-2-one) and L-365, 260
(3R(+)-N-(2,3-dihydro-1 -methyl-2-oxo-5-phenyl-1 H-1,4-bensodiazepin-3-yl)-
N'-(3-methyl-phenyl)urea) which bind preferentially to CCKA and CCKB
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receptors in rat brain respectively (Hill and Woodruff, 1990) were used in an
initial study to discriminate between CCK binding sites. These compounds
were solubilised initially in vehicle (20% dimethyl sulphoxide/80% propylene
glycol v/v) to a concentration of 10 mM (Dourish et at., 1988). They were
further diluted in DDD water and HEPES buffer to a concentration of 10 pM.
During the wash procedure in ice-cold HEPES buffer as described in
section 6.2.5., it became apparent that the antagonist vehicle did not rinse
completely away from the sections, and upon subsequent autoradiographic
exposure, sections which had been incubated with either antagonist or
antagonist vehicle were markedly fogged. Indeed it was still possible to
identify the outline of the incubation puddle around the majority of these
sections. Although no mention is made of the antagonist vehicle used by Hill
and Woodruff (1990), the concentrations of antagonist used were 100 fold
lower for L-365, 260 (100 nM) and 1000 fold lower for L-364, 718 (10 nM). It
is possible that the aforementioned problem could have been avoided if both
antagonists had been further dissolved in buffer to concentrations similar to
that used by Hill and Woodruff, (1990).
11. Statistics
Comparison of indexed mean grain density values between groups was
made by performing a one-way ANOVA on the 3 treatment groups to obtain a




6.3.1. Qualitative distribution of CCK8S binding sites within rat midbrain
Localisation of [125I]-CCK8S binding sites within discrete brain areas was
determined using the rat atlas of Paxinos and Watson, (1982). The
abbreviations used in the labelling of the autoradiographs and stained
marker sections were obtained from the same source.
1. I.c.v. morphine-treated and i.c.v. vehicle-treated groups
[125I]-CCK8S binding sites, visualised as darker areas of silver grain
density were clearly localised in the SON of the hypothalamus in both groups
of animals (Figs. 6.3.1.1.A.a. and 6.3.1.1.B.a.), although less intensively in
the vehicle group and this was statistically significant on quantification
(section 6.3.2.). [125I]-CCK8S binding sites were also visually apparent within
the anterior cingulate cortex, frontoparietal cortex and the caudate putamen
in both groups. The thalamus which lies above the third ventricle
demonstrated specific [125I]-CCK8S binding and this would appear to be have
been specific to the i.c.v. vehicle group (Fig. 6.3.1.1.B.a.). Similarly [125l]-
CCK8S binding within the reticular thalamic nuclei was specific to morphine-
treated animals.
Non-specific [125I]-CCK8S binding (Figs. 6.3.1.1.A.b. and 6.3.1.1.B.b.) in
the sections adjacent to those in Fig. 6.3.1.1.A.a. and Fig. 6.3.1.1.B.a.
respectively, as defined with an excess of unlabelled CCK8S (1 pM),
demonstrates that the majority of the [125I]-CCK8S binding seen in the total
binding images corresponds to specific [125I]-CCK8S binding. The stained
marker sections (Figs. 6.3.1.1.A.C. and 6.3.1.1.B.C.) clearly contain both SON
and so the lack of [125I]-CCK8S binding (Figs. 6.3.1.1.A.a. and 6.3.1.1.B.a.)
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within the SON can not be attributed to damaged or missing SON.
2. Salt loaded group and untreated controls
[125I]-CCK8S binding sites were very densely labelled within the SON of
salt-loaded animals (Fig. 6.3.1,2.A.a.) and specific [125I]-CCK8S binding in
this region was clearly increased in these animals compared with the
untreated controls (Fig. 6.3.1.2.B.a.). [125I]-CCK8S binding appeared to be
homogeneous throughout the dorsal oxytocin neurone-rich region of the
nucleus. [125I]-CCK8S binding sites were also labelled within the anterior
cingulate cortex, frontoparietal cortex and the caudate putamen in both
groups of animals. [125I]-CCK8S binding was also present in the region
adjacent to the third ventricle in both groups and may have been specifically
localised within the anterior paraventricular thalamic nucleus (which lies
beside the third ventricle).
Non-specific [125I]-CCK8S binding (Figs. 6.3.1.2.A.b. and 6.3.1.2.B.b.) in
the sections adjacent to those described above demonstrates that total [125l]-
CCK8S binding seen in Figs. 6.3.1.2.A.a. and 6.3.1.2.B.a. corresponds to
specific [125I]-CCK8S binding.
6.3.2. Quantitative analysis of [125I]-CCK8S binding within the supraoptic
nucleus
Specific [125I]-CCK8S binding in the SON increased significantly by 2.4 fold
(p<0.01) after i.c.v. morphine treatment compared with the i.c.v. vehicle-
treated group and by 1.4 fold (p<0.05) compared with the untreated control
group (Fig. 6.3.2.1.). There was no difference in [125I]-CCK8S binding
between the morphine-treated group and the salt-loaded group. Salt-loading
significantly increased [125I]-CCK8S binding site density by 1.5 fold (p<0.05)
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compared with the untreated controls. Specific [125I]-CCK8S binding was




Figure (6.3.1.1 .A.; overleaf)- i.e.v. morphine-treated group
a) and b) are representative autoradiographs showing total [125I]-CCK8S
binding and non-specific [125I]-CCK8S binding respectively, demonstrated by
silver grain deposition obtained from 10 pm transverse sections. The
difference in [125I]-CCK8S binding between a) and b) demonstrates that the
majority of [125I]-CCK8S binding in a) clearly localised within the SON, ACg,
FrPaM, CPu and Rt corresponds to specific [125I]-CCK8S binding.
c) and d) stained sections showing rostrally located SON adjacent to optic
chiasm. Scale bar=1 mm.
Abbreviations used: SON-supraoptic nucleus, ACg-anterior cingulate





Figure (6.3.1.1.B.; overleaf)- i.e.v. vehicle-treated group
a) and b) are representative autoradiographs showing total [125I]-CCK8S
binding and non-specific [125I]-CCK8S binding respectively, demonstrated by
silver grain deposition obtained from 10 pm transverse sections. As with Fig.
6.3.1.1.A. the difference in [125I]-CCK8S binding between a) and b)
demonstrates that the majority of [125I]-CCK8S binding in a) clearly localised
within the SON, ACg, FrPaM, CPu and Th (lying above the third ventricle)
corresponds to specific [125I]-CCK8S binding.
c) and d) stained sections showing rostrally located SON adjacent to optic
chiasm. Scale bar=1 mm.
Abbreviations used: SON-supraoptic nucleus, ACg-anterior cingulate
cortex, FrPaM-frontoparietal cortex, motor area, CPu-caudate putamen, Th-




Figure (6.3.1.2.A.; overleaf)- saline-treated group
a) and b) are representative autoradiographs showing total [125I]-CCK8S
binding and non-specific [125I]-CCK8S binding respectively, demonstrated by
silver grain deposition obtained from 10 pm transverse sections. The
difference in [125I]-CCK8S binding between a) and b) demonstrates that the
majority of [125I]-CCK8S binding in a) clearly localised within the ACg, FrPaM,
CPu and PVA corresponds to specific [125I]-CCK8S binding. In this group
binding within the SON was very dense compared with the other labelled
areas.
c) and d) stained sections showing rostrally located SON adjacent to optic
chiasm. Scale bar=1 mm.
Abbreviations used: SON-supraoptic nucleus, ACg-anterior cingulate
cortex, FrPaM-frontoparietal cortex, motor area, CPu-caudate putamen, PVA-






Figure (6.3.1.2.B.; overleaf)- unoperated control group
a) and b) are representative autoradiography showing total [125I]-CCK8S
binding and non-specific [125I]-CCK8S binding respectively, demonstrated by
silver grain deposition obtained from 10 pm transverse sections. The
difference in [125I]-CCK8S binding between a) and b) demonstrates that the
majority of [125I]-CCK8S binding in a) clearly localised within the SON, ACg,
FrPaM, CPu and PVA corresponds to specific [125I]-CCK8S binding.
c) and d) stained sections showing rostrally located SON adjacent to optic
chiasm. Scale bar=1 mm.
Abbreviations used: SON-supraoptic nucleus, ACg-anterior cingulate
cortex, FrPaM-frontoparietal cortex, motor area, CPu-caudate putamen, PVA-























Figure (6.3.2.1.)- Silver grain density (mm2 silver deposit/mm2 of field);
corrected for non-specific binding and expressed as a ratio to the unoperated
control group. * p<0.05, # p<0.02, ** p<0.01; calculated using Student's t-





CCK8S binding in rat brain with specific reference to the SON
The autoradiographic technique employed in this study used a peptide
labelled with 125l. Different brain regions have been reported to show no
differences from each other in the way they absorb emitted particles from this
radionuclide (Davenport and Hall, 1988). As a result detection of binding
throughout the brain regions mentioned should have been homogeneous.
CCK is extremely abundant in the mammalian cerebral cortex (layers ll-lll,
V-VI) and has been ascribed a putative role as a neurotransmitter in this
region (Vanderhaeghen and Schiffman, 1992). Little is known of its
physiological function although a possible neurotransmitter interaction with
y-amino butyric acid (GABA) has been intimated. CCK8S binding sites were
clearly localised in the anterior cingulate cortex and frontoparietal cortex in
all four treatment groups. Similarly CCK8S binding sites were localised
within the caudate putamen in each group and the intensity of labelling did
not appear to differ significantly between groups in agreement with the study
of Day eta!., (1989).
CCK8S binding increases in the SON of salt-loaded rats and homozygous
Brattleboro rats (Day et ai, 1989). Salt-loading has subsequently been
successfully used as a positive control for CCK8S binding within the SON in
this present study. Other studies using different radioactively labelled
ligands to probe for CCK binding sites have also reported the presence of
CCK receptors within the SON (Carlberg et at., 1992). It has been suggested
that the increase in CCK8S binding in the SON of salt-loaded rats occurs in
the rostrally located dorsal oxytocin rich half of the nucleus (Day et at., 1989),
primarily at CCKA receptors (Hinks et at., 1993), and autoradiographical
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competition studies have shown that the change reflects an increase in
binding site density (Bmax) rather than affinity (Kd), (Day et at., 1989).
The present results demonstrate that there is an increase in specific
CCK8S binding site density within the SON in morphine dependent rats
compared with i.c.v. vehicle-treated and untreated control rats (Fig. 6.3.2.1.).
Recently it has been shown that salt-loading induces a small increase in
CCKb and a much larger increase in CCKA receptor content within the
hypothalamus (Hinks et at., 1993) and that this is associated with increased
levels of preproCCK mRNA and oxytocin mRNA. Thus in rats treated
chronically with morphine the increase in CCK8S binding site density within
the SON (Fig. 6.3.2.1.) may be a result of upregulated synthesis of CCK
reflecting increased activity of endogenous CCK control of magnocellular
oxytocin neurone activation. The implications of this increase in CCK binding
site density (which may reflect an increase in functional CCK receptor
content) within the SON, in terms of the development of tolerance and
dependence in SON oxytocin neurones is discussed later.
Thus far we have looked at the situation where CCK8S binding site
density increases within the SON. However in animals which received an
i.c.v. infusion of vehicle for 5 days, CCK8S binding was significantly
attenuated compared with the unoperated controls (Fig. 6.3.2.1.). The
vehicle infusate consisted of sterile, pyrogen-free distilled water which would
tend to decrease tonicity of cerebrospinal fluid. Since a hypertonic stimulus
upregulates CCK8S binding within the SON as shown in this present study
and previously (Day et at., 1989; Blackburn et at., 1990), simplistically one
might expect a hypotonic stimulus to have the converse effect, causing
downregulation of CCK8S binding. Although this is a reasonable assumption
156
Chapter 6
since magnocellular neurones are directly osmosensitive (Leng et at., 1982;
Oliet and Bourque, 1993) a problem arises from the fact that the infusion rate
of vehicle (1 pl/h) into a much larger ventricular space would have been
unlikely to change local osmotic conditions in the SON region due to diffusion
throughout the ventricle. The region anterior and ventral to the third ventricle
(AV3V region) is itself intrinsically osmosensitive and includes the nucleus
medianus which has been reported to contain CCK8-immunoreactive cell
bodies (Kawano et at., 1989). Ablation of structures in the AV3V region
markedly impairs the neuronal response of supraoptic neurones to systemic
hyperosmotic stimulation (Leng et at., 1989), indicative of neuronal
projections from the AV3V region to the SON. Recently it has been reported
that brief osmotic stimulation of the organum vasculosum of the lamina
terminalis (OVLT) which projects to the AV3V region and to the SON,
produces a sustained enhancement of magnocellular neurosecretory cell
firing rate because the osmotically-induced increase in firing in OVLT
neurones is itself long-lasting (Bourque et at., 1993). One explanation for the
observed decrease in CCK8S binding in i.c.v. vehicle-treated rats therefore
may be that infusion of vehicle directly into the vicinity of the AV3V region
could change local conditions in osmolality thereby affecting the neuronal
population which would subsequently modulate activity of the magnocellular
neurones in the SON.
Since the autoradiographic resolution obtained was of a fairly low order in
the present study there was no means by which the components within the
SON to which the silver grains were localised could be identified. One way
in which this could be achieved however, would be to combine tissue
receptor autoradiography with immunocytochemistry allowing visualisation of
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CCK8S binding sites with identified components, be they neuronal,
presynaptically located or on glial cells. Interestingly, within the SON, the
glial cell bodies and the magnocellular neuronal dendrites which receive the
majority of synaptic contacts are located in the ventral glial lamina
(Armstrong et at., 1982) and as already mentioned oxytocin cells tend to be
located more dorsally than vasopressin cells (Sofroniew et at., 1981). The
glial cell processes which normally pervade the whole nucleus, retract
following saline drinking especially from the dorsal region of the nucleus
(Theodosis et at., 1984). Thus, the increase in specific CCK binding within
the SON after saline drinking may be localised to the cell bodies of the
magnocellular neurosecretory cells.
CCK involvement in development of tolerance and dependence
It was quickly realised from early studies that CCK could antagonise
opiate-induced analgesia in the rat (Itoh et at., 1982), and since central
administration of CCK8S has been shown to be a potent antagonist of opiate
analgesia produced by foot shock and morphine it has been suggested that
endogenous CCK could act physiologically as a specific functional opiate
antagonist in pain-mediating pathways (Faris et at., 1983). Against these
early studies have come reports suggesting that CCK is actually analgesic in
its own right (Hill et at., 1987b; Hong and Takemori, 1989), although these
results are probably best explained by the high administration doses of CCK
employed throughout these experiments.
Magnocellular neurones within the SON respond to chronic morphine
treatment further with a reduction in density of available ^.-opioid binding
sites and this is thought to account at least in part to morphine tolerance in
relation to oxytocin secretion (Sumner et a!., 1990). CCK receptors and p-
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opioid receptors are located on the cell bodies of supraoptic oxytocin
neurones (Inenaga etai, 1990; Jarvis et al., 1992; Oliet and Bourque, 1992).
CCK8S has been reported to inhibit the binding of p-ligands to their
respective receptors in rat brain homogenates and this suppressive effect is
almost completely blocked by the CCK antagonist proglumide implying that
the inhibition is mediated by CCK receptors (Wang and Han, 1992). Thus
the receptors responsible for mediating the effects of morphine and CCK8S
on oxytocin neurone electrical activity may converge on the same effector
component at the cellular level to mediate a neurosecretory response.
Binding to p-receptors in the rat brain activates a pertussis-toxin-sensitive G-
protein (Pumford et al., 1993) which has been postulated to act via a protein
phosphatase regulated pathway to reduce dihydropyridine Ca2+ channel
sensitivity (Armstrong and White, 1992), and blocking of these channels
attenuates morphine withdrawal excitation of oxytocin neurones in the SON
(Munro et al., 1993). The role of central CCK receptor activation on Ca2+
channel function remains to be fully defined. Although morphine and CCK
mediated effects on magnocellular oxytocin neurones do not appear to
involve a Ca2+ component acutely, the development of tolerance and
dependence in these neurones does involve such a component.
Consequently binding to CCK receptors may alter the balance of this effector
component displacing it away from opioid receptor availability with
subsequent development of tolerance to the inhibitory actions of morphine.
Oxytocin neurones would then be able to function normally in morphine-
treated rats as has been indicated by similar plasma oxytocin concentrations




This scenario has a physiological relevance since endogenous opioid
restraint is thought to be an important factor in the control of oxytocin
secretion throughout gestation leading into parturition. In late pregnant rats
this endogenous opioid inhibition of oxytocin release is centrally mediated
(Douglas et at., 1993). Pregnancy has been shown to alter the binding of
opioids within the SON (Sumner et at., 1992) with a down-regulation of p-
receptors. Thus a tolerance-like state of oxytocin neurones to the inhibitory
actions of endogenous opioids during pregnancy could be partly attributed to
a manifestation of increased CCK binding within the SON, similar to that
seen in the morphine treated animals of the present study. Removal of
increased opioid tone either within the SON or on excitatory inputs to
oxytocin neurones within the SON at the end of pregnancy would enable
dendritically released oxytocin and CCK to facilitate oxytocin neurone









Cholecystokinin (CCK) is a 33 amino acid peptide originally isolated in the
gastrointestinal tract before being shown to be widely distributed throughout
the CNS. The sulphated octapeptide (CCK8S) is the predominant form
present in the CNS and has been attributed functions as a neurotransmitter
throughout the brain (Crawley, 1992). A number of studies have focussed on
the potential for CCK to act as an endogenous opioid antagonist within
neuronal systems (Itoh et al., 1982; Faris et al., 1983; Han, 1992; Zhou et ai,
1993), based in part on evidence such as CCK colocalisation with opioid
peptides in thalamus and brainstem nociceptive neurones (Gall, 1987).
CCK has been immunocytochemically colocalised within supraoptic
oxytocin neurones (Vanderhaeghen et al., 1981; Martin et al., 1983a; Hokfelt
et al., 1988), whilst CCK8S excites both supraoptic putative oxytocin and
vasopressin neurones in vitro via activation of a non-selective cationic
conductance (Jarvis et al., 1992). A similar response is seen for
magnocellular cells isolated from their dendritic field and afferent input by an
enzymatic neuronal separation procedure (Oliet and Bourque, 1992). The
depolarising response is tetrodotoxin resistant, persists in Ca2+-free media,
and is reversibly attenuated by the high affinity antagonist L-365,260
indicating that the receptors are CCKB receptors post-synaptically located on
the oxytocin neurones (Jarvis et al., 1992). In addition direct administration
of CCK8S into the SON stimulates oxytocin release measured by
microdialysis into blood and within the SON itself (Neumann et al., 1993).
Both [i- and K-opioid receptors are present within the SON (Sumner et al.,
1990). Application of the pt-opioid agonist morphine to the SON in the
perfused hypothalamic slice inhibits putative oxytocin neurone electrical
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activity (Wakerley et al., 1983a; inenaga et al., 1990). Dynorphin which is
selective for the K-type receptor inhibits both vasopressin and oxytocin
neurone electrical activity (Inenaga et al., 1990; Bourque et al., 1993).
Recently it has been reported using conventional intracellular recording
techniques (which permit the relative involvement of separate ionic currents
involved in cell function to be identified) that K-receptor agonists suppress
excitatory synaptic inputs to the SON by a probable pre-synaptic mode of
action although post-synaptic suppression has not been excluded (Inenaga
et al., 1994). In addition K-receptor agonists were also shown to attenuate
the duration of the Ca2+ component of the action potential in SON neurones
whilst a p-receptor agonist was largely without effect on this Ca2+ component
(Inenaga et al., 1994).
In the previous chapter CCK8S binding was shown to increase within the
SON of morphine dependent rats and it was proposed that this may alter the
balance of a shared post-effector component away from the inhibitory effects
of p-opioid receptor occupancy towards that of the excitatory effects
mediated by the CCK receptor. As yet the cellular mode of action by which
CCK exerts a facilitatory influence on magnocellular electrical activity has not
been described, whilst morphine tolerance in these neurones may be
associated with activation of a pertussis-toxin-sensitive G protein (Pumford et
al., 1993).
In a preliminary series of studies the direct actions of CCK8S and opiates
(particularly morphine) on magnocellular neurosecretory cells were
investigated in vitro using the hypothalamic slice preparation to try and
establish if a two way functional relationship on the electrical activity of
magnocellular neurosecretory cells occurs between CCK and opiates;
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implicative perhaps of a shared second messenger component mediating
effects on neuronal electrical activity.
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7.2. MATERIALS AND METHODS
7.2.1. Actions of CCK and opioids on supraoptic magnocellular
neuronal firing rate
1. Animals
Virgin female Sprague-Dawley rats (body weight 200-300 g) housed under
standard conditions (see General Methods, section 2.1.) were used
throughout these experiments.
2. Electrophysiology
Animals were killed by decapitation using a guillotine (Harvard Apparatus
Ltd, Kent). A midline skin incision was then made over the dorsal surface of
the skull and the skin retracted. Scissors were then inserted into the foramen
magnum and the bone lateral to this on either side was carefully sheared
towards the rostral end of the cerebellum. The dorsal surface of the skull
was then removed with a pair of bone nibblers to expose the brain. Using a
scalpel incisions were made at the most rostral and caudally accessible
regions of the cerebral hemispheres. This loosened the dura which was then
completely removed to prevent damaging the soft brain tissue. The brain
was then lifted gently to expose the optic nerves which were cut with either a
small pair of scissors or a scalpel. Once cut, the scalpel was inserted
underneath the ventral surface of the brain to aid its removal from the cranial
vault. The brain was then bathed in oxygenated (95% 0^5% C02), ice-cold
medium before being blocked at the optic nerves and mammillary bodies.
This block of tissue was fixed with cyanocrylate adhesive to the stage of a
Vibraslice microtome (Campden Instruments Ltd, UK) rostral end uppermost
and immediately immersed in the pre-cooled bathing medium in the
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Vibraslice chamber. One or two 400 pm coronal sections containing SON
were cut and transferred from the Vibraslice chamber to the perfused well of
the recording chamber (Model QL-2; Fine Science Tools) and covered with a
single piece of gauze swab (Vernon-Carus Ltd, Lancashire) to prevent the
slices from moving in the well and to aid perfusion of the oxygenated bathing
medium over the slice surface. Flow rate of the bathing medium was set to
between 1-2 ml/min and the temperature of the bathing medium at the slice
interface was maintained at 34°C. The slices were then left for 2 h to
equilibrate before recording.
Extracellular recordings from magnocellular supraoptic neurones were
made from a glass microelectrode (20-50 MOhm; filled with 0.9% NaCI)
pulled on a Narishige electrode puller (Narishige, Japan) and then via an
M707A probe and associated amplifier (World Precision Instruments, Inc,
USA). Neuronal spike activity was discriminated from background using a
spike processer (Digitimer D.130) which was connected to a digital to
analogue converter (CED 1401) enabling data to be stored on a Spike 2
software programme (version 3.22 CED Ltd, Cambridge) for later analysis.
The microelectrode was positioned in the dorsal region of the anteriorly
located SON to enhance the likelihood of finding magnocellular oxytocin-like
(continuously firing) cells.
When an apparently suitable cell was located, a 10-20 min control period
was taken to enable the cell to establish a stable firing pattern. Mean firing
rate was measured in 10 s bins and averaged over 5-10 min. Drugs were
dissolved in bathing medium and superfused from a modified gravity feed
system consisting of separate reservoirs (50 ml polypropylene syringes; B.
Braun, GmbH) maintained at 37°C, which allowed direct switch over between
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drugs. A drug flow through time of 2-3 min was estimated by superfusing 5%
Alcian Blue dye from the reservoirs incorporated into the gravity feed system
and measuring the time taken for the dye to appear in the recording chamber
at the point where the hypothalamic slice would normally be placed.
The frequency and pattern of firing were not enough to identify a cell as
exclusively magnocellular and so it was important to monitor the shape of the
associated action potential, since magnocellular neurone action potentials
have a characteristic Ca2+ dependent shoulder on the repolarisation phase
both in vivo (Renaud and Bourque, 1989) and in vitro (Bourque and Renaud,
1985b) in the hypothalamic explant where magnocellular cells can be
positively identified by antidromic activation.
3. Experimental protocol
Six out of a total of seven continously firing (oxytocin-like) magnocellular
neurosecretory cells were perfused intially with CCK8S (106M) given by bath
application for 10-15 minutes. This was then followed by co-perfusion with
CCK8S and morphine (10"6M) until the cell adopted a stable firing pattern, or
in the case of cells (a)-(c) until firing rate was completely abolished. In cells
where firing rate was not completely inhibited [eg cells (e) and (f)] the
perfusion was switched to morphine alone (10'6M) to enable the full inhibitory
effect of morphine on cell electrical activity to be determined. To verify if
these inhibitory effects on cell activity were opioid mediated, naloxone (106
M) was co-perfused with morphine [cell (f)] in an attempt to antagonise the
morphine mediated effects on cell firing rate. Finally, cell (g) was perfused
initially with morphine for 10 minutes before being co-perfused with morphine
and CCK8S.
In the case of one cell which appeared to fire in a phasic fashion typical of
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vasopressin cells the K-selective agonist U50, 488H (frans-(±)-3,4-dichloro-
A/-methyl-A/-(2-[1 -pyrrolidinyl]cyclohehexyl) benzeneacetamide, methane
sulphate salt) was used to antagonise the CCK8S-mediated excitation since
p-opioid agonists such as morphine are largely without effect on vasopressin
neurones (Inenaga et al., 1990).
4. Bathing medium
The slice was cut and left to equilibrate for 2 h in standard medium (mM);
NaCI 124, KCI 5, NaP04.2H20 1.2, NaHC03 26, glucose 10, MgS04 1.3,
CaCI2 2.4.
For recording purposes and to aid spontaneous activity of magnocellular
neurosecretory cells Ca2+ was lowered to 0.75mM.
5. Statistics
Data are expressed as mean ± SEM. Comparisons were made within
groups of cells with Student's f-test (Paired). For individual cells, significant
effects of treatment were sought by calculating the mean ± 95% confidence
limits over a 5-10 minute period during a given treatment. These were then
compared for the test periods and if the 95% confidence limits of the two
mean values did not overlap, then p<0.05 was taken as being the




7.3.1. Actions of CCK8S and opioids on supraoptic magnocellular
neuronal firing rate
In six out of seven magnocellular continuously firing oxytocin-like cells
tested, spontaneous activity was increased by more than 3-fold (p<0.02;
Paired f-test) from a mean basal firing rate of 1.28 ± 0.33 spikes/s after
addition to the bathing media of CCK8S (10-6 M), (see Table 7.3.1.1. and Fig.
7.3.1.1.a.-f.). 10 min after an initial effect on firing rate was observed the
cells were perfused concomitantly with CCK8S and morphine (10-6 M) which
resulted in an attenuation of firing rate to 0.96 ± 0.34 spikes/s (p<0.005;
Paired f-test); a 4 fold reduction in firing rate below that seen during
perfusion with CCK8S alone. Firing rate during perfusion with CCK8S and
morphine returned to a level seen during the control period (no sig. diff.;
Paired f-test). The inhibitory effect of morphine on this CCK8S-induced
excitation was variable between the six individual cells with cells (a)-(c)
exhibiting a complete suppression of firing rate, whilst in cells (e) and (f) co-
perfusion of CCK8S and morphine although significantly attenuating the
CCK8S excitation (p<0.05 by 95% confidence limits) did not abolish it
completely. However further perfusion with morphine alone (10"6 M) did
completely abolish cell activity (p<0.05) and in the case of cell (f) this action
was significantly antagonised by naloxone (106 M), (p<0.05). In one cell, (g),
morphine was perfused first and significantly reduced firing rate to 1.7 ± 0.1
spikes/s from a basal level of 4.4 ± 0.1 spikes/s (p<0.05) and this inhibition
was then partially reversed by CCK8S (p<0.05).
The remaining cell had a mean basal firing rate of 0.32 ±0.13 spikes/s
and was analysed separately as this cell appeared to fire in a phasic manner
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characteristic of a putative vasopressin cell (Fig. 7.3.1.2.). As with the other
6 cells, this cell was also excited when perfused with CCK8S; firing rate
increasing to 5.41 ± 0.55 spikes/s (p<0.05 by confidence limits). Subsequent
co-perfusion with the K-selective agonist U50, 488H (10-6 M) resulted in a
marked attenuation in firing rate to 0.96 ± 0.40 spikes/s (p<0.05). This was
then fully antagonised (p<0.05) by addition to the perfusion medium of
naloxone (10*5 M) which once more increased firing rate to 3.79 ± 0.85
spikes/s.
Experimental Protocol
Control period CCK8S (1 pM) CCK8S (1 pM)








0.96 ± 0.34 **
(6)
Table (7.3.1.1.)- Effect of CCK8S and morphine on maqnocellular cellular
activity in the hypothalamic slice preparation. After addition to the bathing
medium of CCK8S (10-6 M), there was an increase in magnocellular
neurosecretory cell mean firing rate (* p<0.02; Paired West) followed by a
marked reduction in mean firing rate after simultaneous perfusion with
CCK8S (10-6 M) and morphine (10-6 M), (** p<0.005; Paired t-test). Numbers
of cells are in parentheses.
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Figure (7.3.1.1.; overleaf)- Electrical activity of continuously firing
magnocellular neurosecretory cells recorded from the supraoptic nucleus in
the hypothalamic slice preparation. Cells (a)-(f) represent those cells
summarised in Table 7.3.1.1. Cells (a)-(d) were initially excited (p<0.02;
Paired f-test) following bath application of CCK8S (10-6 M). Simultaneous
perfusion of CCK8S and morphine (10-6 M) completely suppressed the
CCK8S-induced excitation in cells (a)-(c), although cell (d) appeared to be
unaffected in terms of firing rate. Cells (e) and (f) were also initially excited
by perfusion with CCK8S although on this occassion co-perfusion of
morphine with CCK8S although attenuating firing rate to a level comparable
with that of the control period (p<0.05 by confidence limits), did not
completely suppress firing rate as with cells (a)-(c). However subsequent
perfusion with morphine (10-6 M) alone did abolish firing rate (p<0.05) and
this was antagonised by naloxone (10-5 M) in cell (f), (p<0.05). Cell (g) was
initially inhibited by morphine (106 M), (p<0.05) and this inhibition was
partially reversed by CCK8S (106M), (p<0.05).
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Figure (7.3.1.2.)- Electrical activity of a phasically firing maqnocellular
neurosecretory cell recerded frgm the supraeptic nucleus in the hypethalamic
slice preparation. The cell was excited following bath application of CCK8S
(106 M) as shown by the increase in firing rate (p<0.05 by confidence limits)
and apparent decrease in interburst interval. Cell firing rate was then
significantly attenuated (p<0.05) during simultaneous perfusion with U50,





A functional interaction between CCK8S and opioids (particularly
morphine) on magnocellular neurosecretory activity within the SON was
indicated from results obtained from the hypothalamic slice preparation. The
limitations of this electrophysiological approach using conventional
extracellular recording techniques make it difficult to positively identify a cell
as being vasopressinergic or oxytocinergic in nature. Both cell types show a
depolarising response in vitro in the hypothalamic explant to a bolus infusion
of CCK8S (Jarvis et al., 1992); this preparation permits both antidromic
identification of magnocellular neurones and a greater maintenance of
synaptic input enabling the two separate cell types to fire in a recognisably
characteristic fashion (Bourque and Renaud, 1991).
CCK receptors have been shown to be post-synaptically located on
oxytocin neurones (Jarvis et al., 1992; Oliet and Bourque, 1992) although
there is more dispute as to the location of p-opioid receptors. It is likely that
they are located on or close to the cell bodies of magnocellular oxytocin
neurones, since morphine can inhibit the electrical activity of putative
oxytocin neurones in the SON in vitro (Wakerley et al., 1983a; Inenaga et al.,
1990). In the present study the excitatory effect of CCK8S on magnocellular
neurones was completely suppressed by simultaneous perfusion with
morphine (Table 7.3.1.1.), whilst morphine inhibition of SON putative
oxytocin neurone firing rate was partially reversed by CCK8S (Fig. 7.3.1.1.g).
In one vasopressin-like cell (Fig. 7.3.1.2.) the CCK8S mediated excitation
was markedly reduced by the k-opioid selective agonist U50, 488H, which
confirms previous reports that vasopressin neurones are sensitive to k- but
not p-opioid agonists (Inenaga et al., 1990). Thus this opioid inhibition of
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CCK8S-induced excitation of firing rate would appear to be common to both
cell types within the SON despite evidence that K-opioid agonists seem to
mediate inhibition in magnocellular neurones by a different mode of action
from p-agonists (Inenaga et at., 1994), as in other neuronal preparations
(North, 1986).
Although acute effects of CCK8S on magnocellular cell activity do not
appear to involve a Ca2+ component, a mixed cationic conductance is
involved (Jarvis et at., 1992), whilst the exact post-receptor mechanisms
which mediate the excitation remain to be resolved. Morphine has been
reported to inhibit neurones by activating a K+ conductance thereby
sustaining a more prolonged after hyperpolarisation, which may in turn with
continued administration attenuate an associated Ca2+ conductance (North,
1989) and this may be G protein mediated. It has been speculated using a
rat brain homogenate preparation that morphine and CCK may converge on
the same post-receptor component to mediate their respective effects on cell
activity (Wang and Han, 1992). Thus morphine may apparently antagonise
the excitatory action of CCK8S on magnocellular putative oxytocin neurone
function by displacing the balance of such an effector component (which for
magnocellular neurones remains to be exclusively defined) and subsequent
effects on cellular activity away from the CCK receptor to mediate its
suppressive effect on electrical activity of the cell.
Ultimately it would be of considerable interest to determine whether such a
relationship on magnocellular oxytocin cell electrical activity also exists
between CCK and morphine when the cell is initially inhibited by morphine;
that is could endogenous CCK8S antagonise the inhibitory action of
morphine? As mentioned previously, preliminary studies have intimated that
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this may be the case (Fig. 7.3.1.I.e. and f.), although further work is
obviously required before such results can be verified. CCK has been
proposed to act as an endogenous opioid antagonist (Faris et al., 1983;
Higgins, 1992) and CCK8S binding site density within the SON is increased
in morphine dependent rats (Munro et al., 1993). If synthesis of the CCK8S
precursor preproCCK is also increased in these animals as is the case when
the magnocellular oxytocin system is activated by salt-loading and
dehydration (Flinks et al., 1993; O'Shea and Gundlach, 1993) then increased
endogenous CCK function upon oxytocin cell electrical activity could be a
partial candidate for the development of tolerance and dependence in these
neurones; although the increased availability of CCK receptors may be
sufficient for the excitatory actions of dendritically released CCK to
antagonise the inhibitory actions of morphine and to help sustain withdrawal
excitation of oxytocin neurones once initiated.
Although the increase in CCK8S binding within the SON during tolerance
and dependence probably reflects an increase in binding site density rather
than receptor affinity (Day et al., 1989) no studies have been completed
concerning CCK-mediated excitation on magnocellular putative oxytocin
neurone electrical activity from morphine tolerant hypothalamic slices. Such
an approach is complicated by the requirement for tolerance to be
maintained in vitro, and therefore the amount of morphine required to be
added to the bathing medium during recording to maintain this state.
Comparison of firing rate from supraoptic oxytocin cells between morphine
tolerant and naive slices after perfusion with CCK8S would hopefully provide
a more thorough insight into CCK receptor function during tolerance and
dependence. The relative involvement of the two receptor subtypes could
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also be elucidated from such a series of experiments. It has been proposed
that CCK8S exerts its excitatory influence on magnocellular neurosecretory
cells via a post-synaptically located CCKB receptor (Jarvis et al., 1992), yet
osmotic activation of the magnocellular neurosecretory system has been
reported to upregulate primarily CCKA receptor density within the SON (Hinks
et al., 1993). This apparent conflict of findings may be due to magnocellular
neurones being able to separately regulate CCK receptor subtypes
consequent upon mode of activation. In the case of magnocellular neurones
these two receptor subtypes may function via differing post-effector
mechanisms to initiate the electrical event and if CCK and morphine do share
a common pool of second messenger such as a specific G protein, then it is
possible that only one of the CCK receptor subtypes has access to this pool,








Recently it has become progressively clearer that the physical phenomena
of tolerance and dependence can exist within a neuronal system as two
separate entities. As such they are not necessarily co-expressed during
prolonged opiate exposure especially at the level of the single neurone
(Christie et ai, 1987). The ongoing search for a site expressing a cellular
component associated with dependence is far from resolved. Physical
dependence as demonstrated by withdrawal excitation of neurones upon
administration of the appropriate specific antagonist would appear to be a
complex phenomenon requiring the maintenance of a functionally integrated
neural network to synapse onto the neuronal population used to demonstrate
withdrawal. The purpose of the following discussion therefore is to outline a
scheme for withdrawal excitation of oxytocin neurones in the morphine
dependent rat (see Fig. 7.1.).
The magnocellular oxytocin neurosecretory system located within the SON
of the hypothalamus has been studied extensively in terms of cellular
signalling leading to activation of neurones, as have the afferents which input
to these neurones to modulate their activity upon application of an
appropriate stimulus.
Acute administration of the p-opioid agonist morphine inhibits electrical
activity of supraoptic putative oxytocin neurones in vitro (Wakerley et at.,
1983a; Inenaga et al., 1990). Continued administration of morphine results
in the development of tolerance to and dependence upon the central
inhibitory actions of morphine in vivo in these neurones. During this period
normal electrical excitability returns to the cell. It is thought that this return to
normal excitability occurs via upregulation of excitatory synaptic input to the
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oxytocin neurones within the SON. Subsequent removal of this opioid
inhibition by administration of naloxone enables the oxytocin neurone to
respond in the appropriate hyperexcitable fashion; hypersecretion of oxytocin
from the neurohypophysis into blood as demonstrated previously (Pumford et
al., 1991) and throughout this thesis, occurring as a direct result of an
increase in electrical activity of supraoptic oxytocin neurones in conjunction
with removal of opioid tone by naloxone at the level of the neurohypophysis.
Systemic administration of sulphated cholecystokinin octapeptide (CCK8S)
acts on the gastric vagus in the gastrointestinal tract to activate centrally
ascending, probably noradrenergic, pathways which project to the SON to
selectively activate magnocellular oxytocin neurones (Kendrick et al., 1991).
These pathways which involve the A2 cell group which projects from the
nucleus tractus solitarius (Sawchenko and Swanson, 1992) and possibly the
A6 cell group of the locus coeruleus which also projects to the SON (Wilkin
et al., 1989) mediate release of noradrenaline and serotonin within the SON
as measured by microdialysis (Kendrick et al., 1991), whilst noradrenaline is
principally excitatory to magnocellular oxytocin neurones (Yamashita et al.,
1987). Initial blood sampling studies were able to show that prior
intravenous administration of morphine could dose-dependently inhibit
systemic CCK8S stimulation of oxytocin release into blood from the
neurohypophysis in both morphine naive and morphine dependent rats by a
central mode of action. However the oxytocin response to stimulation by
systemic CCK8S was restored in morphine dependent rats; therefore
tolerance to the central inhibitory actions of morphine on this excitatory input
to oxytocin secretion must have developed. The development of tolerance
would appear to have been quantifiable since the oxytocin response was
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inhibited by morphine to a greater degree in the morphine naive rats. Similar
blood sampling studies were also to demonstrate that prior intravenous
administration of the a2 agonist clonidine could also suppress the oxytocin
response to systemic stimulation by CCK8S as well as significantly
attenuating naloxone-precipitated morphine withdrawal release of oxytocin
from the neurohypophysis into blood. At the level of the locus coeruleus, a2-
and p-mediated receptor effects have been shown to converge on the same
post-receptor mechanism (Aghajanian and Wang, 1987) and this may also
be the case for the noradrenergic afferents mentioned previously which
project to the SON to modulate magnocellular neurosecretory cell activity,
and even the SON oxytocin cells themselves, although clonidine has been
reported to be without effect on basal firing rate of supraoptic neurones in
vitro (Randle et at, 1984). Despite clonidine attenuation of the morphine
withdrawal response, perhaps by a pre-synaptic mode of action at the level of
the locus coeruleus or within the SON itself, the probable activation of this
pathway by systemic CCK8S did not initiate withdrawal in magnocellular
oxytocin neurones which reinforces the complex nature of this characterising
dependence phenomenon.
Calcium (Ca2+) is a ubiquitous ion involved in a variety of cellular
processes within the CNS. Movement of Ca2+ from the extracellular
compartment into neurones can initiate exocytotic release of
neurotransmitters from axon terminals, cell bodies and terminal processes
(Pow and Morris, 1989; Scott et at, 1991). The L-type voltage-activated Ca2+
channel blocker verapamil has been shown to inhibit the expression of
several behavioural signs associated with naloxone-precipitated withdrawal
in the morphine dependent rat depending upon route of administration
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(Bongianni et al., 1986; Baeyens etal., 1987). The present study was able to
extend these findings to the magnocellular neurosecretory system and show
that verapamil when given centrally attenuates withdrawal-induced secretion
of oxytocin both from the neurohypophysis and within the SON and
subsequently withdrawal excitation of oxytocin neurones by a central mode of
action (Munro et al., 1993). Both the terminals in the neurohypophysis and
the cell bodies within the SON of magnocellular oxytocin neurones express
L- and N-type Ca2+ channels although the cell bodies do not express T-type
Ca2+ channels suggesting that these neurones differentially regulate the
expression of Ca2+ channels (Fisher et al., 1992). Differential regulation of
magnocellular oxytocin neurone function and ultimately oxytocin release both
within the SON and from the neurohypophysis has also been shown after
application of an osmotic stimulus to both SON, whereupon neither
intravenously administered naloxone nor morphine have any effect on
osmotically stimulated intranuclear oxytocin release, whereas morphine does
block oxytocin release from the neurohypophysis; perhaps via a central
inhibitory action on the firing rate of oxytocin neurones (Munro et al., 1994).
Intracerebroventricular administration of a specific oxytocin antagonist can
completely suppress the spontaneous occurence of the milk-ejection reflex in
the suckled lactating rat (Freund-Mercier and Richard, 1984) and oxytocin
excites magnocellular oxytocin neurones in vitro (Yamashita et al., 1987)
probably by binding directly to oxytocin binding sites located upon dendritic
processes within the SON (Freund-Mercier and Stoeckel, 1993). Oxytocin is
also released within the SON during morphine withdrawal in a Ca2+
dependent manner (Neumann et al., 1993). The present results clearly
demonstrate that endogenous central oxytocin is required for the full
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expression of withdrawal in magnocellular oxytocin neurones since acute
intracerebroventricular injection followed by infusion of a specific oxytocin
antagonist referred to as Manning 16 (Manning et al., 1989) significantly
attenuated withdrawal hypersecretion of oxytocin from the neurohypophysis
into blood.
Oxytocin is colocalised within magnocellular oxytocin neurones with
cholecystokinin (CCK) and this latter peptide has been widely attributed
functions as a neurotransmitter throughout the brain (Crawley, 1992). The
sulphated octapeptide fragment of CCK (CCK8S) predominates and CCK8S
directly excites magnocellular neurosecretory cells in vitro (Jarvis et ai,
1992; Oliet and Bourque, 1992) and this excitation can be suppressed by
morphine as demonstrated here. Furthermore microinjection of CCK8S into
the SON induces release of oxytocin measured by microdialysis (Neumann et
al., 1993) probably from dendritic processes (Pow and Morris, 1989) and so
endogenous CCK may function in an autocrine manner to enhance the
electrical activity of magnocellular oxytocin neurones during morphine
withdrawal. Activation of the magnocellular oxytocinergic system is
associated with increased electrical activity of the neurones. Rats
challenged with an ongoing osmotic stimulus achieved by salt-loading with
2% sodium chloride demonstrate both upregulated CCK8S binding and
synthesis of preproCCK mRNA within the SON (Hinks et al., 1993) and this is
also the case for rats which have been dehydrated previously (O' Shea and
Gundlach, 1993). Specific [125I]CCK8S binding was also increased in the
SON of morphine dependent rats (Munro et al., 1993) and thus co-release of
CCK with oxytocin during naloxone-precipitated morphine withdrawal may act
at these sites to contribute towards maintaining the enhanced electrical
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activity of these neurones during the withdrawal process. Preliminary
electrophysiological studies were able to demonstrate that morphine can
suppress CCK8S-induced excitation of supraoptic putative oxytocin neurone
firing rate and it has been speculated that CCK and morphine may share a
common pool of second messenger to mediate their effects on neuronal
function (Wang and Han, 1992). These initial findings were extended to
show morphine antagonism of CCK8S mediated excitation, and partial
CCK8S antagonism of morphine inhibition of putative oxytocin neurone firing
rate. Thus the development of tolerance to the inhibitory actions of morphine
in these neurones may be the result of increased endogenous CCK activity
offsetting morphine inhibition of oxytocin cell electrical activity.
These results suggest that withdrawal excitation of magnocellular oxytocin
neurones within the SON involves a cellular component originating from the
noradrenergic cell groups of the brainstem and such excitatory noradrenergic
inputs may become more active during morphine withdrawal. However it may
be that they are tonically upregulated during dependence as demonstrated
by tolerance to the central inhibitory actions of morphine on systemic CCK8S
stimulation of release from the neurohypophysis; such that increased release
of noradrenaline within the SON per se need not necessarily be part of the
withdrawal process in these neurones. This in itself may increase the
expression of several components within the SON excitatory to oxytocin
neurones such as the increase in CCK8S binding site density in morphine
dependent rats. Such plasticity may manifest itself on other excitatory
mechanisms by increasing oxytocin and Ca2+ channel binding site density for
example, which could enhance the proposed autoexcitatory action of oxytocin
during withdrawal excitation. Release of noradrenaline within the SON after
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removal of central morphine inhibition by administration of naloxone may
subsequently be amplified compared with the control situation. This
enhanced release of noradrenaline which itself may be Ca2+ dependent could
then excite oxytocin neurones directly (Yamashita et at., 1987) by increasing
a voltage dependent Ca2+ conductance. Dendritic release of oxytocin and
CCK in conjunction with the increase in synaptic drive from the noradrenergic
cell groups could then continue until the availability of a readily accessible
substrate such as Ca2+ which appears to be of paramount importance to the
normal functioning of magnocellular neurones in response not only to
withdrawal excitation, but to a variety of stimuli had become sufficiently
depleted to bring the withdrawal process to its natural conclusion.
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Figure 7.1. (overleaf)- Scheme based on data presented in this thesis to
summarise sequence of events leading to excitation of oxytocin neurones
following naloxone-precipitated morphine withdrawal in dependent rats.
Excitatory input activity (located both pre- and post-synaptically) to
magnocellular oxytocin neurones within the SON may be upregulated due to
ongoing p-receptor occupancy by morphine. Removal of this inhibition upon
initiation of withdrawal has a number of cumulative effects to induce an
increase in electrical activity of the cell (1). Pre-synaptic release of
noradrenaline from brainstem noradrenergic afferents such as neurones of
the nucleus tractus solitarius increases cell firing rate, in a Ca2+ dependent
manner (2); such inputs may provide increased stimulation to the morphine-
inhibited oxytocin neurone to enable resumption of normal electrical
excitability. Ca2+ influx through L-type voltage-activated Ca2+ channels
during cell depolarisation initiates exocytotic release of oxytocin and CCK
from dendritic processes located in the ventral rim of the SON (3). Local
release of these two peptides sustains the withdrawal process by further
exciting the oxytocin neurones (4). Eventually depletion of Ca2+ or another
readily available excitatory substrate results in the attenuation of the
withdrawal process and its gradual drawing to an end. Other synaptic inputs
(not shown) may be required for the full expression of withdrawal in these
neurones.
Abbreviations used: SON-supraoptic nucleus, OT-oxytocin, CCK-
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Intracerebroventricular (i.c.v.) verapamil attenuates morphine withdrawal
excitation of oxytocin neurones in anaesthetized rats
G. Munro, G. Leng* and J.A. Russell
Department of Physiology, University Medical School, Edinburgh EH8 9AG and
*Department of Neurobiology, AFRC Babraham Institute, Cambridge CB2 4AT
i.c.v. infusion of morphine for 5 days in the rat leads to tolerance and
dependence in magnocellular oxytocin neurones (Pumford et a I. 1991). Naloxone
then provokes a withdrawal excitation of oxytocin neurone firing rate and
consequently a hypersecretion of peptide from the posterior pituitary.
Magnoceilular oxytocin neurone action potentials have a Ca:+-dependent shoulder
and opening of centrally located voltage-activated Ca:+ channels has been
implicated in withdrawal excitation of neurones. Tn behavioural studies the L-tvpe
CaJ+ channel antagonist verapamil inhibits withdrawal signs in morphine-
dependent rats (Baeyens et al. 1987). We have given verapamil i.c.v. to see if it
affects withdrawal excitation of magnocellular oxytocin neurones. Female
Sprague-Dawlev rats were anaesthetized with ether and the left lateral cerebral
ventricle cannulated for subsequent injection whilst the right ventricle was fitted
with a cannula connected to a subcutaneous osmotic mini-pump to deliver
morphine sulphate (up to 50 ps. /fi"' h~'). On day six of infusion, under urethane
anaesthesia (1'25 g kg"', i.p.), a femoral artery and vein were cannuiated for blood
sampling and injections. Plasma oxytocin was measured by specific radio¬
immunoassay. Verapamil (160 ug in 5 ul 0*9% NaC'l) or vehicle was injected I.c.v.
10 min after an initial blood sample. Naloxone (5 mg kg"1) injected i.v. 10 min after
i.c.v. vehicle raised plasma oxytocin by 761 + 155 pg ml"' (mean ± s.e.m., n= 7)
but after naloxone and I.c.v. verapamil the increase was only '276 + 192 pg mi"'
(n=7. P<0'05, Mann-Whitnev U test). In a further experiment on morphine
dependent rats the supraoptic nucleus was exposed by ventral surgery to record via
a microeiectrode the extracellular activity of antidromically identified putative
oxytocin neurones (continuously active, excited by r.v. CCK3S, 20 ag kg"')
(Pumford et al. 1991). Naloxone increased the firing rate of continuous ceils (mean
basal + s.e.m., 2'3 ± 1*4 spikes s"', a = 5 cells in five rats) by 4-7 + 1-0 spikes s"'
(PcO-Oo, Wilcoxon) and i.c.v. verapamil suppressed this withdrawal excitation,
abolishing firing in three cells for ca 12 min and reducing firing in two cells by 6'3
and 3-5 % (P < O'Oo by confidence limits). These results show that verapamil given
centrally diminishes withdrawal excitation of oxytocin neurones, and indicate
involvement of activation of L-tvpe Ca-+ channels in this excitation.
Supported by the AFRC. G.M. is an AFRC Research Student.
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102P MORPHINE TOLERANCE/DEPENDENCE INCREASES CHOLECYSTOKININ (CCIO BINDING IN THE RAT
SUPRAOPTIC NUCLEUS (SON)
G. Munro, K.M. Pumforci, 3c J.A. Russeil, Department ofPhysiology, Universiry Medical School, Teviot Place, Edinburgh EH8 9AG.
Magnoceiluiar oxytocin neurones in che SON appear to co-produce CCK. These neurones are directly excited by CCK, this being
reversed by morphine. Chronic i.e.v. iniiision of morphine leads to tolerance and dependence in oxytocin neurones (Pumford et al. 1991).
CCK may be an endogenous opioid antagonist involved in the development of tolerance. We have used autoradiography to quantify CCK
binding within the SON in morphine-treated rats to seek evidence for a roie of CCK in morpnine tolerance of oxytocin neurones. Under
ether anaesthesia female Sprague-Dawiev rats were fitted with an i.c.v. cannula to inliise morphine sulphate (up to 50ug/h) or vehicle
(1 pl/h) from a subcutaneous osmotic mini-oump. After 5 days the rats were decapitated, their brains rapidly removed and frozen onto
cryostat chucks on dry ice. A riirther group of rats was given 2% w/v NaCI to drink for 48h as a positive control, since it has previously
been shown that this treatment increases CCK binding within the SON (Day et al.. i989); a control group was given water. lOum
transverse brain sections on gelatinised siiaes were incubated with [125I]CCK8 with or without excess uniabeiled CCK8 to determine
Total Binding (TB) and Non-Specific Binding (NSB) respectively; specific CCK binding was denned as (TB-NSB). The sections were
then apposed to Hvpertilm [3H] for 4 days. Films were then processed, tissue sections fixed and che autoradiograpns of SON profiles
viewed unaer a microscope (objective xlO) for quantificauon using a Joyce-Loebi uMagiscan image analyser. Results were expressed as
mean density of silver deposit over the measured area of dorsal SON (202 x I33um). Each frlm processed contained sections from at
least one animal from each treatment group; the untreated group measurement on each film was used to calculate relative values from the
measurements for each treatment group on the film, to overcome variability between films.
Specific [I25I]CCK8 binding in the SON increased by 2.4 fold (P<0.01) alter i.c.v. morphine treatment (n=6, mean relative value ± s.e.
mean: 1.37 = 0.18) compared with the vehicle treated group (n=6, 0.57 = 0.1). There was no difference between the morphine-treated
group and the sait loaded group (n=3, 1.48 ± 0.15); in both, binding was significantly increased (P<0.05) relative to the untreated
controls. The increase in specific CCK8 binding within the SON, which may. reflect an increase in receptor density, after chronic
morphine treatment indicates that increased activity of endogenous CCK mechanisms within the SON couid play a roie in the
development of morphine tolerance and dependence in oxytocin neurones in the rat.
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104P EXCITATION BY MORPHINE WITHDRAWAL INDUCES c-fos EXPRESSION IN MAGNOCELLULAR
OXYTOCIN NEURONES
L.E. Johnstone, M. HamamuraL G. Munro & J.A. Russell. Dept of Physiology, University Medical School, Teviot Place. Edinburgh
EH8 9AG and rDept ofPhysiology, Jichi Medicai School, Japan.
Magnoceilular oxytocin (OXT) neurones are inhibited by acute morphine but develop tolerance and dependence during
intracerebroventricular (i.c.v.) morphine infusion over 5d (Bicknell et al. 1988). Withdrawal induced acutely by naloxone (NLX)
increases OXT neurone firing rate 3.5 fold in dependent rats but has no effect in controls, ana as a result oxytocin secretion is greatly-
increased. Vasopressin neurones are unaffected. We have studied whether withdrawal activates the eariy onset gene, c-fos. ana
stimulates production of Fos in dependent OXT neurones. To establish morphine dependence, virgin female Sprague Dawley rats, n=8.
were implanted with a lateral i.c.v. cannula, under ether anaesthesia, to infuse morpnine suiphate (up to 50ug/h) from a subcutaneous
osmotic minipump; controls were given vehicle (lul/h). In the first study after i.c.v. morphine intusion for 5d a femoral vein was
cannulated, under urethane anaesthesia (1.25g/kg i.p.), for injection 2h later of NLX (5mg/kg) or vehicle. The rats were decapitated
0.5h after NLX, the brains removed, frozen on dry ice and stored at -70°C. 20um cryostat sections through the hypothalamus were
hybridised with ^S-labelled oligonucleotide c-fos mRNA probe and exposed on film for 3 weeks (Hamamura et al 1991).
Autoradiographs were viewed by microscope (xlO objective) and gram density above background over the supraoptic nucleus (SON)
was measured with a Joyce Loebl image analyser. In the SON c-fos mRNA was barely detected in vehicle injected rats (n=4, mean grain
density ± s.e. 0.8 ± 0.8% field area) whereas NLX induced c-fos mRNA expression (n=4, 13.3 ± 1.8%, p<0.001, t-test). In the second
study after i.c.v. morphine or vehicle infusion for 5d conscious rats were given either s.c. NLX or venicle(n=6 per group). The rats were
decapitated 90min later and the brains removed, frozen on dry ice ana stored at -70°C. 15um cryostat sections through hypothalamus
were immuno-cytochemically processed using Fos antibody (Oncogene Sciences) ana peroxidase labelled second antibody detected by
the glucose oxidase-nickel-DAB method(Shu et al 1988). Sections were viewed at xlO mag and the density of Fos positive nuclei in the
SON calculated by counting and by measuring the area of each SON profile with the image analyser. In the i.c.v. vehicle group after i.v.
vehicle or NLX, and in the i.c.v. morphine group after i.v. vehicle, the density of Fos positive neurones in the SON was <1 neurone/
104pm: but in the morpnine/NLX group the density was 22.6±3.30(mean= s.e,p<O.OOOLANOVA). Activation of the c-fos gene in SON
neurones during morphine withdrawal may be confined to oxytocin neurones, and a consequence of their increased firing rate.
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